PFD WEEK 2017

Proud to be a

Platinum Sponsor

Fellow's Day Lunch Program Sponsor

Allied Health Professionals Lunch Program Sponsor

Please visit us at the Allergan Booth

MEET THE EXPERTS

Weds 10/4  5:30 PM - 6:30 PM  Sangeeta Mahajan, MD

Weds 10/4  6:30 PM - 7:30 PM  Michael Kennelly, MD

Thurs 10/5  10:30 AM - 11:00 AM  Karyn Eilber, MD

Thurs 10/5  5:30 PM - 6:30 PM  Michael Kennelly, MD

Fri 10/6  10:00 AM - 10:30 AM  Sangeeta Mahajan, MD

Allergan sincerely appreciates the AUGS and Urogynecology community for your continued focus and support in bringing excellence to patient care
Dear fellow AUGS Friends and Colleagues,

Welcome to the AUGS 38th Annual Scientific Meeting in beautiful Providence, Rhode Island, where the city motto is, “What Cheer!”

The 2017 AUGS Pelvic Floor Disorders (PFD) Week is the go-to meeting for healthcare professionals interested in or actively practicing Female Pelvic Medicine and Reconstructive Surgery. We are excited to kick off the meeting festivities.

The 2017 Program Committee and I have created a robust scientific program showcasing national and international research of the highest caliber on relevant topics that can be immediately implemented into your practices. This year’s event features a wide array of learning opportunities, including 18 workshops chaired by experts in the field, 25 roundtable discussions, and more than 200 oral, oral poster, poster, and video presentations.

New conference features include a clinical seminar and surgical tutorial as well as a master surgeon session. Other meeting highlights are the not-to-be-missed interactive and lively debates, and three very relevant expert panels on product liability, payment reform, and prevention of urinary incontinence incorporating the most up-to-date evidence on behavioral and basic science.

PFD Week is a great opportunity to connect with friends and colleagues—old and new! We encourage you to utilize our networking events and dedicated Exhibit Hall times to connect with exhibitors and share lessons learned and best practices. For all you divas and divos out there—please join us for the Friday AUGSome Beach Carnival at the WaterFire Arts Center! The AUGSome Beach Carnival is family-friendly and offers a perfect opportunity to relax and showcase your singing and dancing talents. We are all so excited to see your creativity during this year’s karaoke challenge!

We hope you enjoy your time in Providence and return home with an expanded network, a renewed spirit, and more knowledge to share.

In Peace and Good Cheer,

Cheryl Iglesia, MD
AUGS PFD Week Program Committee Chair
@cheryliglesia
#PFDWeek

Cheryl Iglesia, MD
AUGS PFD Week Program Committee Chair
@cheryliglesia
#PFDWeek
# TABLE OF CONTENTS

Meeting Information ................................................................. 5  
Continuing Education ............................................................. 7  
Networking Events ................................................................. 8  
Non-Educational Industry Supporters ....................................... 11  
Schedule at-a-Glance .............................................................. 12  
Concurrent Schedule at-a-Glance ............................................ 14  
Pre-Conference Workshop Schedule ....................................... 20  
Fellows’ Day ........................................................................ 22  
Meet the Experts Educational Roundtables ............................ 23  
General Scientific Sessions .................................................... 24  
Special Sessions .................................................................. 25  
Keynote Presentations ............................................................ 26  
Industry Supported Education ................................................... 27  
Scientific Program  
  Tuesday ........................................................................... 28  
  Wednesday ....................................................................... 28  
  Thursday ......................................................................... 28  
  Friday ............................................................................. 36  
  Saturday .......................................................................... 46  
Exhibit Hall Floor Plan ............................................................ 48  
Exhibitor Listing .................................................................. 49  
Exhibitor Directory ................................................................. 51  
AUGS Award Recipients .......................................................... 56  
PFD Research Award Recipients .............................................. 57  
AUGS Leadership .................................................................. 60

---

**ENHANCE YOUR MEETING EXPERIENCE WITH THE PFD WEEK MOBILE APP**

Connect with fellow attendees and access program details all through your mobile device. Search “AUGS PFD Week” in the Apple App Store or Google Play Store to download the app.

- Quickly reference meeting logistics including times and locations
- Search the meeting schedule and build your personal agenda
- Find your favorite speakers and view all the sessions he/she is presenting
- Access the 2017 exhibitor list and navigate the Exhibit Hall
MEETING INFORMATION

ATTENDEE SERVICES DESK HOURS

Tuesday, October 3
7:30 a.m. – 5:00 p.m.

Wednesday, October 4
7:15 a.m. – 5:30 p.m.

Thursday, October 5
6:15 a.m. – 6:00 p.m.

Friday, October 6
6:15 a.m. – 5:30 p.m.

Saturday, October 7
6:15 a.m. – 1:30 p.m.

EXHIBIT HALL HOURS

Wednesday, October 4 | 5:30 p.m. – 7:30 p.m.
5:30 p.m. – 7:30 p.m.
Welcome Reception in the Exhibit Hall

Thursday, October 5 | 10:30 a.m. – 6:30 p.m.
10:30 a.m. – 11:00 a.m.
Break in Exhibit Hall

11:45 a.m. – 1:30 p.m.
Lunch in Exhibit Hall

5:30 p.m. – 6:30 p.m.
Exhibit Hall Happy Hour

Friday, October 6 | 9:45 a.m. – 2:45 p.m.
9:45 a.m. – 10:15 a.m.
Break in Exhibit Hall

1:00 p.m. – 2:45 p.m.
Lunch in Exhibit Hall

SPEAKER READY ROOM

Room 558 A
AUGS provides a room for all speakers to review and submit their presentations before their session. To better serve you, this process must be completed at least three hours prior to your session.

Tuesday, October 3
6:30 a.m. – 6:30 p.m.

Wednesday, October 4
6:30 a.m. – 6:30 p.m.

Thursday, October 5
6:30 a.m. – 4:30 p.m.

Friday, October 6
6:30 a.m. – 6:00 p.m.

Saturday, October 7
7:30 a.m. – 10:00 a.m.

FIND GARRETT POPCORN IN THE EXHIBIT HALL

Celebrate the return of PFD Week to Chicago early with Garrett Popcorn! What makes this treat even sweeter? Find the hidden popcorn in the Exhibit Hall and your reward could be free registration to PFD Week 2018 in Chicago!
Stop by AUGS Booth #317 to

Discover all that We Offer

Join AUGS, Renew Your Membership, or Just Stop In

Grab a special treat at the Welcome Reception on Wednesday, October 4 at 5:30 p.m. – 7:30 p.m.!

- NEW! Test the POP-Q Interactive Assessment Tool, which is now also available as an app
- NEWLY EXPANDED TOPICS! Take home copies of our Patient Fact Sheets and other patient resources
- LEARN how you can participate in the AUGS Urogynecology Quality Registry (AQUIRE) – Your tool for PQRS and MIPS reporting
- DISCOVER how to become a member or learn more about your AUGS membership benefits

Dedicated to Research, Education, and Advocacy
WHO SHOULD ATTEND

PFD Week is for physicians, nurses, physical therapists, students, researchers, educators, and other healthcare professionals interested in Female Pelvic Medicine and Reconstructive Surgery. New treatment techniques and developments in both surgical and non-surgical settings will be shared through a variety of educational formats designed to encourage interactive discussion. Scientific material will be presented through lectures, posters, videos, recorded surgeries, and tips and tricks presentations.

EDUCATIONAL GOALS AND OBJECTIVES

• Describe and discuss the pathophysiology of pelvic floor disorders, including pelvic organ prolapse, urinary incontinence, fecal incontinence, and sexual dysfunction
• Identify risk factors and the epidemiology of pelvic floor disorders
• Delineate the impact of pelvic floor disorders on the quality of life for women who suffer from these conditions
• Review and discuss the tools to assess and quantify pelvic floor disorders
• Explain non-surgical and surgical treatments used to manage pelvic floor disorders
• Identify methods for preventing lower urinary tract symptoms
• Review methods for treating mesh related complications
• Identify methods to avoid nerve injury during pelvic surgery
• Describe indications for uterine preservations during prolapse surgery

EDUCATION CREDITS

Creighton University designates this live activity for a maximum of 32.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. (10/3=7.0 credits; 10/4=7.0 credits; 10/5=6.25 credits; 10/6=7.0 credits; 10/7=4.75 credits) AAPA accepts AMA category 1 credit for the PRA from organizations accredited by ACCME.

Nurses CE

Creighton University Health Sciences Continuing Education designates this activity for up to 32.0 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity (10/3=7.0 credits; 10/4=7.0 credits; 10/5=6.25 credits; 10/6=7.0 credits; 10/7=4.75 credits)

Accreditation Statement

This activity has been planned and implemented by Creighton University Health Sciences Continuing Education (HSCE) and the American Urogynecologic Society (AUGS) for the advancement of patient care. Creighton University Health Sciences Continuing Education is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.
NETWORKING EVENTS

SPECIAL INTEREST GROUPS (SIGS) BUSINESS MEETINGS

AUGS Special Interest Groups (SIGs) provide a sense of community and focused education around specific areas of interest in the field of FPMRS. All attendees are welcome to join the SIG meetings to learn more about each SIG’s activities and become involved with AUGS. The SIGs below will be meeting during PFD Week.

Advanced Practice, Physical Therapy, and Allied Health (APPTAH)
Chair: Ingrid Harm-Ernandes, PT, WCS, BCBPMD
Vice Chair: Jan Baker, MS, APRN
Meeting Information: Wednesday, October 4, 4:30 p.m. – 6:00 p.m.
Ballroom A

Basic Science
Chair: Matthew Fraser, PhD
Vice Chair: Marianna Alperin, MD, MS
Meeting Information: Friday, October 6, 6:45 a.m. – 7:45 a.m.
Room 553

Electronic Medical Record (EMR)
Chair: Adam S. Holzberg, DO, FACOG
Vice Chair: Audrey E. Curtis, MD
Meeting Information: Thursday, October 5, 6:45 a.m. – 7:45 a.m.
Room 551

Fellows
Chair: Lauren Siff, MD
Vice Chair: Emily Wu, MD
Meeting Information: Fellows’ Day, Wednesday, October 4, 7:45 a.m. – 5:00 p.m.
Ballroom B

Fellowship Program Directors
Chair: Felicia Lane, MS, MD
Vice Chair: Elizabeth Geller, MD
Meeting Information: Fellowship Program Directors’ Workshop, Wednesday, October 4, 8:00 a.m. – 4:00 p.m.
Room 555

Global Health
Chair: Joan L. Blomquist, MD
Vice Chair: Rahel Nardos, MD
Meeting Information: Wednesday, October 4, 4:30 p.m. – 6:00 p.m.
Providence Ballroom I & IV (Omni)

Mesh/Graft Use in Pelvic Reconstructive Surgery
Chair: Vince Lucente, MD, FACOG
Vice Chair: Andrew P. Cassidenti, MD
Meeting Information: Wednesday, October 4, 4:30 p.m. – 6:00 p.m.
Rotunda (Convention Center)

Private Practice
Chair: Jorge F. Peacher, MD
Vice Chair: Magdalene Karon, MD
Meeting Information: Friday, October 6, 6:45 a.m. – 7:45 a.m.
Room 555

PFD WEEK WELCOME RECEPTION
Wednesday, October 4
5:30 p.m. – 7:30 p.m. | Exhibition Hall AB
Kick-off PFD Week at the Welcome Reception! This is your first opportunity to catch up with colleagues while you meet with industry exhibitors and enjoy light refreshments.

EXHIBIT HALL HAPPY HOUR
Thursday, October 5
5:30 p.m. – 6:30 p.m. | Exhibition Hall AB
Join AUGS in the Exhibit Hall for a happy hour and celebration of PFD Week. Visit the 2017 exhibitors and stop by the AUGS booth, while you mingle with peers and make new connections.

FELLOWSHIP PROGRAM MEET-AND-GREET FOR RESIDENTS
Thursday, October 5
5:30 p.m. – 6:30 p.m. | Exhibition Hall AB (rear of hall)
During the Exhibit Hall happy hour, residents will have an opportunity to learn more about FPMRS fellowship programs from across the country.

AUGSOME BEACH CARNIVAL
Friday, October 6
7:00 p.m. – 11:00 p.m. | WaterFire Arts Center
Join AUGS for a beach party, complete with carnival-inspired games, food, drinks, and much more. As always, the AUGSSome event is home to the Karaoke Challenge — sign up now in the AUGS booth! All ticket sales benefit the PFD Research Foundation.
Change doesn’t take commitment, leadership, or collaboration...

It takes all three.

As leaders in Urology, we relentlessly pursue new science to make a difference in patients’ lives. We make it our priority to stay on the cutting edge of urologic research to address unmet clinical and patient needs. And our commitment extends beyond product development. We seek to support the Urology community and to improve the lives of patients with urologic disease.

Changing tomorrow together, today.
You can now use the POP-Q Interactive Assessment Tool to show pelvic floor exam results to your patients on your desktop computer or mobile device.

- Enter POP-Q Scores
- Visually Demonstrate Captured Patient Measurements
- Educate Patients Before and After Surgery
- Option to Print Patient-Specific Results

Now Available at www.augs.org/patient-services/pop-q-tool
THANK YOU TO THE 2017 PFD WEEK SPONSORS!

### PLATINUM LEVEL SPONSORS

<table>
<thead>
<tr>
<th>Allergan</th>
<th>Coloplast</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boston Scientific</td>
<td>Medtronic, Inc.</td>
</tr>
</tbody>
</table>

### GOLD LEVEL SPONSOR

- Astellas

### BRONZE LEVEL SPONSORS

<table>
<thead>
<tr>
<th>Caldera Medical</th>
<th>Neomedic International</th>
<th>Thermi</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intuitive Surgical</td>
<td>Sciton</td>
<td>Viveve</td>
</tr>
</tbody>
</table>

### COPPER LEVEL SPONSORS

<table>
<thead>
<tr>
<th>ACell</th>
<th>Innovation Compounding, Inc.</th>
<th>V-Revive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethicon</td>
<td>Pelvalon</td>
<td></td>
</tr>
</tbody>
</table>
## TUESDAY, OCTOBER 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m. – 5:00 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td>8:30 a.m. – 12:00 p.m.</td>
<td>Pre-Conference Workshops</td>
</tr>
<tr>
<td>1:30 p.m. – 5:00 p.m.</td>
<td>Pre-Conference Workshops</td>
</tr>
</tbody>
</table>

## WEDNESDAY, OCTOBER 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15 a.m. – 5:30 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td>7:45 a.m. – 5:00 p.m.</td>
<td>Fellows’ Day</td>
</tr>
<tr>
<td>8:00 a.m. – 3:00 p.m.</td>
<td>Program Directors’ Workshop</td>
</tr>
<tr>
<td>8:30 a.m. – 12:00 p.m.</td>
<td>Pre-Conference Workshops</td>
</tr>
<tr>
<td>11:45 a.m. – 1:15 p.m.</td>
<td>The Future of Treating Moderate to Severe Dyspareunia: A New, Locally Administered Treatment for Moderate to Severe Dyspareunia Due to Menopause supported by AMAG</td>
</tr>
<tr>
<td>1:00 p.m. – 5:00 p.m.</td>
<td>Pre-Conference Workshops</td>
</tr>
<tr>
<td>3:00 p.m. – 3:45 p.m.</td>
<td>Bonus Session: Post or Perish</td>
</tr>
<tr>
<td>4:00 p.m. – 4:45 p.m.</td>
<td>Bonus Session: Future of Medicine and Technology: The Art of the Possible</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>SIG Meetings: Advanced Practice, Physical Therapy, and Allied Health (APPTAH); Global Health; Mesh/Graft Use in Pelvic Reconstructive Surgery</td>
</tr>
<tr>
<td>5:30 p.m. – 7:30 p.m.</td>
<td>Welcome Reception in the Exhibit Hall</td>
</tr>
</tbody>
</table>

## THURSDAY, OCTOBER 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:15 a.m. – 6:00 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td>6:30 a.m. – 7:30 a.m.</td>
<td>The Use of Multimodal Analgesia to Reduce Opioid Use in Urogynecological Procedures supported by Pacira</td>
</tr>
<tr>
<td>6:45 a.m. – 7:45 a.m.</td>
<td>Meet the Experts Educational Roundtables</td>
</tr>
<tr>
<td>6:45 a.m. – 7:45 a.m.</td>
<td>SIG Meeting: Electronic Medical Records (EMR)</td>
</tr>
<tr>
<td>8:00 a.m. – 8:15 a.m.</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td>8:15 a.m. – 9:15 a.m.</td>
<td>General Scientific Session</td>
</tr>
<tr>
<td>9:15 a.m. – 10:30 a.m.</td>
<td>State of the Society Presidential Address</td>
</tr>
<tr>
<td>10:30 a.m. – 11:00 a.m.</td>
<td>Break in the Exhibit Hall</td>
</tr>
<tr>
<td>11:00 a.m. – 11:45 a.m.</td>
<td>Scientific Concurrent Sessions 1–3</td>
</tr>
<tr>
<td>11:00 a.m. – 12:00 p.m.</td>
<td>Clinical Seminar: Abnormal Uterine Bleeding: Wading through the Evidence on Evaluation and Treatment Effectiveness</td>
</tr>
<tr>
<td>11:45 a.m. – 1:30 p.m.</td>
<td>Lunch in the Exhibit Hall</td>
</tr>
<tr>
<td>12:00 p.m. – 1:30 p.m.</td>
<td>Improving Your Efficiency: New Digital Resources to Address Physician Needs supported by Boston Scientific</td>
</tr>
<tr>
<td>1:30 p.m. – 2:00 p.m.</td>
<td>Sling Selections and What to do When They Fail!</td>
</tr>
<tr>
<td>2:00 p.m. – 2:30 p.m.</td>
<td>Raymond A. Lee Lecture: Life-long Learning, Loving What You Do, and Paying It Forward</td>
</tr>
<tr>
<td>2:30 p.m. – 2:40 p.m.</td>
<td>FPMRS Journal Update</td>
</tr>
<tr>
<td>2:45 p.m. – 4:00 p.m.</td>
<td>General Scientific Session II</td>
</tr>
<tr>
<td>4:00 p.m. – 4:15 p.m.</td>
<td>Break</td>
</tr>
</tbody>
</table>
4:15 p.m. – 5:15 p.m.  Scientific Concurrent Sessions 4–6  Ballroom A–E  See pages 14-15
4:15 p.m. – 5:15 p.m.  Surgical Tutorial: Laparoscopic and Robotic Sacrocolpopexy Pearls  Room 551  See page 25
5:30 p.m. – 6:30 p.m.  Exhibit Hall Happy Hour  Exhibition Hall AB
5:30 p.m. – 6:30 p.m.  Fellowship Program Meet-and-Greet for Residents  Exhibition Hall AB (rear of hall)

**FRIDAY, OCTOBER 6**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:15 a.m. – 5:30 p.m.</td>
<td>Registration Open</td>
<td>Exhibit Level Atrium</td>
</tr>
<tr>
<td>6:45 a.m. – 7:45 a.m.</td>
<td>Meet the Experts Educational Roundtables</td>
<td>Rotunda</td>
</tr>
<tr>
<td>6:45 a.m. – 7:45 a.m.</td>
<td>SIG Meetings: Basic Science, Private Practice</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>8:00 a.m. – 8:05 a.m.</td>
<td>Welcome and Introduction</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>8:05 a.m. – 8:15 a.m.</td>
<td>PFD Research Foundation Update</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>8:15 a.m. – 8:45 a.m.</td>
<td>Mesh Removal Debate</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>8:45 a.m. – 9:45 a.m.</td>
<td>General Scientific Session III</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>9:45 a.m. – 10:15 a.m.</td>
<td>Break in the Exhibit Hall</td>
<td>Exhibition Hall AB</td>
</tr>
<tr>
<td>10:15 a.m. – 10:50 a.m.</td>
<td>J. Marion Sims Lecture: Vesico-Vaginal Fistula: Historical Understanding, Medical Ethics, and Modern Sensibilities</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>10:50 a.m. – 11:35 a.m.</td>
<td>Prevention of Urinary Incontinence: A Behavioral and Basic Science Perspective</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>11:35 a.m. – 11:55 a.m.</td>
<td>Treatment of Non-Neurogenic Urinary Retention: When and When Not to Intervene – Recommendations from the AUA</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>11:55 a.m. – 1:00 p.m.</td>
<td>General Scientific Session IV</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>1:00 p.m. – 2:30 p.m.</td>
<td>Laser Applications in Vaginal Health Specifically Related to GSM, SUI, and Atrophy supported by Alma Lasers</td>
<td>Room 555</td>
</tr>
<tr>
<td>1:00 p.m. – 2:30 p.m.</td>
<td>Single-Incision Slings: Data, Barriers, and the Patient Experience supported by Coloplast</td>
<td>Room 552</td>
</tr>
<tr>
<td>1:00 p.m. – 2:45 p.m.</td>
<td>Lunch in the Exhibit Hall</td>
<td>Exhibition Hall AB</td>
</tr>
<tr>
<td>2:45 p.m. – 4:00 p.m.</td>
<td>Scientific Concurrent Sessions 7–9</td>
<td>Ballroom A–E</td>
</tr>
<tr>
<td>3:15 p.m. – 5:00 p.m.</td>
<td>Video Café</td>
<td>Room 553</td>
</tr>
<tr>
<td>4:00 p.m. – 4:15 p.m.</td>
<td>Break</td>
<td>Exhibit Level Atrium</td>
</tr>
<tr>
<td>4:15 p.m. – 5:30 p.m.</td>
<td>Scientific Concurrent Sessions 10–12</td>
<td>Ballroom A–E</td>
</tr>
<tr>
<td>7:00 p.m. – 11:00 p.m.</td>
<td>AUGSome Beach Carnival and Karaoke Challenge</td>
<td>WaterFire Arts Center</td>
</tr>
</tbody>
</table>

**SATURDAY, OCTOBER 7**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. – 1:30 p.m.</td>
<td>Registration Open</td>
<td>Exhibit Level Atrium</td>
</tr>
<tr>
<td>8:30 a.m. – 8:35 a.m.</td>
<td>Announcements and Preview of 2018</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>8:35 a.m. – 9:30 a.m.</td>
<td>General Scientific Session V</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>9:30 a.m. – 10:30 a.m.</td>
<td>Insights on How to Navigate Product Controversy</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>10:30 a.m. – 10:45 a.m.</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45 a.m. – 11:30 a.m.</td>
<td>Master Surgeon Presentations</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>General Scientific Session VI</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>12:30 p.m. – 1:30 p.m.</td>
<td>What Are Urogynecologists Going to Get Paid and How?</td>
<td>Exhibition Hall C</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**KEY:**  
= Virtual Conference  
= This session requires a ticket
## THURSDAY, OCTOBER 5 | 11:00 a.m. – 11:45 a.m.

<table>
<thead>
<tr>
<th>TIME</th>
<th>SCIENTIFIC CONCURRENT SESSION 1 — SURGERY SESSION</th>
<th>SCIENTIFIC CONCURRENT SESSION 2 — QUALITY OF LIFE/HEALTH SERVICES RESEARCH SESSION</th>
<th>TIME</th>
<th>SCIENTIFIC CONCURRENT SESSION 3 — BASIC SCIENCE SESSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 a.m. – 11:04 a.m.</td>
<td>Oral Poster 1 — RESPONSIVENESS AND MINIMALLY IMPORTANT DIFFERENCE OF SF-6D AND EQ-5D UTILITY SCORES FOR THE TREATMENT OF PELVIC ORGAN PROLAPSE</td>
<td>Oral Poster 7 — RECOVERING SEXUAL SATISFACTION AFTER PROLAPSE SURGERY</td>
<td>11:00 a.m. – 11:04 a.m.</td>
<td>Oral Poster 13 — BIG POTASSIUM (BK) CHANNEL REGULATES IN VIVO UROTHELIAL CYTOKINE RELEASE INDUCED BY LIPOPOLYSACCHARIDE: NEW INSIGHT INTO UROTHELIAL INNATE IMMUNE RESPONSE IN PATHOGENESIS OF URINARY TRACT INFECTION</td>
</tr>
<tr>
<td>11:04 a.m. – 11:08 a.m.</td>
<td>Oral Poster 2 — THE PATIENT PERSPECTIVE ON PELVIC FLOOR DISORDERS SURGICAL ADVERSE EVENTS</td>
<td>Oral Poster 8 — THE PURSUIT OF MOBILE APPLICATIONS FOR PATIENTS WITH PELVIC FLOOR DISORDERS</td>
<td>11:04 a.m. – 11:08 a.m.</td>
<td>Oral Poster 14 — IN VIVO EVALUATION OF THE HOST RESPONSE TO AN ELASTOMERIC MESH: AN ALTERNATIVE TO POLYPOLYPROPYLENE MESH</td>
</tr>
<tr>
<td>11:08 a.m. – 11:12 a.m.</td>
<td>Oral Poster 3 — PREDICTIVE FACTORS OF POSTOPERATIVE FAILURE FOLLOWING VAGINAL RECONSTRUCTIVE SURGERY</td>
<td>Oral Poster 9 — INCONTINENCE &amp; INTIMATE PARTNERS CLINICAL TRIAL: THE SEXUAL BENEFIT OF SUCCESSFUL TREATMENT (IMPACT)</td>
<td>11:08 a.m. – 11:12 a.m.</td>
<td>Oral Poster 15 — THE IMPACT OF COMMON VAGINAL LUBRICANTS ON E. COLI</td>
</tr>
<tr>
<td>11:12 a.m. – 11:16 a.m.</td>
<td>Oral Poster 4 — PREDICTORS OF SUCCESS AT 5 YEARS POST-IMPLANT OF THE INTERSTIM SYSTEM FOR OVERACTIVE BLADDER</td>
<td>Oral Poster 10 — TOPICAL LIDOCAINE FOR URODYNAMIC TESTING: A DOUBLE BLINDED RANDOMIZED CONTROL TRIAL</td>
<td>11:12 a.m. – 11:16 a.m.</td>
<td>Oral Poster 16 — RETHINKING THE URINARY CATHERETER: LESS TRAUMA THROUGH BETTER DESIGN — A SHEEP MODEL</td>
</tr>
<tr>
<td>11:16 a.m. – 11:20 a.m.</td>
<td>Questions for Oral Posters 1–4</td>
<td>Questions for Oral Posters 7–10</td>
<td>11:16 a.m. – 11:20 a.m.</td>
<td>Questions for Oral Posters 13–16</td>
</tr>
<tr>
<td>11:20 a.m. – 11:24 a.m.</td>
<td>Oral Poster 5 — A RANDOMIZED CONTROLLED TRIAL OF POST-OPERATIVE PELVIC FLOOR PHYSICAL THERAPY AFTER VAGINAL RECONSTRUCTIVE SURGERY</td>
<td>Oral Poster 11 — LONG TERM SEXUAL FUNCTION AFTER OBSTETRIC ANAL SPHINCTER INJURIES</td>
<td>11:20 a.m. – 11:24 a.m.</td>
<td>Oral Poster 17 — DETERMINATION OF LOXL1 AND FIBULIN-5 LEVELS IN THE VAGINAL SECRETIONS OF WOMEN WITH AND WITHOUT PELVIC ORGAN PROLAPSE</td>
</tr>
<tr>
<td>11:24 a.m. – 11:28 a.m.</td>
<td>Oral Poster 6 — ENHANCED RECOVERY AFTER UROGYNECOLOGIC SURGERY: A SURVEY OF PATIENT EXPERIENCE</td>
<td>Oral Poster 12 — ACCIDENTAL BOWEL LEAKAGE EVALUATION (ABLE): A NEW PATIENT-CENTERED VALIDATED MEASURE OF ACCIDENTAL BOWEL LEAKAGE SYMPTOMS</td>
<td>11:24 a.m. – 11:28 a.m.</td>
<td>Oral Poster 18 — THE URINARY MICROBIOME IN WOMEN WITH MIXED URINARY INCONTINENCE</td>
</tr>
<tr>
<td>11:28 a.m. – 11:32 a.m.</td>
<td>Video 2 — PERSISTENT VAGINAL LEAKAGE IN THE SETTING OF AN APICAL VAGINAL SINUS TRACT</td>
<td>Video 3 — SACROCLOPOPEXY MODIFICATION IN THE SETTING OF A PELVIC KIDNEY</td>
<td>11:28 a.m. – 11:32 a.m.</td>
<td>Oral Poster 19 — NATURAL HISTORY OF AN ACUTE URINARY TRACT INFECTION IN A YOUNG WOMAN</td>
</tr>
<tr>
<td>11:32 a.m. – 11:36 a.m.</td>
<td>Questions for Oral Posters 5–6</td>
<td>Questions for Oral Posters 11–12</td>
<td>11:32 a.m. – 11:36 a.m.</td>
<td>Oral Poster 20 — EXPLORATION OF A REGENERATIVE EXTRACELLULAR MATRIX BIOSCAFFOLD IN SACROCLOPOPEXY: IMPACT ON VAGINAL SMOOTH MUSCLE</td>
</tr>
<tr>
<td>11:36 a.m. – 11:40 a.m.</td>
<td></td>
<td></td>
<td>11:36 a.m. – 11:40 a.m.</td>
<td>Oral Poster 21 — IMPACT OF A REGENERATIVE ECM BIOSCAFFOLD ON VAGINAL SMOOTH MUSCLE</td>
</tr>
<tr>
<td>11:40 a.m. – 11:45 a.m.</td>
<td></td>
<td></td>
<td>11:40 a.m. – 11:45 a.m.</td>
<td>Questions for Oral Posters 17–21</td>
</tr>
</tbody>
</table>

## THURSDAY, OCTOBER 5 | 4:15 p.m. – 5:15 p.m.

<table>
<thead>
<tr>
<th>TIME</th>
<th>SCIENTIFIC CONCURRENT SESSION 4 — HOT TOPICS IN SURGERY AND QUALITY OF LIFE SESSION</th>
<th>TIME</th>
<th>SCIENTIFIC CONCURRENT SESSION 5 — EPIDEMIOLOGY AND OTHER PELVIC FLOOR DISORDERS SESSION</th>
<th>TIME</th>
<th>SCIENTIFIC CONCURRENT SESSION 6 — BASIC SCIENCE II SESSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:15 p.m. – 4:19 p.m.</td>
<td>Oral Poster 22 — MATERNAL LOWER URINARY TRACT INJURY AT THE TIME OF PERIPARTUM HYSTERECTOMY</td>
<td>4:15 p.m. – 4:19 p.m.</td>
<td>Oral Poster 31 — GENOME-WIDE ASSOCIATION STUDY FOR URINARY AND FECAL INCONTINENCE IN WOMEN</td>
<td>4:15 p.m. – 4:19 p.m.</td>
<td>Oral Poster 41 — CHARACTERIZATION OF THE T CELL POPULATION IN VAGINAL MESH REMOVED FROM WOMEN WITH COMPLICATIONS</td>
</tr>
<tr>
<td>4:19 p.m.</td>
<td>Oral Poster 23 — PATIENT PERSPECTIVE IN PELVIC FLOOR DISORDERS SURGICAL ADVERSE EVENTS</td>
<td>4:19 p.m.</td>
<td>Oral Poster 32 — PREDICTORS OF SUCCESS AT 5 YEARS POST-IMPLANT OF THE INTERSTIM SYSTEM FOR OVERACTIVE BLADDER</td>
<td>4:19 p.m.</td>
<td>Oral Poster 42 — THE IMPACT OF COMMON VAGINAL LUBRICANTS ON E. COLI</td>
</tr>
<tr>
<td>4:19 p.m.</td>
<td>Oral Poster 24 — THE PATIENT PERSPECTIVE ON PELVIC FLOOR DISORDERS SURGICAL ADVERSE EVENTS</td>
<td>4:19 p.m.</td>
<td>Oral Poster 33 — THE PURSUIT OF MOBILE APPLICATIONS FOR PATIENTS WITH PELVIC FLOOR DISORDERS</td>
<td>4:19 p.m.</td>
<td>Oral Poster 43 — RETHINKING THE URINARY CATHERETER: LESS TRAUMA THROUGH BETTER DESIGN — A SHEEP MODEL</td>
</tr>
<tr>
<td>4:19 p.m.</td>
<td>Oral Poster 25 — PREDICTORS OF SUCCESS AT 5 YEARS POST-IMPLANT OF THE INTERSTIM SYSTEM FOR OVERACTIVE BLADDER</td>
<td>4:19 p.m.</td>
<td>Oral Poster 34 — THE PURSUIT OF MOBILE APPLICATIONS FOR PATIENTS WITH PELVIC FLOOR DISORDERS</td>
<td>4:19 p.m.</td>
<td>Oral Poster 44 — THE IMPACT OF COMMON VAGINAL LUBRICANTS ON E. COLI</td>
</tr>
<tr>
<td>4:19 p.m.</td>
<td>Oral Poster 27 — PREDICTORS OF SUCCESS AT 5 YEARS POST-IMPLANT OF THE INTERSTIM SYSTEM FOR OVERACTIVE BLADDER</td>
<td>4:19 p.m.</td>
<td>Oral Poster 36 — THE PURSUIT OF MOBILE APPLICATIONS FOR PATIENTS WITH PELVIC FLOOR DISORDERS</td>
<td>4:19 p.m.</td>
<td>Oral Poster 46 — THE IMPACT OF COMMON VAGINAL LUBRICANTS ON E. COLI</td>
</tr>
<tr>
<td>4:19 p.m.</td>
<td>Oral Poster 29 — PREDICTORS OF SUCCESS AT 5 YEARS POST-IMPLANT OF THE INTERSTIM SYSTEM FOR OVERACTIVE BLADDER</td>
<td>4:19 p.m.</td>
<td>Oral Poster 38 — THE PURSUIT OF MOBILE APPLICATIONS FOR PATIENTS WITH PELVIC FLOOR DISORDERS</td>
<td>4:19 p.m.</td>
<td>Oral Poster 48 — THE IMPACT OF COMMON VAGINAL LUBRICANTS ON E. COLI</td>
</tr>
<tr>
<td>4:19 p.m.</td>
<td>Oral Poster 40 — PREDICTORS OF SUCCESS AT 5 YEARS POST-IMPLANT OF THE INTERSTIM SYSTEM FOR OVERACTIVE BLADDER</td>
<td>4:19 p.m.</td>
<td>Oral Poster 40 — THE PURSUIT OF MOBILE APPLICATIONS FOR PATIENTS WITH PELVIC FLOOR DISORDERS</td>
<td>4:19 p.m.</td>
<td>Oral Poster 50 — RETHINKING THE URINARY CATHERETER: LESS TRAUMA THROUGH BETTER DESIGN — A SHEEP MODEL</td>
</tr>
</tbody>
</table>

## CONCURRENT SCHEDULE AT-A-GLANCE
<table>
<thead>
<tr>
<th>Time</th>
<th>Oral Poster</th>
<th>Time</th>
<th>Oral Poster</th>
<th>Time</th>
<th>Oral Poster</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:19 p.m. – 4:23 p.m.</td>
<td>Oral Poster 23 — CORRELATION OF VIRTUAL REALITY SIMULATION AND DRY LAB ROBOTIC TECHNICAL SKILLS</td>
<td>4:19 p.m. – 4:23 p.m.</td>
<td>Oral Poster 32 — OPERATING ROOM EFFICIENCY: EXAMINING THE ROLE OF PERSONNEL HANDOFFS</td>
<td>4:19 p.m. – 4:23 p.m.</td>
<td>Oral Poster 42 — OVEREXPRESSION OF ORNITHINE DECARBOXYLASE (ODC) IN BLADDER UROTHELIUM RECAPITULATES OVERACTIVE BLADDER (OAB) PHENOTYPE</td>
</tr>
<tr>
<td>4:23 p.m. – 4:27 p.m.</td>
<td>Oral Poster 24 — DID THE 2015 NATIONAL HEALTH INSURER POLICY REQUIREING PRIOR AUTHORIZATION FOR NON-VAGINAL HYSTERECTOMY ROUTES INCREASE UTILIZATION OF VAGINAL HYSTERECTOMY?</td>
<td>4:23 p.m. – 4:27 p.m.</td>
<td>Oral Poster 33 — FACE: FEMALE PELVIC MEDICINE &amp; RECONSTRUCTIVE SURGERY AWARENESS CAMPAIGN: INCREASING EXPOSURE</td>
<td>4:23 p.m. – 4:27 p.m.</td>
<td>Oral Poster 43 — DETECTING UROPATHOGENS IN A UROGYNECOLOGIC POPULATION: A COMPARISON OF UTI DIAGNOSTIC THRESHOLDS</td>
</tr>
<tr>
<td>4:27 p.m. – 4:31 p.m.</td>
<td>Oral Poster 25 — DOES MESH WEIGHT AFFECT TIME TO FAILURE AFTER ROBOTIC-ASSISTED LAPAROSCOPIC SACROCLOPOPEXY?</td>
<td>4:27 p.m. – 4:31 p.m.</td>
<td>Oral Poster 34 — VARIATION IN PATIENT REFERRAL NETWORKS TO FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGEONS ACROSS THE UNITED STATES</td>
<td>4:27 p.m. – 4:31 p.m.</td>
<td>Oral Poster 44 — THE VAGINAL AND URINARY MICROBIOME IN PREMENOPAUSAL WOMEN WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME AS COMPARED TO NORMAL CONTROLS: A COHORT STUDY</td>
</tr>
<tr>
<td>4:31 p.m. – 4:35 p.m.</td>
<td>Questions for Oral Posters 22–25</td>
<td>4:31 p.m. – 4:35 p.m.</td>
<td>Questions for Oral Posters 31–34</td>
<td>4:31 p.m. – 4:35 p.m.</td>
<td>Questions for Oral Posters 41–44</td>
</tr>
<tr>
<td>4:35 p.m. – 4:39 p.m.</td>
<td>Oral Poster 26 — TOBACCO USE, PSYCHIATRIC, IMMUNOSUPPRESSIVE, AND CHRONIC PAIN CONDITIONS ARE PREVALENT IN WOMEN WITH SYMPTOMATIC MESH COMPLICATIONS UNDERGOING MESH REMOVAL SURGERY</td>
<td>4:35 p.m. – 4:39 p.m.</td>
<td>Oral Poster 35 — REFRACATORY PUDENDAL PAIN AND PELVIC FLOOR DYSFUNCTION CAUSED BY INTRAPELVIC NERVE ENTRAPMENT: A REVIEW OF 50 CONSECUTIVE CASES</td>
<td>4:35 p.m. – 4:39 p.m.</td>
<td>Oral Poster 45 — LACTOBACILLUS SPECIES INHIBIT GROWTH OF E. COLI</td>
</tr>
<tr>
<td>4:39 p.m. – 4:43 p.m.</td>
<td>Oral Poster 27 — PERIOPERATIVE OUTCOMES IN PATIENTS WITH HEREDITARY DISORDERS OF CONNECTIVE TISSUE: A RETROSPECTIVE COHORT STUDY</td>
<td>4:39 p.m. – 4:45 p.m.</td>
<td>Oral Poster 36 — PELVIC FLOOR AND OBURATOR INTERNUS MYOFASCIAL PAIN IS COMMON IN PATIENTS WITH PELVIC FLOOR SYMPTOMS</td>
<td>4:39 p.m. – 4:43 p.m.</td>
<td>Oral Poster 46 — CAN PHARMACOGENETICS BE USED TO PREDICT THE RESPONSE TO FESOTERODINE FUMARATE?</td>
</tr>
<tr>
<td>4:43 p.m. – 4:47 p.m.</td>
<td>Oral Poster 28 — PREDICTORS FOR LONG-TERM POSTOPERATIVE FOLLOW-UP IN A COHORT OF PELVIC ORGAN PROLAPSE PATIENTS</td>
<td>4:45 p.m. – 4:49 p.m.</td>
<td>Oral Poster 38 — COST-EFFECTIVENESS OF ROUTINE POSTOPERATIVE RETROGRADE VOIDING TRIALS FOLLOWING GYNECOLOGICAL PROCEDURES</td>
<td>4:43 p.m. – 4:47 p.m.</td>
<td>Oral Poster 47 — EFFECT OF ESTROGEN THERAPY ON THE PREMENOPAUSAL INFLAMMATORY BLADDER STATE</td>
</tr>
<tr>
<td>4:47 p.m. – 4:51 p.m.</td>
<td>Questions for Oral Posters 26–28</td>
<td>4:49 p.m. – 4:53 p.m.</td>
<td>Questions for Oral Posters 35–38</td>
<td>4:47 p.m. – 4:51 p.m.</td>
<td>Questions for Oral Posters 45–47</td>
</tr>
<tr>
<td>4:51 p.m. – 4:55 p.m.</td>
<td>Oral Poster 29 — IDENTIFYING PREDICTORS OF POSTDISCHARGE SURGICAL RECOVERY FOLLOWING LAPAROSCOPIC SACROCLOPOPEXY: A PROSPECTIVE LONGITUDINAL STUDY</td>
<td>4:53 p.m. – 4:57 p.m.</td>
<td>Oral Poster 39 — RANDOMIZED CONTROLLED TRIAL TO ASSESS THE IMPACT OF INTRAURETHRAL LIDOCAINE ON URODYNAMIC VOIDING PARAMETERS</td>
<td>4:51 p.m. – 4:55 p.m.</td>
<td>Oral Poster 48 — THE ROLE OF BACTERIAL VIRUSES IN THE FEMALE URINARY MICROBIOME</td>
</tr>
<tr>
<td>4:55 p.m. – 4:59 p.m.</td>
<td>Oral Poster 30 — EVALUATING THE IMPACT OF DAYS BETWEEN PROCEDURES ON CLINICAL OUTCOMES: DO SURGEONS GET RUSTY?</td>
<td>4:57 p.m. – 5:01 p.m.</td>
<td>Oral Poster 40 — PREOPERATIVE LABORATORY TESTING PRIOR TO UROGYNECOLOGIC SURGERY: A NECESSARY EVIL OR JUST UNNECESSARY?</td>
<td>4:55 p.m. – 4:59 p.m.</td>
<td>Oral Poster 49 — THE FEMALE GENITOURINARY MICROBIOTA: SHORT-TERM STABILITY, RESILIENCE AND PERI-URETHRAL RELATIONSHIPS</td>
</tr>
<tr>
<td>4:59 p.m. – 5:04 p.m.</td>
<td>Video 5 — AUTOLOGOUS FASCIA LATA SPINAL SLING ANAL SPHINCTEROPLASTY: SALVAGE REPAIR FOR FECAL INCONTINENCE</td>
<td>5:01 p.m. – 5:07 p.m.</td>
<td>Video 7 — RECTOVAGINAL FISTULA REPAIR USING A GRACILIS MUSCLE FLAP AND FULL THICKNESS SKIN GRAFT</td>
<td>4:59 p.m. – 5:07 p.m.</td>
<td>Video 8 — MANAGEMENT OF PRESACRAL BLEEDING</td>
</tr>
<tr>
<td>5:04 p.m. – 5:08 p.m.</td>
<td>Questions for Oral Posters 29–30</td>
<td>5:07 p.m. – 5:11 p.m.</td>
<td>Questions for Oral Posters 39–40</td>
<td>5:07 p.m. – 5:12 p.m.</td>
<td>Questions for Oral Posters 48–49</td>
</tr>
<tr>
<td>TIME</td>
<td>SCIENTIFIC CONCURRENT SESSION 7 — SURGERY/ANATOMY SESSION BALLROOM A</td>
<td>TIME</td>
<td>SCIENTIFIC CONCURRENT SESSION 8 — OFFICE-BASED THERAPY AND PATIENT COUNSELING SESSION BALLROOM B/C</td>
<td>TIME</td>
<td>SCIENTIFIC CONCURRENT SESSION 9 — POPULATION STUDIES SESSION BALLROOM D/E</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------------------------</td>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td>Oral Poster 50 — POSTERIOR VAGINAL WALL PROLAPSE ON MRI AND ASSOCIATION WITH DEFECATORY SYMPTOMS</td>
<td>2:45 p.m.</td>
<td>Oral Poster 63 — HOLDING IT TOGETHER: GROUP BEHAVIORAL INTERVENTION IMPROVES URINARY AND BOWEL SYMPTOMS IN OLDER WOMEN</td>
<td>2:45 p.m.</td>
<td>Oral Poster 76 — ASSOCIATION BETWEEN CO-MORBIDITIES AND FEMALE SEXUAL DYSFUNCTION: FINDINGS FROM THE THIRD NATIONAL SURVEY OF SEXUAL ATTITUDES AND LIFESTYLES (NATSAL-3)</td>
</tr>
<tr>
<td>2:49 p.m.</td>
<td>Oral Poster 51 — EFFECT OF MORBID OBESITY ON MID-URETHRAL SLING EFFICACY FOR THE MANAGEMENT OF STRESS URINARY INCONTINENCE</td>
<td>2:49 p.m.</td>
<td>Oral Poster 64 — UREAPLASMA UREALYTICUM AND PAINFUL LOWER URINARY TRACT SYMPTOMS</td>
<td>2:49 p.m.</td>
<td>Oral Poster 77 — MODERN PRACTICE PATTERNS IN WOMEN TREATED FOR NON-NEUROGENIC OVERACTIVE BLADDER: HOW QUICKLY DO PATIENTS PROGRESS TO THIRD-LINE THERAPY?</td>
</tr>
<tr>
<td>2:53 p.m.</td>
<td>Oral Poster 52 — PREOPERATIVE PELVIC FLOOR MUSCLE WEAKNESS AS A RISK FACTOR OF SURGICAL FAILURE OF ANTERIOR VAGINAL WALL PROLAPSE REPAIR</td>
<td>2:53 p.m.</td>
<td>Oral Poster 65 — EARLY AND CONSISTENT IMPROVEMENTS IN URINARY SYMPTOMS AND QUALITY OF LIFE OUTCOMES IN FEMALE OVERACTIVE BLADDER PATIENTS WITH URINARY INCONTINENCE TREATED WITH ONABOTULINUMTOXINA IN A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 4 TRIAL</td>
<td>2:53 p.m.</td>
<td>Oral Poster 78 — WEIGHT AND WEIGHT CHANGE IMPACT STRESS AND URGE URINARY INCONTINENCE SYMPTOMS IN POSTMENOPAUSAL WOMEN</td>
</tr>
<tr>
<td>2:57 p.m.</td>
<td>Oral Poster 53 — POSTERIOR COMPARTMENT SURGERY PROVIDES NO DIFFERENTIAL BENEFIT FOR DEFECATORY SYMPTOMS BEFORE OR AFTER CONCOMITANT MESH AUGMENTED APICAL SUSPENSION</td>
<td>2:57 p.m.</td>
<td>Oral Poster 66 — PRIMIPAROUS WOMEN’S EXPERIENCE AND UNDERSTANDING SURROUNDING OBSTETRIC PERINEAL TRAUMA: A QUALITATIVE STUDY</td>
<td>2:57 p.m.</td>
<td>Oral Poster 79 — PROPHYLACTIC ANTIBIOTICS AT THE TIME OF OBSTETRIC ANAL SPHINCTER INJURY REPAIR: ARE WE MEETING THE MARK?</td>
</tr>
<tr>
<td>3:01 p.m.</td>
<td>Oral Poster 54 — MECHANISM OF ACTION OF URETHRAL BULKING VERSUS MIDURETHRAL SLING MEASURED BY HIGH RESOLUTION MANOMETRY</td>
<td>3:01 p.m.</td>
<td>Oral Poster 67 — ARE WOMEN PREPARED FOR BIRTH? A STUDY OF HOW COUNSELING, PREPARATION AND INFORMED CONSENT AFFECT SATISFACTION AND REGRET AFTER DELIVERY</td>
<td>3:01 p.m.</td>
<td>Oral Poster 80 — STRESS URINARY INCONTINENCE SURGERY IN WASHINGTON STATE BEFORE AND AFTER INTRODUCTION OF THE MESH MIDURETHRAL SLING</td>
</tr>
<tr>
<td>3:05 p.m.</td>
<td>Questions for Oral Posters 50–54</td>
<td>3:05 p.m.</td>
<td>Questions for Oral Posters 63–67</td>
<td>3:05 p.m.</td>
<td>Questions for Oral Posters 76–80</td>
</tr>
<tr>
<td>3:13 p.m.</td>
<td>Oral Poster 56 — THE FAILURE RATE OF A SECONDARY PROCEDURE FOR RECURRENT STRESS URINARY INCONTINENCE FOLLOWING A FAILED MIDURETHRAL SLING IS NOT AFFECTED BY ALTERATION OF THE PRIMARY SLING</td>
<td>3:13 p.m.</td>
<td>Oral Poster 69 — TOILETING HABITS OF NURSES</td>
<td>3:13 p.m.</td>
<td>Oral Poster 82 — ONLINE PHYSICIAN RATINGS IN FEMALE PELVIC MEDICINE &amp; RECONSTRUCTIVE SURGERY: WHAT DO PATIENTS REALLY WANT?</td>
</tr>
<tr>
<td>3:17 p.m.</td>
<td>Oral Poster 57 — COST-EFFECTIVENESS ANALYSIS OF A PRE-OPERATIVE PELVIC MRI TO IDENTIFY PATIENTS AT HIGH RISK OF SURGICAL FAILURE</td>
<td>3:17 p.m.</td>
<td>Oral Poster 70 — A COST-EFFECTIVENESS ANALYSIS OF BOTOX BOTULINUM-A TOXIN AS FIRST-LINE TREATMENT FOR OVERACTIVE BLADDER</td>
<td>3:17 p.m.</td>
<td>Oral Poster 83 — URINARY INCONTINENCE REMISSION BY SUBTYPE AND RELATION TO INDICATORS OF SEVERITY</td>
</tr>
<tr>
<td>3:21 p.m.</td>
<td>Oral Poster 58 — ORAL POSTERS 50–54</td>
<td>3:21 p.m.</td>
<td>Oral Poster 71 — PELVIC ORGAN PROLAPSE AND URINARY INCONTINENCE AFTER BARIATRIC SURGERY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TIME</td>
<td>Scientific Concurrent Session 10 — Surgery Session BALLROOM A</td>
<td>TIME</td>
<td>Scientific Concurrent Session 11 — Hot Topics in Urogynecology II Session BALLROOM B/C</td>
<td>TIME</td>
<td>Scientific Concurrent Session 12 — Novel Technologies and Neuromodulation Session BALLROOM D/E</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------------------------------------------</td>
<td>-----------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>3:21 p.m. –</td>
<td>Oral Poster 58 — Impact of Morbid Obesity on Perioperative Outcomes in Women Undergoing Reconstructive Pelvic Organ Prolapse Surgery</td>
<td>3:21 p.m. –</td>
<td>Oral Poster 71 — Therapeutic Outcomes for Females and Males in the INSITE Study for Overactive Bladder</td>
<td>3:25 p.m. –</td>
<td>Oral Poster 85 — Patient Understanding: Health Literacy in Women with Pelvic Floor Disorders</td>
</tr>
<tr>
<td>3:29 p.m. –</td>
<td>Questions for Oral Posters 55–58</td>
<td>3:25 p.m. –</td>
<td>Questions for Oral Posters 68–71</td>
<td>3:29 p.m. –</td>
<td>Questions for Oral Posters 81–85</td>
</tr>
<tr>
<td>3:33 p.m. –</td>
<td>Oral Poster 60 — Does Surgical Correction of a Wide Pre-Operative Genital Hiatus Impact Anatomic Failure After Robotic-Assisted Laparoscopic Sacrocolpopexy?</td>
<td>3:29 p.m. –</td>
<td>Oral Poster 72 — A Pilot Study Evaluating a Non-Invasive Method to Characterize Bladder Geometry for Overactive Bladder</td>
<td>3:33 p.m. –</td>
<td>Oral Poster 86 — What the Internet Says About Vaginal Mesh: Sentiment Analysis of Websites Related to Graft Use in Pelvic Reconstructive Surgery</td>
</tr>
<tr>
<td>3:37 p.m. –</td>
<td>Oral Poster 61 — Reduction of Genital Hiatus Size Decreases Anatomic Failure After Native Tissue Vaginal Vault Suspension</td>
<td>3:33 p.m. –</td>
<td>Oral Poster 73 — Myofascial Pain in Patients with Symptoms of Urinary Tract Infection</td>
<td>3:37 p.m. –</td>
<td>Oral Poster 87 — Cost Impact of Elective Cesarean Delivery on Future Pelvic Floor Disorders</td>
</tr>
<tr>
<td>3:41 p.m. –</td>
<td>Oral Poster 62 — Levator Ani Subtended Volume in Patients with Mesh Augmentation and Surgical Failure</td>
<td>3:41 p.m. –</td>
<td>Oral Poster 74 — Fecal Incontinence Symptoms and Impact in Older Versus Younger Women Seeking Care</td>
<td>3:41 p.m. –</td>
<td>Oral Poster 88 — Bladder and Bowel Dysfunction in Patients with Spinal Stenosis</td>
</tr>
<tr>
<td>3:45 p.m. –</td>
<td>Video 12 — Retropubic Robotic Excision of Mesh for the Treatment of Midurethral Slings and Transvaginal Prolapse Mesh Erosion into the Bladder</td>
<td>3:45 p.m. –</td>
<td>Oral Poster 75 — Variation in Pessary Counseling Prior to Surgery for Pelvic Organ Prolapse</td>
<td>3:45 p.m. –</td>
<td>Video 13 — Minimally Invasive Cystoscopic Suture Excision</td>
</tr>
<tr>
<td>3:55 p.m. –</td>
<td>Questions for Oral Posters 60–62</td>
<td>3:50 p.m. –</td>
<td>Questions for Oral Posters 72–75</td>
<td>3:53 p.m. –</td>
<td>Questions for Oral Posters 86–88</td>
</tr>
</tbody>
</table>

**FRIDAY, OCTOBER 6 | 4:15 p.m. – 5:30 p.m.**

<table>
<thead>
<tr>
<th>TIME</th>
<th>Scientific Concurrent Session 11 — Hot Topics in Urogynecology II Session BALLROOM B/C</th>
<th>TIME</th>
<th>Scientific Concurrent Session 12 — Novel Technologies and Neuromodulation Session BALLROOM D/E</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:15 p.m. –</td>
<td>Oral Poster 89 — Enhanced Recovery Program for Outpatient Urogynecologic Surgery</td>
<td>4:15 p.m. –</td>
<td>Oral Poster 102 — Rate and Predictors of Urinary Incontinence at 12 Months Postpartum</td>
</tr>
<tr>
<td>4:19 p.m. –</td>
<td>Oral Poster 90 — Does Variation in Bony Landmarks Predict Success with Sacral Neuromodulation: One Size Fits All?</td>
<td>4:19 p.m. –</td>
<td>Oral Poster 103 — Early Post-Injection Urinary Tract Infection (UTI) Predicts Recurrent UTI After Onabotulinum Toxin A</td>
</tr>
<tr>
<td>4:23 p.m. –</td>
<td>Oral Poster 91 — Impact of Preemptive Analgesia on Postoperative Pain after Cystoscopy with Hydrodistention for Painful Bladder Syndrome/Interstitial Cystitis: A Pilot Study</td>
<td>4:23 p.m. –</td>
<td>Oral Poster 104 — Educational and Electronic Referral Interventions in Improving Incontinence Screening Among Primary Care Physicians</td>
</tr>
<tr>
<td>4:27 p.m. –</td>
<td>Oral Poster 92 — Do Spinals Increase Rates of Urinary Retention: A Randomized Controlled Trial</td>
<td>4:27 p.m. –</td>
<td>Oral Poster 105 — Fractional CO2 Laser of the Vagina for Genitourinary Syndrome of Menopause: Is the Out-of-Pocket Cost Worth the Outcome of Treatment</td>
</tr>
<tr>
<td>4:27 p.m. –</td>
<td>Oral Poster 115 — Patient-Important Critical Content and the Role of Peer Support for Women Undergoing Surgery for Pelvic Floor Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:31 p.m. –</td>
<td>Oral Poster 116 — Lower Urinary Tract Symptoms in a Chronic Pain Population</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:31 p.m. –</td>
<td>Oral Poster 117 — Can Women with Levator Ani Tear on MR Images Effectively Increase Urethral Closure Pressure During a Volutinal Pelvic Floor Muscle Contraction? A Focus on Postpartum Women at High Risk for Levator Ani Tear from Recent Vaginal Childbirth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:31 p.m. –</td>
<td>Oral Poster 118 — Transforming Community-Based Continence Promotion: The Bowel Movement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:31 p.m. – 4:35 p.m.</td>
<td>Oral Poster 93 — DOES PREOPERATIVE PELVIC PROLAPSE STAGE PREDICT RISK OF PERIOPERATIVE COMPLICATIONS DURING VAGINAL RECONSTRUCTIVE SURGERY?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:31 p.m. – 4:35 p.m.</td>
<td>Oral Poster 106 — RATES OF OBSTETRIC ANAL SPHINCTER INJURIES BEFORE AND AFTER TRAINING INVOLVING PERINEAL PROTECTION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:31 p.m. – 4:35 p.m.</td>
<td>Oral Poster 119 — ELECTRICAL STIMULATION OF AFFERENT NERVES IN THE FOOT WITH TRANSCUTANEOUS ADHESIVE PAD ELECTRODES IN WOMEN WITH OAB: COMPARISON OF DIFFERENT STIMULATION DURATIONS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:35 p.m. – 4:39 p.m.</td>
<td>Questions for Oral Posters 89–93</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:35 p.m. – 4:39 p.m.</td>
<td>Questions for Oral Posters 102–106</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:35 p.m. – 4:39 p.m.</td>
<td>Questions for Oral Posters 115–119</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:39 p.m. – 4:43 p.m.</td>
<td>Oral Poster 94 — DOES GABAPENTIN REDUCE OPIOID USE POSTOPERATIVELY? (“GROUP STUDY”): A RANDOMIZED CONTROLLED TRIAL IN WOMEN UNDERGOING RECONSTRUCTIVE PELVIC SURGERY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:39 p.m. – 4:43 p.m.</td>
<td>Oral Poster 107 — COMPARISON OF ANORECTAL MANOMETRY TESTING IN LEFT LATERAL AND DORSAL LITHOTOMY POSITIONS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:39 p.m. – 4:43 p.m.</td>
<td>Oral Poster 124 — PROSPECTIVE NON-COMPAREATIVE STUDY TO ASSESS THE EFFECTIVENESS OF A PIXEL CO2 LASER SYSTEM IN THE TREATMENT OF VULVOVAGINAL ATROPHY: INTERIM ANALYSIS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:43 p.m. – 4:47 p.m.</td>
<td>Oral Poster 95 — PRIMARY PELVIC ORGAN PROLAPSE SURGERY USING DELAYED ABSORBABLE SUTURE: ONE-YEAR OUTCOMES COMPARING ANTERIOR WALL SUCCESS IN VAGINAL UTEROSACRAL LIGAMENT SUSPENSION VERSUS SACRAL COLPOPEXY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:43 p.m. – 4:47 p.m.</td>
<td>Oral Poster 108 — CONNECTING THE DOTS: RELATIONSHIPS BETWEEN REVIEW OF SYSTEMS RESPONSES AND CHRONIC UROGYNECOLOGIC PAIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:43 p.m. – 4:47 p.m.</td>
<td>Oral Poster 121 — DENERVATION OF THE TRIGONE FOR TREATMENT OF URGENCY URINARY INCONTINENCE ASSOCIATED WITH OVERACTIVE BLADDER</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:47 p.m. – 4:51 p.m.</td>
<td>Oral Poster 96 — INDELWELLING VS IMMEDIATE REMOVAL OF FOYLE CATHETER AFTER ROBOTIC ASSISTED LAPAROSCOPIC SACROCOLPOPEXY: A RANDOMIZED PROSPECTIVE STUDY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:47 p.m. – 4:51 p.m.</td>
<td>Oral Poster 109 — EASY TO FIND BUT DIFFICULT TO UNDERSTAND? ANALYZING THE READABILITY OF ONLINE UROGYNECOLOGIC PATIENT INFORMATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:47 p.m. – 4:51 p.m.</td>
<td>Oral Poster 122 — ACCURACY OF REPORTING METHODS FOR PERIOPERATIVE COMPLICATIONS AFTER SUB-URETHRAL SLINGS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:51 p.m. – 4:55 p.m.</td>
<td>Oral Poster 97 — OUTCOMES OF RECURRENT RECTOVAGINAL FISTULA REPAIR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:51 p.m. – 4:55 p.m.</td>
<td>Oral Poster 110 — OPIOID REQUIREMENTS AFTER VAGINAL HYSTERECTOMY WITH MINIMALY INVASIVE SACROCOLPOPEXY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:51 p.m. – 4:55 p.m.</td>
<td>Oral Poster 123 — ANALYSIS OF DIFFERENT REFERENCE LINE BY USING DYNAMIC MAGNETIC RESONANCE IMAGING IN POSTERIOR VAGINAL WALL PROLAPSE AND A NOVEL PARAMETER: EXPOSED VAGINAL LENGTH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:55 p.m. – 4:59 p.m.</td>
<td>Oral Poster 98 — IS MESH EXPOSURE AFTER LAPAROSCOPIC SACROCOLPOPEXY A MYTH IN THE ERA OF THE LIGHT WEIGHT POLYPROPYLENE MESH?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:55 p.m. – 4:59 p.m.</td>
<td>Oral Poster 111 — URINARY SYMPTOMS AND THEIR EFFECT ON QUALITY OF LIFE IN WOMEN LIVING WITH HIV: A CROSS-SECTIONAL STUDY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:55 p.m. – 4:59 p.m.</td>
<td>Oral Poster 120 — BACLOFEN: A FORGOTTEN DRUG FOR VOIDING DYSFUNCTION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:59 p.m. – 5:03 p.m.</td>
<td>Questions for Oral Posters 94–98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:59 p.m. – 5:03 p.m.</td>
<td>Questions for Oral Posters 107–111</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:59 p.m. – 5:03 p.m.</td>
<td>Questions for Oral Posters 120–124</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:03 p.m. – 5:07 p.m.</td>
<td>Oral Poster 99 — PREDICTORS OF OPIOID ADMINISTRATION IN THE ACUTE POST OPERATIVE PERIOD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:03 p.m. – 5:07 p.m.</td>
<td>Oral Poster 112 — NORMAL POP-0 VALUES IN THE AVERAGE GYN POPULATION: REVISITING THE POSSP STUDY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:03 p.m. – 5:07 p.m.</td>
<td>Oral Poster 125 — DEVELOPMENT OF A NEUROSTIMULATOR IMPLANT TECHNIQUE FOR TIBIAL NERVE STIMULATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:07 p.m. – 5:11 p.m.</td>
<td>Oral Poster 100 — A NOVEL STRUCTURED FELLOW TRAINING PATHWAY FOR ROBOTIC-ASSISTED SACROCOLPOPEXY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:07 p.m. – 5:11 p.m.</td>
<td>Oral Poster 113 — RISK OF ACUTE CARDIAC MORBIDITY FOLLOWING SURGERY FOR PELVIC ORGAN PROLAPSE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:07 p.m. – 5:11 p.m.</td>
<td>Oral Poster 126 — VAGINAL SACRAL COLPOPEXY: A NATURAL ORIFICE APPROACH TO A GOLD STANDARD PROCEDURE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:11 p.m. – 5:15 p.m.</td>
<td>Oral Poster 101 — PERSISTENT STRESS URINARY INCONTINENCE AFTER SYMMETRICAL MIDURETHRAL SLING PROCEDURE: A SURGICAL SOLUTION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:11 p.m. – 5:15 p.m.</td>
<td>Oral Poster 114 — DOES A RECENT URINARY TRACT INFECTION (UTI) INCREASE THE RISK OF POST-INJECTION UTI AFTER ONABOTULINUM TOXIN A?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:11 p.m. – 5:15 p.m.</td>
<td>Oral Poster 127 — EVALUATION OF SER120 FOR THE TREATMENT OF PATIENTS WITH NOCTURIA DUE TO NOCTURNAL POLYURIA WITH CONCOMITANT OVERACTIVE BLADDER</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:15 p.m. – 5:23 p.m.</td>
<td>Video 14 — VESTIBULECTOMY TECHNIQUE FOR REFRACTORY VULVODYNIA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:15 p.m. – 5:22 p.m.</td>
<td>Video 15 — LOGDETHETOPULOS: CONTROL OF INTRAOPERATIVE HEMORRHAGE WITH PELVIC PRESSURE PACK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:15 p.m. – 5:25 p.m.</td>
<td>Video 16 — EXCISION OF VAGINAL MESH EXPOSURE IN THE BLADDER: A ROBOTIC APPROACH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:23 p.m. – 5:27 p.m.</td>
<td>Questions for Oral Posters 99–101</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:23 p.m. – 5:27 p.m.</td>
<td>Questions for Oral Posters 112–114</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:23 p.m. – 5:27 p.m.</td>
<td>Questions for Oral Posters 125–127</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SAVE THE DATE

PFD WEEK 2018

OCTOBER 9-13, 2018
HYATT REGENCY CHICAGO
CHICAGO, IL
# Pre-Conference Workshop Schedule

**Pre-Conference Workshops require separate registration and are an additional fee.**

## Tuesday, October 3

### 8:30 a.m. – 12:00 p.m.

**Evaluation and Treatment of Vesicovaginal and Rectovaginal Fistulas in Lower Resource Settings**

*Presented by the Global Health SIG*

**Room 550**

**Workshop Director:** Saifuddin T. Mama MD, MPH, FACOG, FACS, FPMRS, Cooper Medical School of Rowan University

**Continence Begins with Prevention: A New Paradigm Using a Transdisciplinary Science Approach**

*Room 555*

**Workshop Director:** Alayne D. Markland, DO, MSc, The University of Alabama at Birmingham

**Challenges in FPMRS Surgical Coding for 2017 and Beyond**

*Presented by the AUGS Coding Committee*

**Ballroom D**

**Workshop Director:** Marc Toglia, MD, Sidney Kimmel School of Medicine

**Quality Improvement Bootcamp**

**Room 552**

**Workshop Director:** Robert F. Flora, MD, MBA, MPH, McLaren Health Care

### 1:30 p.m. – 5:00 p.m.

**Building Academic Success in Urogynecology: Health Services Research and the Power of Big Data**

*This workshop is free for Fellows*

**Room 551**

**Workshop Director:** Donna Mazloomdoost, MD, Pelvic Floor Disorders Network (PFDN) Gynecologic Health and Disease Branch, Eunice Kennedy Shriver, National Institutes of Health

**Comprehensive Approach to Fistula Care**

*Presented by the Global Health SIG*

**Room 550**

**Workshop Director:** Rahel Nardos, MD, MCR, Oregon Health & Science University

**Coding Challenges and Opportunities for Office Based Activities and Procedures for the FPMRS Specialist**

*Presented by the AUGS Coding Committee*

**Ballroom D**

**Workshop Director:** Marc Toglia, MD, Sidney Kimmel School of Medicine

## Wednesday, October 4

### 8:30 a.m. – 12:00 p.m.

**Energy Based Therapies in Gynecology and Vaginal Health: Laser, Light, and Radio-Frequency Therapies**

**Ballroom D**

**Workshop Director:** Kevin Stepp, MD, Carolinas Healthcare System

**Neuropathology of Chronic Pelvic Pain Disorders**

**Room 551**

**Workshop Director:** Bruce S. Kahn, MD, FACOG, Uniformed Services University School of Medicine

**A Transdisciplinary Approach to Maternal Birth Trauma: A Day in the Life of a Perineal Clinic**

**Room 553**

**Workshop Director:** Christina Lewicky-Gaupp, MD, Northwestern University Feinberg School of Medicine

**Robotic and Straight Laparoscopic Sacrocolpopexy 2.0: How to Avoid and Get Out of Trouble**

**Room 552**

**Workshop Directors:** Patrick Culligan, MD, FACOG, FPMRS, Weill Cornell Department of Urology; Peter Rosenblatt, MD, FACOG, FPMRS, Mount Auburn Hospital

**Understanding Mindfulness: Fostering Resilience and Quality of Life in Ourselves and Our Patients**

**Room 550**

**Workshop Director:** David A. Richardson, MD, Henry Ford Health System
12:30 p.m. – 5:00 p.m.

MULTIDISCIPLINARY EVALUATION AND TREATMENT OF VULVAR DISORDERS
Presented by the Advanced Practice, Physical Therapy, and Allied Health SIG
Supported by Allergan
Balloon A
Workshop Director: Julie Starr, APRN, PhD, Missouri Center for Female Continence and Advanced Pelvic Surgery University of Missouri

1:00 p.m. – 4:30 p.m.

EFFECTIVE ACCOUNTABILITY CONVERSATIONS
Room 550
Workshop Director: Mikio A. Nihira, MD, MPH, University of California Riverside, Riverside Community Hospital

TRANSジェンダー SURGERY AND CARE: THE ROLE OF THE UROGYNECOLOGIST
Room 552
Workshop Director: Cecile A. Unger, MD, MPH, Center for Urogynecology & Pelvic Reconstructive Surgery, Center for LGBT Care Obstetrics, Gynecology & Women’s Health Institute, Cleveland Clinic

3:00 p.m. – 5:00 p.m.

BONUS SESSIONS
Bonus Sessions are complimentary.
Post or Perish | Room 553
Wednesday, October 4 | 3:00 p.m. – 3:45 p.m.
Speaker: Brian Jacob, MD, Icahn School of Medicine at Mount Sinai Laparoscopic Surgical Center of New York

Future of Medicine and Technology: The Art of the Possible | Room 553
Wednesday, October 4 | 4:00 p.m. – 4:45 p.m.
Speaker: Michael Ruiz, MedStar Health

3:00 p.m. – 5:00 p.m.

PERIODS ON THE QUALITY PAYMENT PROGRAM AND PERFORMANCE IMPROVEMENT IN UROGYN
Presented by the AUGS Quality Committee
Room 551
Workshop Director: Sarah Boyles, MD, MPH, The Oregon Clinic

AQUIRE is a Qualified Clinical Data Registry (QCDR). AQUIRE meets the reporting requirements for the CMS Merit-Based Incentive Payment System (MIPS).

Developed by urogynecologists for urogynecologists to measure and report healthcare quality patient outcomes:

- FREE Participation for AUGS Members
- Easy Web Data Entry
- Collect and Report on 20 FPMRS Quality Measures
- Fulfill MIPS Reporting Requirements
- Meet MOC Part IV Requirements
- Receive The Urogyn Quality Champion Designation

www.augs.org/clinical-practice/AQUIRE
### WEDNESDAY, OCTOBER 4

**Ballroom B**

Join fellows and faculty from the AUGS community for a full-day program geared toward fellows’ interests. There will be a panel discussion focused on how to find a job after fellowship, including experts from an academia, HMO setting, private practice model, and urology practice model, as well as an expert in contract negotiations.

We look forward to having you join us for this informative and interactive program. Residents are also welcomed to attend Fellows’ Day.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 a.m. – 8:00 a.m.</td>
<td>Breakfast and Welcome</td>
</tr>
<tr>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>Expert Panel Discussion of Job Mentoring</td>
</tr>
<tr>
<td></td>
<td>• Academic Practice – Lieschen Quiroz, MD</td>
</tr>
<tr>
<td></td>
<td>• HMO Practice – Emily Whitcomb, MD</td>
</tr>
<tr>
<td></td>
<td>• Private Practice – Mike Moen, MD</td>
</tr>
<tr>
<td></td>
<td>• Urology Practice – Quinn Lippmann, MD</td>
</tr>
<tr>
<td></td>
<td>• Contract Lawyer</td>
</tr>
<tr>
<td>9:00 a.m. – 9:15 a.m.</td>
<td>Q&amp;A for Panel</td>
</tr>
<tr>
<td>9:15 a.m. – 9:30 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td>9:30 a.m. – 10:45 a.m.</td>
<td>Fellows Abstract Presentations</td>
</tr>
<tr>
<td></td>
<td>Moderators: Taylor Brueseke, MD; Robert F. Flora, MD, MBA, MPH; Marc Toglia, MD</td>
</tr>
<tr>
<td>10:45 a.m. – 11:15 a.m.</td>
<td>Stump the Professor</td>
</tr>
<tr>
<td></td>
<td>Catherine Matthews, MD; Anthony Visco, MD</td>
</tr>
<tr>
<td>11:15 a.m. – 11:30 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>Roundtable Discussions (select one)</td>
</tr>
<tr>
<td></td>
<td>• How to Teach and Lead in the Operating Room – Mikio Nihira, MD</td>
</tr>
<tr>
<td></td>
<td>• Coding/Billing – Marc Toglia, MD</td>
</tr>
<tr>
<td></td>
<td>• Successful Manuscript Submission – Jennifer Wu, MD, MD</td>
</tr>
<tr>
<td></td>
<td>• Global Health Opportunities in FPMRS – Joan Blomquist, MD; Grace Chen, MD</td>
</tr>
<tr>
<td></td>
<td>• QI Project Ideas – Robert F. Flora, MD, MBA, MPH</td>
</tr>
<tr>
<td>12:30 p.m. – 12:45 p.m.</td>
<td>Break</td>
</tr>
<tr>
<td>12:45 p.m. – 1:45 p.m.</td>
<td>Connecting with OAB Patients-Guide for Productive Communication and Gaining Third-Line Treatment Acceptance</td>
</tr>
<tr>
<td></td>
<td>Supported by Allergan</td>
</tr>
<tr>
<td>1:45 p.m. – 2:00 p.m.</td>
<td>AUGS Spotlight</td>
</tr>
<tr>
<td></td>
<td>Meet the President – Halina M. Zyczynski, MD</td>
</tr>
<tr>
<td>2:30 p.m. – 5:00 p.m.</td>
<td>AUGS-SGS Fellows’ Pelvic Research Network (FPRN®) Meeting</td>
</tr>
</tbody>
</table>
### MEET THE EXPERTS EDUCATIONAL ROUNDTABLES

Roundtables have limited availability; pre-registration is required for an additional fee. All roundtables are taking place in the Rotunda (Convention Center).

#### THURSDAY, OCTOBER 5

6:45 a.m. – 7:45 a.m.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Using Acupuncture for Pelvic Floor Issues: Fact or Fiction?</td>
<td>Ilana Addis, MD</td>
</tr>
<tr>
<td>Surgical Anatomy of Vaginal Hysterectomy: Make Your Own Model</td>
<td>Mallika Anand, MD, MS, FACOG</td>
</tr>
<tr>
<td>Sustainable Global Health Programs</td>
<td>Joan Blomquist, MD; Rahel Nardos, MD</td>
</tr>
<tr>
<td>Best Practice in Your Busy Practices</td>
<td>Cassandra Carberry, MD, MS</td>
</tr>
<tr>
<td>Teaching Surgical Skills to Millennials and Digitals</td>
<td>Robert F. Flora, MD, MBA, MPH</td>
</tr>
<tr>
<td>The Gynecologist’s Role in Identifying and Responding to Human Trafficking</td>
<td>Julia Geynisman-Tan, MD</td>
</tr>
<tr>
<td>The Role of 2D Dynamic and 3D Multicompartment Sonographic Imaging</td>
<td>Aparna Hegde, MD</td>
</tr>
<tr>
<td>How to be an Effective Witness in a Deposition</td>
<td>Michael Karram, MD</td>
</tr>
<tr>
<td>Sling Revision: When, Why, and How</td>
<td>Mary Grey Maher, MD, FPMRS</td>
</tr>
<tr>
<td>Research in Action: Beyond Retrospective Chart Reviews</td>
<td>Jameca R. Price, MD, MPH, MCR</td>
</tr>
<tr>
<td>Implementing Enhanced Recovery Programs in Your Clinical Practice</td>
<td>Elisa Rodriguez Trowbridge, MD, FACOG</td>
</tr>
<tr>
<td>Neurourology for the Urogynecologist</td>
<td>Michael J. Kennelly, MD, FACS, FPMRS</td>
</tr>
<tr>
<td>Sex and Chronic Pelvic Pain</td>
<td>Kristene E. Whitmore, MD</td>
</tr>
</tbody>
</table>

#### FRIDAY, OCTOBER 6

6:45 a.m. – 7:45 a.m.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complications After Apical Vaginal Prolapse Surgeries</td>
<td>Samuel S. Badalian, MD, PhD</td>
</tr>
<tr>
<td>Stem Cell and Tissue Engineering Applications in FPMRS</td>
<td>Jeffrey L. Cornella, MD</td>
</tr>
<tr>
<td>Building a Successful Interstim Program</td>
<td>James A. Daucher, MD, MS</td>
</tr>
<tr>
<td>To Poop or Not to Poop</td>
<td>Angel Marie Johnson, MD</td>
</tr>
<tr>
<td>Embryology, Diagnosis, and Treatment of Congenital Anomalies</td>
<td>Saimuddin T. Mama MD, MPH, FACOG, FACS, FPMRS</td>
</tr>
<tr>
<td>The Nighttime Battle Between the Bedroom and Bathroom</td>
<td>Deborah L. Myers, MD</td>
</tr>
<tr>
<td>Actively Managing Academic Mentorship Relationships</td>
<td>Vivian Sung, MD, MPH</td>
</tr>
<tr>
<td>Use of Near Infrared Imaging in Complex Robotic Surgery</td>
<td>Lioudmila Lipetskaia, MD</td>
</tr>
<tr>
<td>Essential Gynecology for the Female Pelvic Medicine Specialist</td>
<td>Christopher Tarnay, MD</td>
</tr>
<tr>
<td>Botulinum Toxin: Practical Applications in Urogynecology</td>
<td>Michael J. Kennelly, MD, FACS, FPMRS</td>
</tr>
<tr>
<td>How to be a Successfully Employed FPMRS Subspecialist</td>
<td>Folusho Stephen Tugbiyele, MD</td>
</tr>
<tr>
<td>Tips and Tricks on the Difficult Vaginal Hysterectomy</td>
<td>Michael Karram, MD</td>
</tr>
</tbody>
</table>
GENERAL SCIENTIFIC SESSIONS

Sling Selections and What to do When They Fail!

Thursday, October 5
1:30 p.m. – 2:00 p.m.

Exhibition Hall C

Moderator: Lynsey Hayward, MD
Speakers: Matthew Barber, MD, MHS; Holly Richter, MD, PhD

This discussion will provide an evidence-based approach to the surgical management of stress urinary incontinence (SUI). Full length midurethral slings are placed via a retropubic or transobturator approach and data exists which may guide an individualized approach. Midurethral slings are the current gold-standard treatment for primary surgical management and have been used for over 20 years. It is also reasonable to consider that there may be some women who develop recurrent SUI.

Mesh Removal Debate

Friday, October 6
8:15 a.m. – 8:45 a.m.

Exhibition Hall C

Moderator: Christopher Tarnay, MD
Speakers: Roger Dmochowski, MD; Miles Murphy, MD, MSPH

The debate regarding optimal management of a patient who has mesh placed and subsequent functional and/or consequences and complications is ongoing. The complexity of functional outcomes related to pelvic floor interventions clearly makes management of mesh complications a multi-factorial undertaking inclusive of optimization of medical, surgical, and social circumstances to benefit the patient. Topics will include the participants’ views on what symptoms are attributed directly to mesh, how much needs to be removed, and the impact of mesh removal on future pelvic floor function.

Prevention of Urinary Incontinence: A Behavioral and Basic Science Perspective

Friday, October 6
10:50 a.m. – 11:35 a.m.

Exhibition Hall C

Moderator: Una Lee, MD
Panelists: Catherine Bradley, MD, MSCE; Marianna Alperin, MD, MS; Gina Northington, MD, MPH

Join us for a scientific discussion on what we know, what we don’t know, and where we are going in the prevention of urinary incontinence. We will review the literature on the pathophysiology of both urgency incontinence and stress urinary incontinence. It is only through a deeper understanding of the potential mechanisms, that we can identify pathways to prevent and treat incontinence now and in the future. This session will spark your clinical understanding and ultimately lead to improved patient care and counseling.

Insights on How to Navigate Product Controversy

Saturday, October 7
9:30 a.m. – 10:30 a.m.

Exhibition Hall C

Moderator: Cheryl Iglesia, MD
Speakers: Julie Cantor MD, JD; Patrick Culligan, MD; Alan Garely, MD

Product controversies are one of the largest mass torts in history, and it has caught the attention of our specialty. This session will provide an overview and update on the mesh product litigation. We will also review the litigation’s timeline, explain multidistrict litigation (MDL), and review key legal issues in the product liability field. The session will also include a discussion with two physicians who have served as experts in this litigation. They will share their perspectives and answer audience questions. The session will also cover the potential impact this MDL may have on our specialty.
Clinical Seminar: Abnormal Uterine Bleeding: Wading Through the Evidence on Evaluation and Treatment Effectiveness
Thursday, October 5
11:00 a.m. – 12:00 p.m.
Room 551
Speaker: Kristen A. Matteson, MD, MPH

Abnormal uterine bleeding (AUB) affects up to 30 percent of women during their reproductive lives and has a major impact on the quality of life of suffering women. While hysterectomy is the definitive treatment for AUB, a multitude of alternative less invasive medical and surgical treatments are available, making selecting the best treatment for the individual patient challenging. This clinical seminar will cover the burden of AUB on women and the healthcare system; the use of FIGO classification system for symptoms and etiologies associated with AUB in order to standardize publications and documentation; and the evidence of effectiveness of treatments for AUB (combined oral contraceptives, progestin, NSAIDs, antifibrinolytics, the levonorgestrel intrauterine system, and endometrial ablation).

Learning Objectives:
• Critically evaluate medical and surgical therapies for AUB not caused by structural abnormalities or systemic diseases
• Develop strategies for choosing the best treatment for patients in his/her practice

Surgical Tutorial: Laparoscopic and Robotic Sacrocolpopexy Pearls
Thursday, October 5
4:15 p.m. – 5:15 p.m.
Room 551
Speaker: Elizabeth Geller, MD; Andrew Sokol, MD

This surgical tutorial will outline strategies to maximize efficiency during both laparoscopic and robotic sacral colpopexy. Tips and tricks will be reviewed for patient positioning and docking, optimizing exposure, dissection, and graft fixation.

Learning Objectives:
• Describe optimal patient positioning and docking
• Discuss time-saving strategies for exposing the vesicovaginal, rectovaginal, and pre-sacral spaces
• Employ different techniques for mesh fixation to the vagina during laparoscopic and robotic sacral colpopexy
• Describe techniques for the efficient use of these minimally invasive techniques for sacralcolpopexy

What Are Urogynecologists Going to Get Paid and How?
Saturday, October 7
12:30 p.m. – 1:30 p.m.
Exhibition Hall C
Panelists: Jonathan Gleason, MD; Mitchell Schuster, MD; Samantha Pulliam, MD

This timely session will raise awareness about our professions revenue problem, value transformation, and its implications. Reimbursements are down with no indication of a bounce back. This session will inform you about how value transformation will impact FPMRS, your practice, and how we treat patients with pelvic floor disorders.

SPECIAL SESSIONS

Master Surgeon Presentations
Saturday, October 7
10:45 a.m. – 11:30 a.m.

Exhibition Hall C
Get a first-hand look at real-world surgeries on Saturday morning. This session will showcase Laparoscopic Nerve Sparing Surgery and Laparoscopic Hysteropexy and provide an overview of how to control massive blood loss while in the operating room.

LAPAROSCOPIC NERVE SPARING SURGERY
Moderator: Marlene Corton, MD
Surgeon: Nucelio Lemos, MD, PhD

LAPAROSCOPIC HYSTEROPEXY SURGERY
Moderator: Felicia Lane, MD
Surgeon: Beri Ridgeway, MD
KEYNOTE PRESENTATIONS

RAYMOND A. LEE LECTURE
Thursday, October 5
2:00 p.m. – 2:30 p.m.
Exhibition Hall C

The Raymond A. Lee Endowment is a named lectureship created by AUGS to honor one person annually who contributed to the development and surgical advancement of urogynecology and to further advance the knowledge and teaching of gynecologic surgery through ongoing AUGS educational programs.

Life-long Learning, Loving What You Do, and Paying it Forward
Presented by Marie Fidela Rustia Paraiso, MD

This lectureship will detail Dr. Paraiso’s 20-year journey from striving for work-life balance to achieving personal and professional satisfaction. She will discuss the importance of teamwork, mentorship, self-assessment and reflection, and lifelong learning.

Dr. Marie Fidela Paraiso is Professor of Surgery at Cleveland Clinic Lerner College of Medicine, Section Head of Urogynecology at the Cleveland Clinic in Cleveland, OH. She is a graduate of the University of Notre Dame and Indiana University School of Medicine. She completed her OB/GYN residency at Good Samaritan Hospital in Cincinnati and her fellowship in Advanced Pelvic Surgery and Minimally Invasive Gynecology at the Cleveland Clinic. She is Board Certified in OB/GYN and Female Pelvic Medicine and Reconstructive Surgery. She was Section Head for Urogynecology and Reconstructive Pelvic Surgery at the University of Missouri, Kansas City prior to returning to Cleveland Clinic in 1998, where she currently works. She has completed three executive courses in leadership: Leadership in Healthcare, Leadership in Surgery, and Fast Track Leadership.

Nationally, Dr. Paraiso served twice on the Board of Directors for the American Urogynecologic Society (AUGS) 2000-2003 and 2007-2010, and on the Board Trustees for the American Association of Gynecologic Laparoscopists from 2012-2014. She is currently Secretary Treasurer of AAGL and will serve as President in 2019. Dr. Paraiso has lectured throughout North America, Europe, the Middle East, Asia, Central and South America, and Australia. She has published over 135 manuscripts, 20 book chapters, and a 2014 textbook for Office Gynecology.

J. MARION SIMS LECTURE
Friday, October 6
10:15 a.m. – 10:50 a.m.
Exhibition Hall C

The J. Marion Sims Lecture is presented annually at PFD Week to continue to educate today’s gynecological surgeon about the importance of supporting and encouraging innovation within women’s health.

Generous support for the J. Marion Sims Lecture is provided by ABOG.

Vesico-Vaginal Fistula: Historical Understanding, Medical Ethics, and Modern Sensibilities
Presented by L. Lewis Wall, MD, DPhil

The 2017 J. Marion Sims Lecture will be delivered by Dr. L. Lewis Wall, Selina Okin Kim Conner Professor in Arts and Sciences at Washington University in St. Louis. The lecture will address the contributions to fistula surgery made by Dr. Sims in the 19th Century and the controversies that have arisen concerning his operations in the last several decades.

L. Lewis Wall received his medical degree from the University of Kansas School of Medicine and completed his residency training in obstetrics and gynecology at Duke University Medical Center. Dr. Wall did sub-specialty fellowship training in female urology and urodynamics at the University of London (St. George’s Hospital) and St. Mary’s Hospital for Women and Children in Manchester, England.

He is board-certified in both general obstetrics and gynecology and in the sub-specialty of female pelvic medicine and reconstructive surgery. In addition to his clinical qualifications, he has a master’s degree in bioethics from the Center for Human Bioethics at Monash University in Australia.

Dr. Wall has a longstanding interest in the health problems of women in Africa. He founded the Worldwide Fistula Fund in 1995, a not-for-profit public charity dedicated to providing care for women who have developed obstetric fistulas from prolonged obstructed labor.
INDUSTRY SUPPORTED EDUCATION

Wednesday, October 4

11:45 a.m. – 1:15 p.m.
THE FUTURE OF TREATING MODERATE TO SEVERE DYSPAREUNIA: A NEW, LOCALLY ADMINISTERED TREATMENT FOR MODERATE TO SEVERE DYSPAREUNIA DUE TO MENOPAUSE.
Rotunda
Supported by AMAG

12:00 p.m. – 1:30 p.m.
CONNECTING WITH OAB PATIENTS-GUIDE FOR PRODUCTIVE COMMUNICATION AND GAINING THIRD-LINE TREATMENT ACCEPTANCE
Ballroom A
Supported by Allergan
Faculty: Karyn Eilber, MD, Cedars-Sinai Medical Center, Beverly Hills, CA
*Available to registrants of Multidisciplinary Evaluation and Treatment of Vulvar Disorders workshop only

12:45 p.m. – 1:45 p.m.
CONNECTING WITH OAB PATIENTS-GUIDE FOR PRODUCTIVE COMMUNICATION AND GAINING THIRD-LINE TREATMENT ACCEPTANCE
Ballroom B
Supported by Allergan
Faculty: Michael Kennelly, MD, Charlotte Continence Center, Charlotte, NC
*Available to registrants of Fellows Day only

Thursday, October 5

6:30 a.m. – 7:30 a.m.
THE USE OF MULTIMODAL ANALGESIA TO REDUCE OPIOID USE IN UROGYNECOLOGICAL PROCEDURES
Room 552
Supported by Pacira
Faculty: Javier D. Lasala, MD; Catrina Crisp, MD

Friday, October 6

1:00 p.m. – 2:30 p.m.
IMPROVING YOUR EFFICIENCY: NEW DIGITAL RESOURCES TO ADDRESS PHYSICIAN NEEDS
Room 555
Supported by Boston Scientific
Faculty: Peter Rosenblatt MD, FACOG, FPMRS, Mount Auburn Hospital

1:00 p.m. – 2:30 p.m.
LASER APPLICATIONS IN VAGINAL HEALTH SPECIFICALLY RELATED TO GSM, SUI, AND ATROPHY
Room 555
Supported by Alma Lasers
Faculty: G. Willy Davila, MD, Chairman, Department of Gynecology, Head of the Section of Urogynecology and Reconstructive Pelvic Surgery, Cleveland Clinic Florida; Yona Tadir, MD, Professor, Obstetrics and Gynecology, Beckman Laser Institute and Medical Clinic, University of California Irvine; Yair Leopold, VP of Alma Lasers Surgical

1:00 p.m. – 2:30 p.m.
SINGLE-INCISION SLINGS: DATA, BARRIERS, AND THE PATIENT EXPERIENCE
Room 552
Supported by Coloplast
Faculty: Mickey Karram, M.D. (Cincinnati, Ohio), Prof. Jan-Paul Roovers, MD (Amsterdam, The Netherlands)
TUESDAY, OCTOBER 3

8:30 a.m. – 12:00 p.m.
PRE-CONFERENCE WORKSHOPS
See page 20 for details

1:30 p.m. – 5:00 p.m.
PRE-CONFERENCE WORKSHOPS
See page 20 for details

WEDNESDAY, OCTOBER 4

7:45 a.m. – 5:00 p.m.
FELLOWS’ DAY — BALLROOM B
See page 22 for details

8:00 a.m. – 4:00 p.m.
FELLOWSHIP PROGRAM DIRECTORS’ WORKSHOP — ROOM 555

8:30 a.m. – 12:00 p.m.
PRE-CONFERENCE WORKSHOPS
See page 20 for details

11:45 a.m. – 1:15 p.m.
INDUSTRY-SUPPORTED EDUCATION — THE FUTURE OF TREATING MODERATE TO SEVERE DYSpareunia: A NEW, LOCALLy ADMINISTERED TREATMENT FOR MODERATE TO SEVERE DYSpareunia DUE TO MENOPAUSE — ROTUNDA
Supported by AMAG

1:00 p.m. – 5:00 p.m.
PRE-CONFERENCE WORKSHOPS
See page 20 for details

3:00 p.m. – 3:45 p.m.
POST OR PERISH — ROOM 553
Brian Jacob, MD, Icahn School of Medicine at Mount Sinai Laparoscopic Surgical Center of New York

4:00 p.m. – 4:45 p.m.
FUTURE OF MEDICINE AND TECHNOLOGY: THE ART OF THE POSSIBLE — ROOM 553
Michael Ruiz, MedStar Health

4:30 p.m. – 6:00 p.m.
ADVANCED PRACTICE, PHYSICAL THERAPY, AND ALLIED HEALTH (APPTAH) SIG BUSINESS MEETING — ROOM 553
GLOBAL HEALTH SIG BUSINESS MEETING — SOUTH COUNTY (OMNI HOTEL)
MESH/GRAFT USE IN PELVIC RECONSTRUCTIVE SURGERY SIG BUSINESS MEETING — ROTUNDA (CONVENTION CENTER)

THURSDAY, OCTOBER 5

6:30 a.m. – 7:30 a.m.
INDUSTRY-SUPPORTED EDUCATION — THE USE OF MULTIMODAL ANALGESIA TO REDUCE OPIOID USE IN UROGYNECOLOGICAL PROCEDURES — ROOM 552
Supported by Pacira

6:45 a.m. – 7:45 a.m.
MEET THE EXPERTS EDUCATIONAL ROUNDTABLES — ROTUNDA
See page 23 for details

6:45 a.m. – 7:45 a.m.
ELECTRONIC MEDICAL RECORDS (EMR) SIG BUSINESS MEETING — ROOM 551
See page 8 for details

8:15 a.m. – 8:27 a.m.
Paper 1 — CHANGES OVER TIME IN ANTERIOR AND POSTERIOR VAGINAL SUPPORT AFTER CESAREAN Versus VAGINAL BIRTH
V. L. Handa1, J. L. Blomquist2, A. Munoz3,
1Johns Hopkins, Baltimore, MD; 2Greater Baltimore Medical Center, Baltimore, MD; 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

8:27 a.m. – 8:37 a.m.
Paper 2 — CONTROLLING ANAL INCONTINENCE IN WOMEN BY PERFORMING ANAL EXERCISES WITH MANOMETRIC-ASSISTED BIOFEEDBACK OR LOPERAMIDE: THE CAPABLE TRIAL
1Obstetrics, Gynecology & Women’s Health Institute, Cleveland Clinic, Cleveland, OH; 2Medicine, University of Alabama at Birmingham, Birmingham, AL; 3OBGYN and Medicine, University of North Carolina, Chapel Hill, NC; 4Urology, University of Pennsylvania, Philadelphia, PA; 5OBGYN, University of New Mexico, Albuquerque, NM; 6Permanente, Kaiser, San Diego, CA; 7OBGYN, Duke University, Durham, NC; 8OBGYN, Brown University, Providence, RI; 9RTI International, Research Triangle Park, NC; 10Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh Medical Center, Pittsburgh, PA; 11Department of Internal Medicine, University of Texas at Houston, Houston, TX

8:37 a.m. – 8:47 a.m.
Paper 3 — DIFFERENTIAL IMPACT OF FECAL INCONTINENCE SUBTYPES ON TREATMENT EFFICACY IN WOMEN USING THE VAGINAL BOWEL CONTROL SYSTEM
1Obstetrics and Gynecology, University of Alabama at Birmingham,
9:15 a.m. – 10:30 a.m.

**PAPER SESSION**

**SCIENTIFIC CONCURRENT SESSION 1:**

11:00 a.m. – 11:45 a.m.

**SCIENTIFIC CONCURRENT SESSION 2:**

11:45 a.m. – 12:30 a.m.

**BREAK IN THE EXHIBIT HALL**

12:30 p.m. – 1:45 p.m.

**LUNCHEON**

1:45 p.m. – 2:45 p.m.

**SPLASH**

2:45 p.m. – 3:00 p.m.

**BREAK IN THE EXHIBIT HALL**

3:00 p.m. – 4:15 p.m.

**SESSIONS**

4:15 p.m. – 5:30 p.m.

5:30 p.m. – 6:30 p.m.

**PRESIDENTIAL ADDRESS**

6:30 p.m. – 7:00 p.m.

**PRESIDENTIAL BREAKFAST**

7:00 a.m. – 8:30 a.m.
SCIENTIFIC PROGRAM (CONTINUED)

THURSDAY, OCTOBER 5 (Continued)

11:24 a.m. – 11:28 a.m.
Oral Poster 6 – ENHANCED RECOVERY AFTER UROGYNECOLOGIC SURGERY: A SURVEY OF PATIENT EXPERIENCE
M. F. Schmidt1, S. Evans1, S. Podwika2, A. T. Knisely3, B. Sarosiek4, L. L. Hullfish5, E. Trowbridge1. 1OB/GYN, University of Virginia, Charlottesville, VA; 2OB/GYN and Urology, University of Virginia, Charlottesville, VA

11:28 a.m. – 11:34 a.m.
Video 2 – PERSISTENT VAGINAL LEAKAGE IN THE SETTING OF AN APICAL VAGINAL SINUS TRACT
D. Bastawros, M. Kennelly, K. Stepp. Carolinas Health Care System, Charlotte, NC

11:34 a.m. – 11:40 a.m.
QUESTIONS FOR ORAL POSTERS 5–6

11:00 a.m. – 11:45 a.m.
SCIENTIFIC CONCURRENT SESSION 2: QUALITY OF LIFE/HEALTH SERVICES RESEARCH SESSION – BALLROOM B/C
Moderators: Jeannine Miranne, MD; Mikio Nihira, MD

11:00 a.m. – 11:04 a.m.
Oral Poster 7 – RECOVERING SEXUAL SATISFACTION AFTER PROLAPSE SURGERY

11:04 a.m. – 11:08 a.m.
Oral Poster 8 – THE PURSUIT OF MOBILE APPLICATIONS FOR PATIENTS WITH PELVIC FLOOR DISORDERS
N. T. Sudol1, E. Adams-Piper1, R. Perry2, K. T. Chen2, L. Lane1. 1FPMRS, UC Irvine, Orange, CA; 2OBGYN, UC Irvine, Orange, CA; 3ICahn School of Medicine at Mount Sinai, New York, NY

11:08 a.m. – 11:12 a.m.
Oral Poster 9 – INCONTINENCE & INTIMATE PARTNERS CLINICAL TRIAL: THE SEXUAL BENEFIT OF SUCCESSFUL TREATMENT (IMPACT)
J. Cunkelman4, T. Dune2, C. J. Joyce3, M. Tulke4, N. El-Kouri5, L. Brubaker1. 1OB/GYN, University of Virginia, Charlottesville, VA; 2Urology, Weill Cornell Medicine, New York, NY; 3Department of Public Health Sciences, Loyola University Chicago, Maywood, IL; 4US Federal Drug Administration, Silver Springs, MD

11:12 a.m. – 11:16 a.m.
Oral Poster 10 – TOPICAL LIDOCAINE FOR URODYNAMIC TESTING: A DOUBLE BLINDED RANDOMIZED CONTROL TRIAL

11:16 a.m. – 11:20 a.m.
QUESTIONS FOR ORAL POSTERS 7–10

11:20 a.m. – 11:24 a.m.
Oral Poster 11 – LONG TERM SEXUAL FUNCTION AFTER OBSTETRIC ANAL SPHINCTER INJURIES
M. O’Shea2, C. Lewicky-Gaupp1, D. R. Gossett1. 1Obstetrics & Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL; 2Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL

11:24 a.m. – 11:28 a.m.
Oral Poster 12 – ACCIDENTAL BOWEL LEAKAGE EVALUATION (ABLE): A NEW PATIENT-CENTERED VALIDATED MEASURE OF ACCIDENTAL BOWEL LEAKAGE SYMPTOMS
R. G. Rogers1, C. Bann2, V. W. Sung3, E. S. Lukacz4, L. A. Arya5, M. D. Barber6, A. D. Markland7, P. Fairchild8, N. Y. Siddiqui9. 1Department of Women’s Health, University of Texas Austin Dell Medical School, Austin, TX; 2RTI International, Research Triangle Park, NC; 3Department of Obstetrics and Gynecology, Brown/ Women and Infants Hospital of Rhode Island, Providence, RI; 4Obstetrics and Gynecology, UC San Diego, La Jolla, CA; 5Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, PA; 6Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA; 7Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH; 8University of Alabama at Birmingham, Birmingham, AL; 9Obstetrics and Gynecology, Duke University, Durham, NC

SCIENTIFIC PROGRAM (CONTINUED)
11:28 a.m. – 11:35 a.m.
Video 3 – SACROCLOPOPEXY MODIFICATION IN THE SETTING OF A PELVIC KIDNEY
E. R. Davidson, J. Ashburn, M. Paraiso.
Cleveland Clinic, Cleveland, OH

11:35 a.m. – 11:40 a.m.
QUESTIONS FOR ORAL POSTERS 11–12

11:40 a.m. – 11:45 a.m.

SCIENTIFIC CONCURRENT SESSION 3: BASIC SCIENCE SESSION – BALLROOM D/E

Moderators: Toby Chai, MD; JP Roovers, MD

11:00 a.m. – 11:04 a.m.
Oral Poster 13 – BIG POTASSIUM (BK) CHANNEL REGULATES IN VIVO URETHRAL CYTOKINE RELEASE INDUCED BY LIPOLYSACCHARIDE: NEW INSIGHT INTO URETHRAL INNATE IMMUNE RESPONSE IN PATHOGENESIS OF URINARY TRACT INFECTION
J. Y. Yeh, L. Alvarez-Lugo, M. Lu, T. C. Chai. Yale School of Medicine, New Haven, CT

11:04 a.m. – 11:08 a.m.
Oral Poster 14 – IN VIVO EVALUATION OF THE HOST RESPONSE TO AN ELASTOMERIC MESH: AN ALTERNATIVE TO POLYPROPYLENE MESH
K. Knight1, S. D. Abramowitch1, P. A. Moalli3.
1Bioengineering, University of Pittsburgh, Pittsburgh, PA; 2Department of Obstetrics and Gynecology and Reproductive Sciences at Magee Womens Hospital, Magee-Womens Research Institute, Pittsburgh, PA; 3Department of OB & GYN, School of Medicine, University of Pittsburgh, Pittsburgh, PA

11:08 a.m. – 11:12 a.m.
Oral Poster 15 – THE IMPACT OF COMMON VAGINAL LUBRICANTS ON E. COLI
K. J. Hung, A. Bergerat-Thompson, M. M. Weinstein, C. Mitchell. OB/GYN, Massachusetts General Hospital, Boston, MA

11:12 a.m. – 11:16 a.m.
Oral Poster 16 – RETHINKING THE URINARY CATHERETER: LESS TRAUMA THRU BETTER DESIGN: A SHEEP MODEL
X. SUN1, A. T. Graziul-Bilska2, K. Vonnahme2, B. T. Webb3, N. Kohli4. 1Ob/Gyn, Brigham and Women’s Hospital, Wellesley, MA; 2Animal Sciences, North Dakota State University, Fargo, ND

11:16 a.m. – 11:20 a.m.
QUESTIONS FOR ORAL POSTERS 13–16

11:20 a.m. – 11:24 a.m.
Oral Poster 17 – DETERMINATION OF LOXL1 AND FIBULIN-5 LEVELS IN THE VAGINAL SECRETIONS OF WOMEN WITH AND WITHOUT PELVIC ORGAN PROLAPSE
B. A. Garcia, T. J. Lechuga, A. Nasiri, D. Chen, F. Lane. Female Pelvic Medicine and Reconstructive Surgery, University of California Irvine, Orange, CA

11:24 a.m. – 11:28 a.m.
Oral Poster 18 – THE URINARY MICROBIOME IN WOMEN WITH MIXED URINARY INCONTINENCE
Y. M. Komesu1, H. E. Richter2, B. Carper3, D. L. Dinwiddie4, V. W. Sung4, E. S. Lukacz2, H. M. Zyczynski2, B. Ridgeway5, N. Y. Siddiqui6, L. A. Arya10, R. G. Rogers7, D. Mazloomdoost9, M. Gantz7,9. 1Obstetrics & Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM; 2Obstetrics & Gynecology, University of Alabama at Birmingham, Birmingham, AL; 3MWRI, Department of Obstetrics, Gynecology and Reproductive Sciences at Magee Womens Hospital, Magee-Womens Research Institute, Pittsburgh, PA; 4Department of Obstetrics and Gynecology, and Reproductive Sciences, University of Vermont College of Medicine, Burlington, VT; 5MWRI, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, School of Medicine, Pittsburgh, PA; 6Obstetrics & Gynecology, University of Pittsburgh, School of Engineering, Pittsburgh, PA

11:28 a.m. – 11:32 a.m.
Oral Poster 19 – NATURAL HISTORY OF AN ACUTE URINARY TRACT INFECTION IN A YOUNG WOMAN
D. Johansen, T. K. Price, R. Limeira, A. J. Wolfe. Microbiology & Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL

11:32 a.m. – 11:36 a.m.
Oral Poster 20 – EXPLORATION OF A REGENERATIVE EXTRACELLULAR MATRIX BIOSCAFFOLD IN SACROCLOPOPEXY: IMPACT ON VAGINAL SMOOTH MUSCLE
R. Liang1, R. M. Shaffer2, C. M. CARTER-BROOKS3, S. Palcsey4, S. D. Abramowitch6, P. A. Moalli3. 1Department of OB & GYN, School of Medicine, University of Pittsburgh, Pittsburgh, PA; 2Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Vermont College of Medicine, Burlington, VT; 3MWRI, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, School of Medicine, Pittsburgh, PA; 4Department of Bioengineering, University of Pittsburgh, School of Engineering, Pittsburgh, PA

11:36 a.m. – 11:40 a.m.
Oral Poster 21 – IMPACT OF A REGENERATIVE ECM BIOSCAFFOLD ON VAGINAL SMOOTH MUSCLE
R. Liang1, S. Palcsey4, S. D. Abramowitch6, P. A. Moalli3. 1MWRI, Department of Obstetrics, Gynecology & Reproductive Science, School of Medicine, University of Pittsburgh, Pittsburgh, PA; 2Department of Bioengineering, School of Engineering, University of Pittsburgh, Pittsburgh, PA

11:40 a.m. – 11:45 a.m.
QUESTIONS FOR ORAL POSTERS 17–21
THURSDAY, OCTOBER 5 (Continued)

11:00 a.m. – 12:00 p.m. ❅ CLINICAL SEMINAR
ABNORMAL UTERINE BLEEDING: WADING THROUGH THE EVIDENCE ON EVALUATION AND TREATMENT EFFECTIVENESS – ROOM 551
Kristen A. Matteson, MD

11:45 a.m. – 1:30 p.m. ❅ LUNCH IN THE EXHIBIT HALL

12:00 p.m. – 1:30 p.m. ❅ INDUSTRY-SUPPORTED EDUCATION — IMPROVING YOUR EFFICIENCY: NEW DIGITAL RESOURCES TO ADDRESS PHYSICIAN NEEDS – ROOM 555
Supported by Boston Scientific

12:00 p.m. – 1:30 p.m. ❅ INDUSTRY-SUPPORTED EDUCATION — ROOM 552
Supported by Medtronic

1:30 p.m. – 2:00 p.m. ❅ DEBATE 1
SLING SELECTIONS AND WHAT TO DO WHEN THEY FAIL! – EXHIBITION HALL C
Moderator: Lynsey Hayward, MD
Speakers: Holly Richter, MD, PhD; Matthew Barber, MD, MHS

2:00 p.m. – 2:30 p.m. ❅ RAYMOND A. LEE LECTURE
LIFE-LONG LEARNING, LOVING WHAT YOU DO, AND PAYING IT FORWARD – EXHIBITION HALL C
Marie Fidela Rustia ParaISO, MD

2:30 p.m. – 2:40 p.m. ❅ FMRS JOURNAL UPDATE – EXHIBITION HALL C
Linda Brubaker, MD, MHS, FACOG

2:40 p.m. – 2:47 p.m. ❅ AUGS–SGS FPRN® UPDATE – EXHIBITION HALL C

2:47 p.m. – 4:03 p.m. ❅ GENERAL SCIENTIFIC SESSION II – EXHIBITION HALL C
Moderators: John Occhino, MD; Rebecca Rogers, MD

2:47 p.m. – 2:57 p.m. Paper 5 – TWO-YEAR OUTCOMES OF SACRAL NEUROMODULATION VS. ONABOTULINUMTOXINA FOR REFRACTORY URGENCY URINARY INCONTINENCE
C. L. Amundsen1, T. S. Wilson2, D. D. Wallace3, S. P. Vasavada4, J. N. Nguyen5, D. L. Myers6, Y. M. Komesu7, A. A. Honeycutt8, H. S. Harvie9, W. T. Gregory10, C. Chemansky11,2, Duke University, Durham, NC; 2RTI International, Research Triangle Park, NC; 3University of Alabama at Birmingham, Birmingham, AL; 4Cleveland Clinic, Cleveland, OH; 5Kaiser Permanente – Bellflower, Downey, CA; 6Brown University, Providence, RI; 7University of New Mexico Health Sciences Center, Albuquerque, NM; 8University of Pennsylvania, Philadelphia, PA; 9Oregon Health and Science University, Portland, OR; 10University of Pittsburgh, Pittsburgh, PA

2:57 p.m. – 3:07 p.m. Paper 6 – A RANDOMIZED, MULTICENTER STUDY OF AN INTRAVESICAL BALLOON TO TREAT FEMALE STRESS URINARY INCONTINENCE (SUI): 12 MONTH RESULTS
S. A. Malik1, H. A. Winkler2, K. Jacoby3, S. J. Kalota4, J. Snyder5, K. J. Cline6, K. Robertson7, R. Kahan8, L. Green9, K. McCanmon10, E. Rovner11, C. R. Rardin12. 1Valley Urogynecology Associates, University of Arizona-Phoenix College of Medicine, Phoenix, AZ; 2Norwell Health, Great Neck, NY; 3Integrity Medical Research, Westlake Terrace, WA; 4Urological Associates of Southern Arizona, Tucson, AZ; 5Genitourinary Surgical Associates, Denver, CO; 6Regional Urological Associates, Shreveport, LA; 7Chesapeake Urology Associates, Glen Burnie, MD; 8WomenCare, Arlington Heights, IL; 9Urolgy of Virginia, Virginia Heights, IL; 10Medical College of South Carolina, Charleston, SC; 11Virginia Women’s Center, Richmond, VA; 12Women and Infants Hospital, Providence, RI

3:07 p.m. – 3:17 p.m. Paper 7 – CANCER RISK AFTER MIDURETHRAL SLING SURGERY USING POLYPROPYLENE MESH: A NATIONWIDE POPULATION-BASED COHORT STUDY
D. Altman1, R. G. Rogers2, L. Yin3, K. Tamussino4, C. B. Iglesia5. 1Department of Clinical Sciences, Karolinska Institutet, Stockholm, Sweden; 2Department of Women’s Health, University of Texas Austin Dell Medical School, Austin, TX; 3Department of Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 4Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria; 5Department of Obstetrics and Gynecology, MedStar Washington Hospital Center / Georgetown University School of Medicine, Washington, DC

3:17 p.m. – 3:27 p.m. Paper 8 – GROSS AND HISTOLOGIC RELATIONSHIPS OF THE RETROPUBIC URETHRA TO LATERAL PELVIC SIDEWALL AND ANTERIOR VAGINAL WALL IN FEMALE CADAVERS: CLINICAL APPLICATIONS TO RETROPUBIC SURGERY
J. J. Hamner1, K. S. Carrick2, M. Corton1. 1Female Pelvic Medicine and Reconstructive Surgery, University of Texas Southwestern, Dallas, TX; 2Pathology, University of Texas Southwestern, Dallas, TX

3:27 p.m. – 3:33 p.m. Tip and Trick 1 – REMOVAL OF VAGINAL CALCULUS WITH SURGICAL DRILL
N. Young-Lin1, L. Lum, L. Rogo-Gupta. Department of Obstetrics and Gynecology, University of California, San Diego, CA
Gynecology/Division of Urogynecology and Pelvic Reconstructive Surgery, Stanford University, Stanford, CA

3:33 p.m. – 3:43 p.m.
Paper 9 – EFFECT OF VAGINAL MESH ON VEGFA EXPRESSION
J. Kowalski, M. Goodheart, C. S. Bradley. Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA

3:43 p.m. – 3:55 p.m.
(Papers 10 and 11 are combined) Paper 10 – COST ANALYSIS OF REUSABLE UNDERWEAR VERSUS DISPOSABLE PADS FOR MILD TO MODERATE URINARY INCONTINENCE

3:55 p.m. – 4:03 p.m.
Video 4 – DECONSTRUCTION OF COLPOCLEISIS AND VAGINAL RESUSPENSION
E. M. English, J. O. DeLancey. OB/GYN, University of Michigan Health System, Ann Arbor, MI

4:03 p.m. – 4:15 p.m.
Oral Poster 22 – MATERNAL LOWER URINARY TRACT INJURY AT THE TIME OF PERIPARTUM HYSTERECTOMY
K. Bochenksa1, A. Peters2, N. K. Ayala3, A. Stroh1, S. A. Collins1, H. M. Zyczynski3, K. Kenton1. 1Female Pelvic Medicine and Reconstructive Surgery, Northwestern University, Chicago, IL; 2Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, PA; 3Obstetrics and Gynecology, Northwestern University, Chicago, IL; 4Gynecologic Oncology, Northwestern University, Chicago, IL; 5Female Pelvic Medicine and Reconstructive Surgery, University of Pittsburgh, Pittsburgh, PA

4:15 p.m. – 4:19 p.m.
Oral Poster 23 – CORRELATION OF VIRTUAL REALITY SIMULATION AND DRY LAB ROBOTIC TECHNICAL SKILLS
L. K. Newcomb3, M. S. Bradley1, T. Truong1, M. Tang1, B. Comstock2, Y. Li1, N. Y. Siddiqui1. 1OBGYN, Duke University Hospital, Durham, NC; 2C-SATS, San Francisco, CA

4:19 p.m. – 4:23 p.m.
Oral Poster 24 – DID THE 2015 NATIONAL HEALTH INSURER POLICY REQUIRING PRIOR AUTHORIZATION FOR NON-VAGINAL HYSTERECTOMY ROUTES INCREASE UTILIZATION OF VAGINAL HYSTERECTOMY?
C. W. Swenson, N. S. Kamdar, E. M. English, D. M. Morgan. Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI

4:23 p.m. – 4:27 p.m.
Oral Poster 25 – DID THE 2015 NATIONAL HEALTH INSURER POLICY REQUIRING PRIOR AUTHORIZATION FOR NON-VAGINAL HYSTERECTOMY ROUTES INCREASE UTILIZATION OF VAGINAL HYSTERECTOMY?
C. W. Swenson, N. S. Kamdar, E. M. English, D. M. Morgan. Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI

4:27 p.m. – 4:31 p.m.
Oral Poster 26 – TOBACCO USE, PSYCHIATRIC, IMMUNOSUPPRESSIVE, AND CHRONIC PAIN CONDITIONS ARE PREVALENT IN WOMEN WITH SYMPTOMATIC MESH COMPLICATIONS UNDERGOING MESH REMOVAL SURGERY

4:31 p.m. – 4:35 p.m.
Questions for Oral Presentations 22-25

4:35 p.m. – 4:39 p.m.
Oral Poster 27 – PERIOPERATIVE OUTCOMES IN PATIENTS WITH HEREDITARY DISORDERS OF CONNECTIVE TISSUE: A RETROSPECTIVE COHORT STUDY
P. Alam1, E. R. Davidson2, J. N. Byrnes3, K. Bochenksa4, M. E. Florian-Rodriguez5, C. M. CARTER-BROOKS6, E. N. Myer7, M. Good8, R. E. Gutman1. 1MedStar Washington Hospital Center/Georgetown University, Washington; 2Cleveland Clinic, Cleveland, OH; 3Mayo Clinic, Rochester, MN; 4Northwestern University, Chicago, IL; 5University of Texas Southwestern Medical Center, Dallas, TX; 6University of Pittsburgh Medical Center/Magee Women’s Hospital, Pittsburgh, PA; 7Johns Hopkins Hospital, Baltimore, MD; 8University of Florida Health, Jacksonville, FL

4:43 p.m. – 4:47 p.m.
Oral Poster 28 – PREDICTORS FOR LONG-TERM POSTOPERATIVE FOLLOW-UP IN A COHORT OF PELVIC ORGAN PROLAPSE PATIENTS
C. Jung1, S. A. Menefee2, J. N. Nguyen3, K. Y. Dyer4. 1Reproductive Medicine, University of California, San Diego, San Diego, CA; 2Female Pelvic Medicine and Reconstructive Surgery, Kaiser Permanente, San Diego, CA; 3Obstetrics & Gynecology, Kaiser Permanente, Downey, CA

4:47 p.m. – 4:51 p.m.
Questions for Oral Presentations 26-28
THURSDAY, OCTOBER 5 (Continued)

4:51 p.m. – 4:55 p.m.
Oral Poster 29 – IDENTIFYING PREDICTORS OF POSTDISCHARGE SURGICAL RECOVERY FOLLOWING LAPAROSCOPIC SACROCOLPOPEXY: A PROSPECTIVE LONGITUDINAL STUDY
M. Heit1, J. S. Carpenter2, R. Stewart3, J. J. Hamner3, K. L. Rand4. 1Female Pelvic Medicine and Reconstructive Surgery, Indiana University School of Medicine, Indianapolis, IN; 2Indiana University School of Nursing, Indianapolis, IN; 3Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN; 4Department of Psychology, Indiana University-Purdue University at Indianapolis (IUPUI), Indianapolis, IN

4:55 p.m. – 4:59 p.m.
Oral Poster 30 – EVALUATING THE IMPACT OF DAYS BETWEEN PROCEDURES ON CLINICAL OUTCOMES: DO SURGEONS GET RUSTY?
L. E. Giugale1, E. S. Lavelle1, C. M. Carter-Brooks1, J. P. Shepherd2. 1Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital of UPMC, Pittsburgh, PA; 2St. Francis Hospital and Medical Center, Hartford, CT

4:59 p.m. – 5:04 p.m.
(Video 5 and Video 6 are combined)
Video 5 – AUTOLOGOUS FASCIA LATA FROM THE THIGH SURGICAL TECHNIQUE VIDEO
M. T. Nguyen1, J. Oliver2, T. Y. Sadun2. 1Obstetrics and Gynecology, Female Pelvic Medicine and Reconstructive Surgery, UCLA; 2David Geffen School of Medicine, Los Angeles, CA

4:00 p.m. – 4:15 p.m.
QUESTIONS FOR ORAL POSTERS 29–30

4:15 p.m. – 5:15 p.m.
SCIENTIFIC CONCURRENT SESSION 5: EPIDEMIOLOGY AND OTHER PELVIC FLOOR DISORDERS SESSION – BALLROOM B/C

4:15 p.m. – 4:19 p.m.
Oral Poster 31 – GENOME-WIDE ASSOCIATION STUDY FOR URINARY AND FECAL INCONTINENCE IN WOMEN
K. L. Penney, F. Grodstein, M. K. Townsend, V. Minassian. Brigham and Women’s, Boston, MA

4:19 p.m. – 4:23 p.m.
Oral Poster 32 – OPERATING ROOM EFFICIENCY: EXAMINING THE ROLE OF PERSONNEL HANDOFFS

4:23 p.m. – 4:27 p.m.
Oral Poster 33 – FACE: FEMALE PELVIC MEDICINE & RECONSTRUCTIVE SURGERY AWARENESS CAMPAIGN: INCREASING EXPOSURE
S. Barr1, C. C. Crisp1, A. B. White1, S. A. Malik1, K. Kenton2. 1OB/GYN, University of Arkansas for Medical Science, Little Rock, AR; 2Banner University Medical Center – Phoenix, Phoenix, AZ

4:27 p.m. – 4:31 p.m.
Oral Poster 34 – VARIATION IN PATIENT REFERRAL NETWORKS TO FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGEONS ACROSS THE UNITED STATES
T. M. Muffly1, J. Hajagos2. 1Female Pelvic Medicine and Reconstructive Surgery, Denver Health, Denver, CO; 2Department of Biomedical Informatics, Stony Brook University, Stony Brook, NY

4:31 p.m. – 4:35 p.m.
QUESTIONS FOR ORAL POSTERS 31–34

4:35 p.m. – 4:39 p.m.
Oral Poster 35 – REFRACTORY PUDENDAL PAIN AND PELVIC FLOOR DYSFUNCTION CAUSED BY INTRAPELVIC NERVE ENTRAPMENT: A REVIEW OF 50 CONSECUTIVE CASES
N. Lemos1, J. Papillon-Smith2, R. Moretti-Marques3, G. Fernandes1, M. Girao1, M. J. Solnik2. 1Obstetrics and Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil; 2Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada

4:39 p.m. – 4:45 p.m.
(Oral poster 36 and oral poster 37 are combined)
Oral Poster 36 – PELVIC FLOOR AND OBTURATOR INTERNUS MYOFASCIAL PAIN IS COMMON IN PATIENTS WITH PELVIC FLOOR SYMPTOMS
M. Meister1, S. Sutcliffe2, A. Badu3, C. Ghetti1, J. L. Lowder2. 1Surgery, Washington University, Saint Louis, MO; 2School of Medicine, Washington University, Saint Louis, MO; 3Obstetrics & Gynecology, Washington University, Saint Louis, MO

4:45 p.m. – 4:51 p.m.
Oral Poster 37 – PELVIC FLOOR AND OBTURATOR INTERNUS MYOFASCIAL PAIN IS CORRELATED WITH LOWER URINARY TRACT SYMPTOM SEVERITY
M. Meister1, S. Sutcliffe2, A. Badu3, C. Ghetti1, J. L. Lowder2. 1Ob/Gyn, Barnes Jewish Hospital/Washington University in Cincinnati, OH; 2Northwestern University Feinberg School of Medicine, Chicago, IL
4:45 p.m. – 4:49 p.m.
Oral Poster 38 – COST-EFFECTIVENESS OF ROUTINE POSTOPERATIVE RETROGRADE VOIDING TRIALS FOLLOWING GYNECOLOGICAL PROCEDURES
R. Wang¹, D. Soeteman², M. R. Hacker², R. Lefevre¹. ¹Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; ²Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA

4:49 p.m. – 4:53 p.m.
QUESTIONS FOR ORAL POSTERS 35–38

4:53 p.m. – 4:57 p.m.
Oral Poster 39 – RANDOMIZED CONTROLLED TRIAL TO ASSESS THE IMPACT OF INTRAURETHRAL LIDOCAINE ON URODYNAMIC VOIDING PARAMETERS
C. K. Kisby¹, E. J. Gonzalez², C. L. Amundsen³, A. G. Visco⁴, W. M. Grill⁵. ¹Obstetrics and Gynecology, Duke Hospital, Durham, NC; ²Biomedical Engineering, Duke University, Durham, NC; ³Female Pelvic Medicine and Reconstructive Surgery, Duke Hospital, Durham, NC

4:57 p.m. – 5:01 p.m.
Oral Poster 40 – PREOPERATIVE LABORATORY TESTING PRIOR TO UROGYNECOLOGIC SURGERY: A NECESSARY EVIL OR JUST UNNECESSARY?
K. Husk, M. Willis-Gray, A. A. Dieter, J. Wu. Urogynecology, University of North Carolina Hospitals, Chapel Hill, NC

5:01 p.m. – 5:07 p.m.
Video 7 – RECTOVAGINAL FISTULA REPAIR USING A GRACILIS MUSCLE FLAP AND FULL THICKNESS SKIN GRAFT
R. Newman¹, B. A. Garcia¹, J. Carmichael², M. Kobayashi³, F. Lane¹. ¹Female Pelvic Medicine & Reconstructive Surgery, University of California Irvine, Orange, CA; ²Colorrectal Surgery, University of California Irvine, Orange, CA; ³Plastic and Reconstructive Surgery, University of California Irvine, Orange, CA

5:07 p.m. – 5:11 p.m.
QUESTIONS FOR ORAL POSTERS 39–40

4:15 p.m. – 4:19 p.m.
Oral Poster 41 – CHARACTERIZATION OF THE T CELL POPULATION IN VAGINAL MESH REMOVED FROM WOMEN WITH COMPLICATIONS
L. Tennyson¹, S. Palcsey², S. D. Abramowitch³, S. D. Abramsowitch¹, P. A. Moalli². ¹Urology, Magee Womens Research Institute, Pittsburgh, PA; ²Magee Womens Research Institute, Pittsburgh, PA; ³Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA

4:19 p.m. – 4:23 p.m.
Oral Poster 42 – OVEREXPRESSION OF ORNITHINE DECARBOXYLASE (ODC) IN BLADDER UROTHELIUM RECAPITulates OVERACTIVE BLADDER (OAB) PHENOTYPE
J. Y. Yeh¹, L. Alvarez-Lugo¹, M. G. Acevedo Alvarez¹, M. Lu¹, W. Hill³, T. C. Chai¹. ¹Yale School of Medicine, New Haven, CT; ²Beth Israel Deaconess Medical Center, Boston, MA

4:45 p.m. – 4:49 p.m.
Oral Poster 43 – DETECTING UROPATHOGENS IN A UROGYNECOLOGIC POPULATION: A COMPARISON OF UTI DIAGNOSTIC THRESHOLDS
T. K. Price¹, E. E. Hilt¹, T. Dune², C. Brincat³, L. Brubaker¹, E. R. Mueller³, P. C. Schreckenberger⁴, A. J. Wolfe¹. ¹Microbiology & Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL; ²Center for Female Pelvic Health, Cornell University, Weill Cornell Medical College, New York, NY; ³Obstetrics & Gynecology and Urology, Loyola University Medical Center, Maywood, IL; ⁴Reproductive Medicine, University of California San Diego, Division of Female Pelvic Medicine and Reconstructive Surgery, La Jolla, CA; ⁵Pathology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL

4:23 p.m. – 4:27 p.m.
Oral Poster 44 – THE VAGINAL AND URINARY MICROBIOME IN PREMENOPAUSAL WOMEN WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME AS COMPARED TO NORMAL CONTROLS: A COHORT STUDY.
K. V. Meriwether¹, V. R. Jala², D. Hobson¹, C. L. Kinman¹, R. Stewart¹, S. L. Francis¹, Z. Lei¹. ¹Obstetrics & Gynecology, University of Louisville, Louisville, KY; ²Microbiology and Immunology, University of Louisville, Louisville, KY

4:27 p.m. – 4:31 p.m.
Oral Poster 45 – LACTOBACILLUS SPECIES INHIBIT GROWTH OF E. COLI
K. J. Hung, A. Bergerat-Thompson, M. M. Weinstein, C. Mitchell. OB/GYN, Massachusetts General Hospital, Boston, MA

4:31 p.m. – 4:35 p.m.
QUESTIONS FOR ORAL POSTERS 41–44

4:35 p.m. – 4:39 p.m.
Oral Poster 45 – LACTOBACILLUS SPECIES INHIBIT GROWTH OF E. COLI
K. J. Hung, A. Bergerat-Thompson, M. M. Weinstein, C. Mitchell. OB/GYN, Massachusetts General Hospital, Boston, MA
SCIENTIFIC PROGRAM

THURSDAY, OCTOBER 5 (Continued)

4:39 p.m. – 4:43 p.m.
Oral Poster 46 – CAN PHARMACOGENETICS BE USED TO PREDICT THE RESPONSE TO FESOTERODINE FUMARATE?
J. Wu¹, T. Wiltshire³, N. Y. Siddiqui², O. Suzuki³, K. Jamieson³, D. Voora³, K. Schmader³. ¹University of North Carolina at Chapel Hill, Chapel Hill, NC; ²Obstetrics & Gynecology, Duke University, Durham, NC; ³Center for Pharmacogenetics & Individualized Therapy, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC; ²Obstetrics & Gynecology, Duke University, Durham, NC

4:43 p.m. – 4:47 p.m.
Oral Poster 47 – EFFECT OF ESTROGEN THERAPY ON THE POSTMENOPAUSAL INFLAMMATORY BLADDER STATE

4:51 p.m. – 4:55 p.m.
Oral Poster 48 – THE ROLE OF BACTERIAL VIRUSES IN THE FEMALE URINARY MICROBIOME
C. Putonti¹, A. Garretto², J. W. Shapiro³, A. J. Wolfe⁴. ¹Bioinformatics, Biology & Computer Science, Loyola University Chicago, Chicago, IL; ²Bioinformatics, Loyola University Chicago, Chicago, IL; ³Biology, Loyola University Chicago, Chicago, IL; ⁴Microbiology and Immunology, Loyola University Chicago, Maywood, IL

4:55 p.m. – 4:59 p.m.
Oral Poster 49 – THE FEMALE GENITOURINARY MICROBIOTA: SHORT-TERM STABILITY, RESILIENCE AND PERI-URETHRAL RELATIONSHIPS
T. K. Price, D. Johansen, A. J. Wolfe. Microbiology & Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL

5:30 p.m. – 6:30 p.m.
EXHIBIT HALL HAPPY HOUR – EXHIBITION HALL AB

FRIDAY, OCTOBER 6

6:45 a.m. – 7:45 a.m.
MEET THE EXPERTS EDUCATIONAL ROUNDTABLES – ROTUNDA (CONVENTION CENTER)
See page 23 for details

6:45 a.m. – 7:45 a.m.
BASIC SCIENCE SIG BUSINESS MEETING – ROOM 553
PRIVATE PRACTICE SIG BUSINESS MEETING – ROOM 555

8:00 a.m. – 8:05 a.m.
WELCOME AND INTRODUCTION – EXHIBITION HALL C

8:15 a.m. – 8:45 a.m.
MESH REMOVAL DEBATE – EXHIBITION HALL C
Moderator: Christopher Tarnay, MD
Speakers: Miles Murphy, MD; Roger Dmochowski, MD

8:45 a.m. – 9:46 a.m.
GENERAL SCIENTIFIC SESSION III – EXHIBITION HALL C
Moderators: Robert Gutman, MD; Deborah Myers, MD
8:45 a.m. – 8:57 a.m.
**Paper 12 – OVEREXPRESSION OF ESTROGEN RECEPTOR BETA IN BLADDER UROTHELIUM PROTECTS AGAINST UROPATHOGENIC E. COLI INFECTION**

J. Y. Yeh, L. Alvarez-Lugo, M. G. Acevedo Alvarez, C. Jain, M. Lu, T. C. Chai. Yale School of Medicine, New Haven, CT

8:57 a.m. – 9:07 a.m.
**Video 9 – EXTRAVERSICAL ROBOTIC URETERAL REIMPLANTATION FOR URETEROVAGINAL FISTULA**


9:07 a.m. – 9:17 a.m.
**Paper 13 – DOES TRANSITION OF URINARY INCONTINENCE FROM ONE SUBTYPE TO ANOTHER REPRESENT PROGRESSION OF DISEASE?**

V. Minassian¹, X. Yan², A. L. Pilzek³, W. F. Stewart⁴. ¹Brigham and Women’s, Boston, MA; ²Sutter Health System, Walnut Creek, CA; ³Geisinger, Danville, PA

9:17 a.m. – 9:27 a.m.
**Paper 14 – PELVIC FLOOR MUSCLE TRAINING VERSUS WATCHFUL WAITING ON PELVIC FLOOR DISORDERS IN POSTPARTUM WOMEN: A SYSTEMATIC REVIEW AND META-ANALYSIS**

Y. Wu¹, N. McNnes², Y. Leong³. ¹Obstetrics and Gynecology, Western University, London, ON, Canada; ²Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

9:27 a.m. – 9:39 a.m.
(Paper 15 and Paper 16 are combined)

9:45 a.m. – 10:15 a.m.
**BREAK IN EXHIBIT HALL – EXHIBITION HALL AB**

10:15 a.m. – 10:50 a.m.
**J. MARION SIMS LECTURE VESICO-VAGINAL FISTULA: HISTORICAL UNDERSTANDING, MEDICAL ETHICS, AND MODERN SENSIBILITIES – EXHIBITION HALL C**

L. Lewis Wall, MD, PhD

11:05 a.m. – 11:35 a.m.
**PREVENTION OF URINARY INCONTINENCE: A BEHAVIORAL AND BASIC SCIENCE PERSPECTIVE – EXHIBITION HALL C**

Moderator: Una Lee, MD

Speakers: Catherine Bradley, MD, Gina Northington, MD; Marianna Alperin, MD

11:35 a.m. – 11:55 a.m.
**TREATMENT OF NON-NEUROGENIC URINARY RETENTION: WHEN AND WHEN NOT TO INTERVENE – RECOMMENDATIONS FROM THE AUA – EXHIBITION HALL C**

Gary Lemack, SUFU President

11:55 a.m. – 1:00 p.m.
**GENERAL SCIENTIFIC SESSION IV – EXHIBITION HALL C**

Moderators: Douglass Hale, MD; Kim Kenton, MD

12:05 p.m. – 12:15 p.m.
**Paper 19 – ROLE OF PROTEASE INHIBITORS IN HEALING OF THE VAGINAL WALL**

M. E. Florian-Rodriguez¹, K. Chin², H. Shi³, J. f. Acevedo³, R. A. Word⁴. ¹Female Pelvic Medicine and Reconstructive Surgery, UT Southwestern, Dallas, TX; ²Obstetrics and Gynecology, Kaiser Permanente, Santa Clara, CA; ³Obstetrics and Gynecology, UT Southwestern Medical Center, Dallas, TX

12:15 p.m. – 12:25 p.m.

12:25 p.m. – 12:35 p.m.
**Poster Session**

**Poster Session**
FRIDAY, OCTOBER 6 (Continued)

12:25 p.m. – 12:35 p.m.
Paper 20 – CHANGES IN VAGINAL MICROENVIRONMENT AS RELATED TO FREQUENCY OF PESSARY REMOVAL IN WOMEN USING PESSARY FOR PELVIC FLOOR DISORDERS
N. Fregosi, D. Hobson, C. L. Kinman, R. Stewart, K. V. Meriwether. Obstetrics and Gynecology, University of Louisville, Louisville, KY

12:35 p.m. – 12:45 p.m.
Paper 21 – PREDICTIVE VALUE OF MICROSCOPIC HEMATURIA FOR UROLOGIC MALIGNANCIES IN WOMEN AND MEN
J. Heft, E. Braxton, N. D. Mercaldo, R. M. Ward. Vanderbilt University, Nashville, TN

12:45 p.m. – 12:55 p.m.
Video 11 – THE 4-WALL SACROSPINOUS LIGAMENT SUSPENSION: SECRETS TO SUCCESS FOR COMPLEX CASES

1:00 p.m. – 2:30 p.m.
INDUSTRY SUPPORTED EDUCATION — LASER APPLICATIONS IN VAGINAL HEALTH SPECIFICALLY RELATED TO GSM, SUI, AND ATROPHY — ROOM 555
Supported by Alma Lasers

1:00 p.m. – 2:30 p.m.
INDUSTRY SUPPORTED EDUCATION — SINGLE-INCISION SLINGS: DATA, BARRIERS, AND THE PATIENT EXPERIENCE — ROOM 552
Supported by Coloplast

1:00 p.m. – 2:45 p.m.
LUNCH IN THE EXHIBIT HALL – EXHIBITION HALL AB

2:45 p.m. – 4:00 p.m.
SCIENTIFIC CONCURRENT SESSION 7: SURGERY/ANATOMY — BALLROOM A
Moderators: Vivian Aguilar, MD; Shawn Menefee, MD

2:45 p.m. – 2:49 p.m.
Oral Poster 50 – POSTERIOR VAGINAL WALL PROLAPSE ON MRI AND ASSOCIATION WITH DEFECATORY SYMPTOMS
M. T. Nguyen1, J. Y. Mei2, C. Tarnay1.
1Obstetrics and Gynecology, Female Pelvic Medicine and Reconstructive Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA; 2OBGYN, UCLA, Los Angeles, CA

2:49 p.m. – 2:53 p.m.
Oral Poster 51 – EFFECT OF MORBID OBESITY ON MID-URETHRAL SLING EFFICACY FOR THE MANAGEMENT OF STRESS URINARY INCONTINENCE

2:53 p.m. – 2:57 p.m.
Oral Poster 52 – PREOPERATIVE PELVIC FLOOR MUSCLE WEAKNESS AS A RISK FACTOR OF SURGICAL FAILURE OF ANTERIOR VAGINAL WALL PROLAPSE REPAIR

2:57 p.m. – 3:01 p.m.
Oral Poster 53 – POSTERIOR COMPARTMENT SURGERY PROVIDES NO DIFFERENTIAL BENEFIT FOR DEFECATORY SYMPTOMS BEFORE OR AFTER CONCOMITANT MESH AUGMENTED APICAL SUSPENSION
D. Arunachalam, D. S. Hale, M. Heit. Urogynecology, Indiana University, Indianapolis, IN

3:01 p.m. – 3:05 p.m.
Oral Poster 54 – MECHANISM OF ACTION OF URETHRAL BULKING VERSUS MIDURETHRAL SLING MEASURED BY HIGH RESOLUTION MANOMETRY
E. J. Wasenda1, A. C. Kirby2, E. S. Lukacz1, C. W. Nager1. 1Department of Reproductive Medicine, Division of Female Pelvic Medicine and Reconstructive Surgery, UC San Diego Health System, La Jolla, CA; 2Department of Obstetrics & Gynecology, Division of Urogynecology, University of Washington, Seattle, WA

3:05 p.m. – 3:09 p.m.
QUESTIONS FOR ORAL POSTERS 50–54

3:09 p.m. – 3:13 p.m.
Oral Poster 55 – TARGET-BASED 3D STRESS MRI MEASUREMENT TECHNIQUE FOR APICAL, PARAVAGINAL AND HIATAL CHANGES AFTER SURGERY FOR ANTERIOR/APICAL PROLAPSE
L. Chen1, B. Xie2, J. O. DeLancey2.
1Biomedical Engineering, University of Michigan, Ann Arbor, MI; 2Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI

3:13 p.m. – 3:17 p.m.
Oral Poster 56 – THE FAILURE RATE OF A SECONDARY PROCEDURE FOR RECURRENT STRESS URINARY INCONTINENCE FOLLOWING A FAILED MIDURETHRAL SLING IS NOT AFFECTED BY ALTERATION OF THE PRIMARY SLING
K. Buono1, A. Alabaster2, P. Mallipeddi2.
1Obstetrics & Gynecology, Kaiser Permanente Medical Center, Santa Clara, CA; 2Division of Research, Kaiser Permanente Medical Center, Oakland, CA; 3FPMRS, Kaiser Permanente Medical Center, Santa Clara, CA
FRIDAY, OCTOBER 6 (Continued)

3:05 p.m. – 3:09 p.m.
QUESTIONS FOR ORAL POSTERS 63–67

3:09 p.m. – 3:13 p.m.
Oral Poster 68 – PATIENT COUNSELING ON STRESS URINARY INCONTINENCE AND/OR PELVIC ORGAN PROLAPSE CONDITIONS USING TRADITIONAL DIAGRAMS VERSUS AN INTERACTIVE COMPUTER PROGRAM
N. Golbari1, G. Lazarou2, B. Grigorescu2. 
1Stony Brook University Medical School, Stony Brook, NY; 2OB/GYN, Winthrop University Hospital, Mineola, NY

3:13 p.m. – 3:17 p.m.
Oral Poster 69 – TOILETING HABITS OF NURSES
M. Brady1, A. Tjaden1, C. Brincat1, L. Brubaker1, W. Adams2. 
1Obstetrics and Gynecology, Loyola University Medical Center, Maywood, IL; 2Health Sciences Division, Loyola University Chicago, Maywood, IL

3:17 p.m. – 3:21 p.m.
Oral Poster 70 – A COST-EFFECTIVENESS ANALYSIS OF BOTOX BOTULINUM-A TOXIN AS FIRST-LINE TREATMENT FOR OVERACTIVE BLADDER
C. M. Carter-Brooks1, J. P. Shepherd2. 
1Urogynecology and Reconstructive Surgery, Magee-Womens Hospital of UPM, PITTSBURGH, PA; 2Urogynecology, St. Francis Medical Center, Hartford, CT

3:21 p.m. – 3:25 p.m.
Oral Poster 71 – THERAPEUTIC OUTCOMES FOR FEMALES AND MALES IN THE INSITE STUDY FOR OVERACTIVE BLADDER
1MetroHealth Medical Center, Cleveland, OH; 2Female Pelvic Medicine, Grand Rapids, MI; 3Stanford University, Stanford, CA; 4Scott & White Hospital, Temple, TX; 5Milford Regional Medical Center, Whitinsville, MA; 6University of Kansas, Kansas City, KS; 
7University of Washington, Seattle, WA; 8University of California, Riverside, CA; 9Clinical, Medtronic, Minneapolis, MN; 10Metro Urology, Woodbury, MN

3:25 p.m. – 3:29 p.m.
QUESTIONS FOR ORAL POSTERS 68–71

3:29 p.m. – 3:33 p.m.
Oral Poster 72 – A PILOT STUDY EVALUATING A NON-INVASIVE METHOD TO CHARACTERIZE BLADDER GEOMETRY FOR OVERACTIVE BLADDER
S. Glass Clark1, A. S. Nagle2, R. Vince1, R. Bernardo1, L. R. Carucci2, A. Carroll1, A. Klausner3, J. E. Speich2. 
1Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, VA; 2Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA; 3Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA

3:33 p.m. – 3:37 p.m.
Oral Poster 73 – MYOFASCIAL PAIN IN PATIENTS WITH SYMPTOMS OF URINARY TRACT INFECTION
B. J. Wolff1, C. J. Joyce1, C. Brincat1, E. R. Mueller2, C. M. Fitzgerald1. 
1Department of Obstetrics/Gynecology and Urology, Loyola University Chicago Stritch School of Medicine and Loyola University Medical Center, Maywood, IL; 2Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI

3:37 p.m. – 3:41 p.m.
Oral Poster 74 – FECAL INCONTINENCE SYMPTOMS AND IMPACT IN OLDER VERSUS YOUNGER WOMEN SEEKING CARE
1Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL; 2University of Alabama at Birmingham, Birmingham, AL

3:41 p.m. – 3:45 p.m.
Oral Poster 75 – VARIATION IN PESSARY COUNSELING PRIOR TO SURGERY FOR PELVIC ORGAN PROLAPSE
A. G. Sammarco, D. M. Morgan, N. S. Kamdar, C. W. Swenson. Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI

3:45 p.m. – 3:50 p.m.
QUESTIONS FOR ORAL POSTERS 68–75

2:45 p.m. – 4:00 p.m.
SCIENTIFIC CONCURRENT SESSION 9: POPULATION STUDIES SESSION – BALLROOM D/E

Moderators: Juana Hutchison-Colas, MD, MBA; Danielle Antosh, MD

2:45 p.m. – 2:49 p.m.
Oral Poster 76 – ASSOCIATION BETWEEN CO-MORBIDITIES AND FEMALE SEXUAL DYSFUNCTION: FINDINGS FROM THE THIRD NATIONAL SURVEY OF SEXUAL ATTITUDES AND LIFESTYLES (NATSAL-3)

2:49 p.m. – 2:53 p.m.
Oral Poster 77 – MODERN PRACTICE PATTERNS IN WOMEN TREATED FOR NON-NEUROGENIC OVERACTIVE BLADDER: HOW QUICKLY DO PATIENTS PROGRESS TO THIRD-LINE THERAPY?

2:53 p.m. – 2:57 p.m.
Oral Poster 78 – WEIGHT AND WEIGHT CHANGE IMPACT STRESS AND URGE URINARY INCONTINENCE SYMPTOMS IN POSTMENOPAUSAL WOMEN
1Department of Obstetrics and Gynecology/Division of Urogynecology and Pelvic Reconstructive Surgery, Stanford University, Menlo Park, CA; 2Department of Medicine/Quantitative Sciences Unit,
Scientific Program

KEY: = Virtual Conference  = This session requires a ticket

3:01 p.m. – 3:05 p.m.
Oral Poster 80 – STRESS URINARY INCONTINENCE SURGERY IN WASHINGTON STATE BEFORE AND AFTER INTRODUCTION OF THE MESH MIDURETHRAL SLING
L. E. Stewart¹, M. A. Eston¹, R. G. Symons², A. C. Kirby¹. ¹Obstetrics and Gynecology, University of Washington, Seattle, WA; ²Surgery and Surgical Outcomes Research Center, University of Washington, Seattle, WA

3:05 p.m. – 3:09 p.m.
QUESTIONS FOR ORAL POSTERS 76–80

3:09 p.m. – 3:13 p.m.
Oral Poster 81 – INCIDENCE AND RISK FACTORS FOR THE DEVELOPMENT OF LOWER URINARY TRACT FISTULAS AFTER Hysterectomy Diagnosed in the Immediate Post-Operative Period: An Analysis of the National Surgery Quality Improvement Program (NSQIP) Database
M. E. Florian-Rodriguez¹, J. J. Hamner¹, D. McIntire², C. Wai¹. ¹Female Pelvic Medicine and Reconstructive Surgery, UT Southwestern, Dallas, TX; ²Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX

3:13 p.m. – 3:17 p.m.
Oral Poster 82 – ONLINE PHYSICIAN RATINGS IN FEMALE PELVIC MEDICINE & RECONSTRUCTIVE SURGERY: WHAT DO PATIENTS REALLY WANT?
K. Asanad, P. S. Parameshwar, J. Houman, A. Moradzadeh, T. Daskivich, J. T. Anger. Urology, Cedars-Sinai Medical Center, Los Angeles, CA

3:17 p.m. – 3:21 p.m.
Oral Poster 83 – URINARY INCONTINENCE REMISSION BY SUBTYPE AND RELATION TO INDICATORS OF SEVERITY
V. Minassian¹, X. Yan², A. L. Pilzek³, W. F. Stewart³. ¹Brigham and Women’s, Boston, MA; ²Sutter Health, Walnut Creek, CA; ³Geisinger, Danville, PA

3:21 p.m. – 3:25 p.m.
Oral Poster 84 – PELVIC ORGAN PROLAPSE AND URINARY INCONTINENCE AFTER BARIATRIC SURGERY
I. Gabriel¹, A. Tavakkoli², V. Minassian¹. ¹Division of Urogynecology, Brigham and Women’s Hospital, Boston, MA; ²Department of Surgery and Center for Weight Management and Metabolic Surgery, Brigham and Women’s Hospital, Boston, MA

3:25 p.m. – 3:29 p.m.
Oral Poster 85 – PATIENT UNDERSTANDING: HEALTH LITERACY IN WOMEN WITH PELVIC FLOOR DISORDERS
A. Sripad², B. Rupp¹, J. Gage³, K. M. Feliciano³, M. Willis-Gray¹, J. Wu¹. ¹Urogynecology and Reconstructive Surgery, UNC Hospitals, Chapel Hill, NC; ²OBGYN, University of North Carolina, Chapel Hill, NC

3:29 p.m. – 3:33 p.m.
QUESTIONS FOR ORAL POSTERS 81–85

3:33 p.m. – 3:37 p.m.
Oral Poster 86 – WHAT THE INTERNET SAYS ABOUT VAGINAL MESH: SENTIMENT ANALYSIS OF WEBSITES RELATED TO GRAFT USE IN PELVIC RECONSTRUCTIVE SURGERY
D. Hobson, K. V. Meriwether, C. L. Kinman, S. L. Francis, R. Stewart. Female Pelvic Medicine and Reconstructive Surgery, University of Louisville School of Medicine, Louisville, KY

3:37 p.m. – 3:41 p.m.
Oral Poster 87 – COST IMPACT OF ELECTIVE CESAREAN DELIVERY ON FUTURE PELVIC FLOOR DISORDERS
D. Patel, J. T. Anger, K. S. Eilber. Urology, Cedars-Sinai, Los Angeles, CA

3:41 p.m. – 3:45 p.m.
Oral Poster 88 – BLADDER AND BOWEL DYSFUNCTION IN PATIENTS WITH SPINAL STENOSIS
S. Dutta, L. A. Cadish, V. Tancioco, F. Lane. Obstetrics and Gynecology, University of California, Irvine, Manhattan Beach, CA

3:45 p.m. – 3:49 p.m.
Video 13 – MINIMALLY INVASIVE CYSTOSCOPIC SUTURE EXCISION
R. Pollard², A. Petrikovets³, J. W. Henderson¹. ¹Female Pelvic Medicine & Reconstructive Surgery, University Hospitals Case Medical Center, Cleveland, OH; ²Urogynecology & Pelvic Reconstructive Surgery, MetroHealth Medical Center, Cleveland, OH

3:49 p.m. – 3:53 p.m.
QUESTIONS FOR ORAL POSTERS 86–88

Stanford University School of Medicine, Stanford, CA; ¹Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA

2:57 p.m. – 3:01 p.m.
Oral Poster 79 – PROPHYLACTIC ANTIBIOTICS AT THE TIME OF OBSTETRIC ANAL SPHINCTER INJURY REPAIR: ARE WE MEETING THE MARK?  
L. E. Giugale¹, A. Fairchild², S. Hasley³, P. Fairchild¹. ¹Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital of UPMC, Pittsburgh, PA; ²Department of Psychology, Barnwell College, University of South Carolina, Columbia, SC
FRIDAY, OCTOBER 6 (Continued)

3:15 p.m. – 5:00 p.m. VIDEO CAFÉ – ROOM 553
Moderators: Peter Jeppson, MD; Tyler Muffly, MD

3:15 p.m. – 3:25 p.m.
Video Poster 1 – ROBOTIC-ASSISTED SACROCOLPOPERINEOPEXY AND MODIFIED ANTERIOR RECTOPEXY FOR TREATMENT OF PELVIC ORGAN PROLAPSE, PERINEAL DESCENT AND DEFECATION DYSFUNCTION

R. Golan, P. Culligan. Urology, New York-Presbyterian Weill Cornell Medicine, New York, NY

3:25 p.m. – 3:33 p.m.
Video Poster 2 – RECTUS FASCIAL SLING AS EASY AS MID-URETHRAL SLING

J. Shaw, C. Cowles. Obstetrics and Gynecology, Tenwek Hospital, Bomet, Kenya

3:33 p.m. – 3:40 p.m.
Video Poster 3 – TRANSVAGINAL URETERAL DISSECTION DURING UTEROSACRAL LIGAMENT SUSPENSION PROCEDURE

M. Sakinci1, D. Maheshwari1, O. Harmanli2. 1Department of Ob/Gyn, University of Massachusetts Medical School-Baystate, Springfield, MA; 2Yale Urogynecology and Pelvic Reconstructive Surgery, Yale School of Medicine, New Haven, CT

3:40 p.m. – 3:48 p.m.
Video Poster 4 – A MODIFIED TRANSVAGINAL MESH COLPOPEXY FOR ANTERIOR AND APICAL PROLAPSE

D. Maheshwari1, O. Harmanli2. 1Department of Ob/Gyn, University of Massachusetts Medical School-Baystate, Springfield, MA; 2Yale Urogynecology and Pelvic Reconstructive Surgery, Yale School of Medicine, New Haven, CT

3:48 p.m. – 3:54 p.m.
Video Poster 5 – ROBOTIC VESICO-VAGINAL FISTULA REPAIR UTILIZING OMENTAL INTERPOSITION

D. Glazier, B. Moore. Virginia Urology, Women’s Health, Midlothian, VA

3:54 p.m. – 4:01 p.m.
Video Poster 6 – UNIQUE APPROACHES TO CONCURRENT PELVIC ORGAN PRLAPSE REPAIR AT TIME OF GYNECOLOGIC CANCER SURGERY

C. P. Chung, M. T. Wakabayashi, T. H. Dellinger, S. J. Lee, E. S. Han. Surgery, City of Hope Medical Center, Duarte, CA

4:01 p.m. – 4:06 p.m. QUESTIONS FOR VIDEO POSTERS 1–6

4:06 p.m. – 4:16 p.m.
Video Poster 7 – SURGICAL FINE PRINTS IN CENTRAL ANTERIOR VAGINAL WALL REPAIR

A. Nieuwoudt. Ziekenhuis Zorgsaam, Terneuzen, Netherlands

4:16 p.m. – 4:23 p.m.
Video Poster 8 – LE FORT PARTIAL COLPOCLEISIS: A LOW-COST MODEL

A. Gupta, S. Kanitsch, S. Herrera, L. Kane. Ob/Gyn, Crozer Chester Medical Center, Philadelphia, PA

4:23 p.m. – 4:32 p.m. QUESTIONS FOR VIDEO POSTERS 7–9

4:32 p.m. – 4:38 p.m.
Video Poster 9 – IDENTIFYING THE DEFECTS: DATA FROM 563 CONSECUTIVE ANTERIOR WALL DISSECTIONS

A. Nieuwoudt. Ziekenhuis Zorgsaam, Terneuzen, Netherlands

4:38 p.m. – 4:45 p.m.
Video Poster 10 – USE OF EXTRACELLULAR MATRIX DURING VAGINAL WALL REPAIR AFTER WIDE EXCISION OF A MESH

W. Chong1, A. D. Garely1, J. A. Fantl1. 1Obstetrics, Gynecology and Reproductive Sciences, Mount Sinai Medical Center/Icahn School of Medicine, New York, NY; 2Obstetrics and Gynecology, South Nassau Communities Hospital, Oceanside, NY

4:45 p.m. – 4:56 p.m. QUESTIONS FOR VIDEO POSTERS 10–12

4:56 p.m. – 5:02 p.m.
Video Poster 11 – A SITE-SPECIFIC TECHNIQUE FOR A POSTERIOR REPAIR

A. Peacher-Seaney, L. Dabney. FPMRS, Icahn School of Medicine at Mount Sinai, New York, NY

5:02 p.m. – 5:07 p.m. QUESTIONS FOR VIDEO POSTERS 10–12

4:00 p.m. – 4:15 p.m. BREAK – EXHIBIT LEVEL ATRIUM

4:15 p.m. – 5:30 p.m. SCIENTIFIC CONCURRENT SESSION 10: SURGERY SESSION – BALLROOM A
Moderators: Oz Harmanli, MD; Heidi Harvie, MD, MSCE, MBA

4:15 p.m. – 4:19 p.m.
Oral Poster 89 – ENHANCED RECOVERY PROGRAM FOR OUTPATIENT UROGYNECOLOGIC SURGERY

E. S. Chang1, B. Sarosiek2, E. Trowbridge1, K. L. Hullfish1. 1Obstetrics & Gynecology, University of Virginia, Charlottesville, VA; 2University of Virginia Health System, University of Virginia, Charlottesville, VA

4:19 p.m. – 4:23 p.m.
Oral Poster 90 – DOES VARIATION IN BONY LANDMARKS PREDICT SUCCESS WITH SACRAL NEUROMODULATION: ONE SIZE FITS ALL?

K. Husk1, L. Norris2, M. Willis-Gray2, K. Borawski1, E. Geller2. 1Urology, University of North Carolina Hospitals, Chapel Hill, NC; 2Urogynecology, University of North Carolina Hospitals, Chapel Hill, NC
4:23 p.m. – 4:27 p.m.  
Oral Poster 91 – IMPACT OF PREEMPITIVE ANALGESIA ON POSTOPERATIVE PAIN AFTER CYSTOSCOPY WITH HYDRODISTENTION FOR PAINFUL BLADDER SYNDROME/INTERSTITIAL CYSTITIS: A PILOT STUDY  
J. Fitzgerald1, C. M. Kunkle2, C. Chen1, M. Abemethy1, J. L. Blomquist1, I. C. Juan1, A. Long1, T. B. Fashokun1.  
1Gynecology and Obstetrics, Johns Hopkins, Baltimore, MD; 2Kaiser, Baltimore, MD; 3Greater Baltimore Medical Center, Baltimore, MD

4:27 p.m. – 4:31 p.m.  
Oral Poster 92 – DO SPINALS INCREASE RATES OF URINARY RETENTION? A RANDOMIZED CONTROLLED TRIAL  
A. Alas1, H. Devakumar1, L. Martin2, E. A. Hurtado2, G. Davila1.  
1OBGYN, University of Texas Health Science Center, San Antonio, TX; 2Female Pelvic Medicine and Reconstructive Surgery, Cleveland Clinic Florida, Weston, FL

4:31 p.m. – 4:35 p.m.  
Oral Poster 93 – DOES PREOPERATIVE PROLAPSE STAGE PREDICT RISK OF PERIOPERATIVE COMPLICATIONS DURING VAGINAL RECONSTRUCTIVE SURGERY?  
A. Thomson1, J. Lanzer1, D. D. Saguan-Burton2, G. M. Northington1.  
1Gynecology, Obstetrics and Reproductive Sciences, Emory University, Atlanta, GA; 2Kaiser Permanente, Jonesboro, GA

4:35 p.m. – 4:39 p.m.  
QUESTIONS FOR ORAL POSTERS 89–93

4:39 p.m. – 4:43 p.m.  
Oral Poster 94 – DOES GABAPENTIN REDUCE OPIOID USE POSTOPERATIVELY? GROUP STUDY: A RANDOMIZED CONTROL TRIAL IN WOMEN UNDERGOING RECONSTRUCTIVE PELVIC SURGERY  
A. Li1, K. Wadsworth1, N. T. Siddiqui1, M. Alarab1, C. D. McDermott1, N. Lemos1, D. Lovatsis1.  
1Obstetrics and Gynecology, Mount Sinai Hospital, Toronto, ON, Canada; 2Anesthesia, Mount Sinai Hospital, Toronto, ON, Canada

4:43 p.m. – 4:47 p.m.  
Oral Poster 95 – PRIMARY PELVIC ORGAN PROLAPSE SURGERY USING DELAYED ABSORBABLE SUTURE: ONE-YEAR OUTCOMES COMPARING ANTERIOR WALL SUCCESS IN VAGINAL UTEROSACRAL LIGAMENT SUSPENSION VERSUS SACRAL COLPOPEXY  
D. Bastawros1, M. E. Tarri1, M. A. Templin1, K. Stepp1, B. Taylor1, E. M. Myers1.  
1Female Pelvic Medicine and Reconstructive Surgery, Carolinas Health Care System, Charlotte, NC; 2Center for Outcomes Research and Evaluation (CORE), Charlotte, NC

4:47 p.m. – 4:51 p.m.  
Oral Poster 96 – INDWELLING VS IMMEDIATE REMOVAL OF FOLEY CATHETER AFTER ROBOTIC ASSISTED LAPAROSCOPIC SACROCOLOPEXY: A RANDOMIZED PROSPECTIVE STUDY  
P. Popiel1, V. Vallabh-Patel1, C. Salamon1.  
Atlantic Health, Clifton, NJ

4:51 p.m. – 4:55 p.m.  
Oral Poster 97 – OUTCOMES OF RECURRENT RECTOVAGINAL FISTULA REPAIR  
J. N. Byrnes1, J. Gebhart1, J. Schmitt1, J. N. Byrnes1.  
1OBGYN, University of California, San Diego, San Diego, CA; 2Kaiser Permanente, San Diego, CA; 3Kaiser Permanente, Charlotte, NC; 4Department of OB/GYN, University of California San Diego, San Diego, CA; 5Department of OB/GYN, Kaiser Permanente, San Diego, CA; 6Department of OB/GYN, Kaiser Permanente, Downey, CA

4:55 p.m. – 4:59 p.m.  
Oral Poster 98 – IS MESH USE POSTOPERATIVELY? GROUP STUDY: A RANDOMIZED CONTROLLED TRIAL IN WOMEN UNDERGOING ROBOTIC ASSISTED SACROCOLOPEXY  
N. Noor1, K. L. Armstrong1, M. Ortega1, V. Demitchouk1, E. Eldrady1.  
1FPMRS,Mount Auburn Hospital, Cambridge, MA; 2OBGYN, Tufts Medical Center, Boston, MA; 3OBGYN, UMass Memorial Medical Center, Worcester, MA

4:59 p.m. – 5:03 p.m.  
QUESTIONS FOR ORAL POSTERS 94–98

5:03 p.m. – 5:07 p.m.  
Oral Poster 99 – PREDICTORS OF OPIOID ADMINISTRATION IN THE ACUTE POST OPERATIVE PERIOD  
M. Willis-Gray1, K. Husk, T. Brueske, J. Wu, A. A. Dieter.  
OBGYN, University of North Carolina at Chapel Hill, Chapel Hill, NC

5:07 p.m. – 5:11 p.m.  
Oral Poster 100: A NOVEL: STRUCTURED FELLOW TRAINING PATHWAY FOR ROBOTIC-ASSISTED SACROCOLOPEXY  
1Department of Reproductive Medicine, Division of FPMRS, University of California, San Diego, San Diego, CA; 2Department of OB/GYN, Division of FPMRS, Kaiser Permanente, San Diego, CA; 3Department of OB/GYN, Division of FPMRS, Kaiser Permanente, Downey, CA

5:11 p.m. – 5:15 p.m.  
Oral Poster 101 – PERSISTENT STRESS URINARY INCONTINENCE AFTER SYNTHETIC MIDURETHRAL SLING PROCEDURE: A SURGICAL SOLUTION  
D. Maheshwari1, K. Jones1, O. Harmanli2.  
1Urogynecology and Pelvic Surgery, University of Massachusetts Medical School-Baystate, Springfield, MA; 2Yale Urogynecology and Pelvic Reconstructive Surgery, Yale School of Medicine, New Haven, CT

5:15 p.m. – 5:23 p.m.  
Video 14 – VESTIBULECTOMY TECHNIQUE FOR REFRACTORY VULVODYNIA  
T. Crous1, N. M. Shah, M. Dawson, K. E. Whitmore.  
Obstetrics and Gynecology, Drexel University, Philadelphia, PA

5:23 p.m. – 5:27 p.m.  
QUESTIONS FOR ORAL POSTERS 99–101
SCIENTIFIC PROGRAM (CONTINUED)

FRIDAY, OCTOBER 6 (Continued)

4:15 p.m. – 4:19 p.m.
Oral Poster 102 – RATE AND PREDICTORS OF URINARY INCONTINENCE AT 12 MONTHS POSTPARTUM
L. E. Giugale1, T. P. Canavan2, P. A. Moalli3, S. Oliphant4. 1Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital of UPMC, Pittsburgh, PA; 2University of Arkansas for Medical Sciences, Little Rock, AR; 3Division of Ultrasound, Magee-Womens Hospital of UPMC, Pittsburgh, PA; 4Magee-Womens Research Institute, Pittsburgh, PA

4:19 p.m. – 4:23 p.m.
Oral Poster 103 – EARLY POST-INJECTION URINARY TRACT INFECTION (UTI) PREDICTS RECURRENT UTI AFTER ONABOTULINUM TOXIN A
J. A. Bickhaus1, M. S. Bradley1, C. L. A. M. undersen2, A. G. Visco3, T. Truong4, Y. Li5, N. Y. Siddiqui1. 1Obstetrics & Gynecology, Duke University, Durham, NC; 2Biostatistics and Bioinformatics, Duke University, Durham, NC

4:23 p.m. – 4:27 p.m.
Oral Poster 104 – EDUCATIONAL AND ELECTRONIC REFERRAL INTERVENTIONS IN IMPROVING INCONTINENCE SCREENING AMONG PRIMARY CARE PHYSICIANS
J. S. Zigman, V. Yuan, S. Amaya, T. Yazdany. Obstetrics and Gynecology, Harbor UCLA Medical Center, Torrance, CA

4:27 p.m. – 4:31 p.m.
P. Lang, M. Karram, Female Pelvic Medicine and Reconstructive Surgery, The Christ Hospital, Cincinnati, OH

4:31 p.m. – 4:35 p.m.
Oral Poster 106 – RATES OF OBSTETRIC ANAL SPHINCTER INJURIES BEFORE AND AFTER TRAINING INVOLVING PERINEAL PROTECTION
J. Yeung1, A. Stecher2, D. Mazloomdoost1, C. C. Crisp3, B. Smith1, S. D. Kleeman1, R. N. Pauls1. 1Female Pelvic Medicine and Reconstructive Surgery, TriHealth Good Samaritan Hospital, Cincinnati, OH; 2Obstetrics & Gynecology, TriHealth Good Samaritan Hospital, Cincinnati, OH

4:35 p.m. – 4:39 p.m.
QUESTIONS FOR ORAL POSTERS 102-106

4:39 p.m. – 4:43 p.m.
Oral Poster 107 – COMPARISON OF ANORECTAL MANOMETRY TESTING IN LEFT LATERAL AND DORSAL LITHOTOMY POSITIONS

4:43 p.m. – 4:47 p.m.
A. M. Hesson, A. G. Sammarco, M. B. Berger, H. K. Haefner. Obstetrics and Gynecology, Michigan Medicine, Ann Arbor, MI

4:47 p.m. – 4:51 p.m.
Oral Poster 109 – EASY TO FIND BUT DIFFICULT TO UNDERSTAND? ANALYZING THE READABILITY OF ONLINE UROGYNECOLOGIC PATIENT INFORMATION
R. Stewart1, S. L. Francis1, K. V. Meriwether1, C. L. Kinman1, D. Hobson1, J. Gaskins2. 1Obstetrics, Gynecology, and Women’s Health, University of Louisville School of Medicine, Louisville, KY; 2University of Louisville School of Public Health and Information Sciences, Louisville, KY

4:51 p.m. – 4:55 p.m.
Oral Poster 110 – OPIOID REQUIREMENTS AFTER VAGINAL HYSTERECTOMY WITH MINIMALLY INVASIVE SACROCOLPOPEXY
N. M. Shah1, J. P. Shepherd2, L. Andriani1, C. Ingraham1, C. B. Iglesia3. 1Georgetown University School of Medicine, Washington; 2University of Pittsburgh Medical Center, Pittsburgh, PA; 3OB/GYN, MedStar Washington Hospital Center, Washington,
4:55 p.m. – 4:59 p.m.
Oral Poster 111 – URINARY SYMPTOMS AND THEIR EFFECT ON QUALITY OF LIFE IN WOMEN LIVING WITH HIV: A CROSS-SECTIONAL STUDY
M. Larouche1, S. Blitz2, J. Raboud3, N. Lipsky4, G. W. Cundiff5, D. M. Money6, HPV in HIV Study Group7. 1Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada; 2Obstetrics and Gynecology, McGill University, Montreal, QC, Canada; 3Women’s Health Research Institute, Vancouver, BC, Canada; 4Toronto General Research Institute, University Health Network, Toronto, ON, Canada.

5:15 p.m. – 5:22 p.m.
Video 15 – LOGOTHETOPULOS: CONTROL OF INTRAOPERATIVE HEMORRHAGE WITH PELVIC PRESSURE PACK
J. Gonzalez1, S. A. Davidson2, T. M. Muffly3. 1University of Colorado School of Medicine, Aurora, CO; 2Denver Health, Denver, CO.

5:22 p.m. – 5:26 p.m.
QUESTIONS FOR ORAL POSTERS 112–114

4:19 p.m. – 4:23 p.m.
Oral Poster 115 – PATIENT-IMPORTANT CRITICAL CONTENT AND THE ROLE OF PEER SUPPORT FOR WOMEN UNDERGOING SURGERY FOR PELVIC FLOOR DISORDERS
A. M. Madsen1, G. C. Dunivan2, R. G. Rogers3, A. M. Parrillo4, V. W. Sung5. 1Urogynecology/Obstetrics and Gynecology, Women and Infants Hospital/ Warren Alpert Medical School of Brown University, Providence, RI; 2University of New Mexico, Albuquerque, NM; 3University of Texas at Austin, Austin, TX.

4:23 p.m. – 4:27 p.m.
Oral Poster 117 – CAN WOMEN WITH LEVATOR ANI TEAR ON MR IMAGES EFFECTIVELY INCREASE URETHRAL CLOSURE PRESSURE DURING A VOLITIONAL PELVIC FLOOR MUSCLE CONTRACTION? A FOCUS ON POSTPARTUM WOMEN AT HIGH RISK FOR LEVATOR ANI TEAR FROM RECENT VAGINAL CHILDBIRTH
Y. Sheng1, J. Miller. 1School of Nursing, University of Michigan, Ann Arbor, MI.

4:27 p.m. – 4:31 p.m.
Oral Poster 118 – TRANSFORMING COMMUNITY-BASED CONTINENCE PROMOTION: THE BOWEL MOVEMENT H. W. Brown1, M. Wise2, S. M. Myers3, J. E. Mahoney4, R. G. Rogers4. 1School of Medicine and Public Health, University of Wisconsin–Madison, Madison, WI; 2School of Pharmacy, University of Wisconsin–Madison, Madison, WI; 3Community-Academic Aging Research Network, Wisconsin Institute for Healthy Aging, Madison, WI; 4Dell Medical School, University of Texas at Austin, Austin, TX.
FRIDAY, OCTOBER 6 (Continued)

4:43 p.m. – 4:47 p.m.
Oral Poster 121 – DENERVATION OF THE TRIGONE FOR TREATMENT OF URGENCY URINARY INCONTINENCE ASSOCIATED WITH OVERACTIVE BLADDER
1Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN; 2Urogynecology, Ghent University, Gent, Belgium; 3University of Calgary, Calgary, AB, Canada; 4Medical University of South Carolina, Charleston, SC; 3University of Sherbrooke, Sherbrooke, QC, Canada; 4University of Antwerp, Antwerp, Belgium

5:03 p.m. – 5:07 p.m.
Oral Poster 125 – DEVELOPMENT OF A NEUROSTIMULATOR IMPLANT TECHNIQUE FOR TIBIAL NERVE STIMULATION
G. W. Stone5, D. D. Gruber1, J. Buller2.
5Obstetrics and Gynecology, Walter Reed National Military Medical Center, Arlington, VA; 2Uniformed Services University of Health Sciences, BETHESDA, MD

5:07 p.m. – 5:11 p.m.
Oral Poster 126 – VAGINAL SACRAL COLPOPEXY: A NATURAL ORIFICE APPROACH TO A GOLD STANDARD PROCEDURE
C. R. Hanes. Urogynecology of Southern Alabama, Mobile, AL

5:11 p.m. – 5:15 p.m.
Oral Poster 127 – EVALUATION OF SER120 FOR THE TREATMENT OF PATIENTS WITH NOCTURIA DUE TO NOCTURNAL POLYURIA WITH CONCOMITANT OVERACTIVE BLADDER
D. M. Van Drie1, H. Lepor2, V. W. Nitti2, M. Cheng3, L. Cheng3, S. Fein3. 1Female Pelvic Medicine and Urogynecology Institute of Michigan, Grand Rapids, MI; 2New York University Medical Center, New York, NY; 3Serenity Pharmaceuticals, LLC, Milford, PA

5:15 p.m. – 5:25 p.m.
Video 16 – EXCISION OF VAGINAL MESH EXPOSURE IN THE BLADDER: A ROBOTIC APPROACH
D. L. OShaughnessy5, C. J. Diblasio2, P. Finamore1. 1Female Pelvic Medicine and Reconstructive Surgery, Northwell Health System, Huntington, NY; 2Urology, Northwell Health System, Huntington Hospital, Huntington, NY

SATURDAY, OCTOBER 7

8:30 a.m. – 8:35 a.m.
ANNOUNCEMENTS AND PREVIEW OF 2018 – EXHIBITION HALL C

8:35 a.m. – 9:30 a.m.
GENERAL SCIENTIFIC SESSION V – EXHIBITION HALL C
Moderators: Emily Lukacz, MD; Vivian Sung, MD

8:35 a.m. – 8:45 a.m.
Paper 23 – EFFECTIVENESS AND SAFETY OF A NEW DISPOSABLE VAGINAL DEVICE FOR THE NON-SURGICAL MANAGEMENT OF PELVIC ORGAN PROLAPSE (POP) IN WOMEN
E. Ziv1, S. Dascalu1, J. May2, T. Erlich3.
1Gynecology-Hertzelia, Hertzelia, Israel; 2Gynecology Ramat Hasharon, Ramat Hasharon, Israel; 3ConTIPI Medical Ltd, Caesarea, Israel

8:45 a.m. – 9:03 a.m.
Paper 24 – THE IMPACT OF A DECISION AID ON TREATMENT DECISION MAKING FOR STRESS URINARY INCONTINENCE
J. J. Navas1, S. Amaya2, T. Yazdany3.
1FPMRS, Harbor-UCLA Medical Center, Torrance, CA; 2LA BioMed, Torrance, CA
9:03 a.m. – 9:13 a.m.
Paper 25 – OVERACTIVE VOIDING BEHAVIOR IN SURGICALLY-INDUCED MENOPAUSAL MICE EXPOSED TO LPS IS MODULATED BY DISTINCT GENE PATHWAYS
M. G. Acevedo Alvarez, J. Y. Yeh, L. Alvarez-Lugo, M. Lu, N. Sukumar, W. Hill, T. C. Chai. 1Urogynecology, Yale University, New Haven, CT; 2Urology, Yale University, New Haven, CT; 3School of Public Health, Yale University, New Haven, CT; 4Nephrology, Beth Israel Deaconess, Boston, MA

9:13 a.m. – 9:23 a.m.
Paper 26 – SEXUAL FUNCTION IN RELATIONSHIPS AFFECTED BY URGE URINARY INCONTINENCE
J. Cunkelman, T. Dune, M. Tulke, E. R. Mueller. 1Food and Drug Administration, Silver Spring, MD; 2Urology, Weill Cornell Medicine, New York, NY; 3Departments of Obstetrics/Gynecology & Urology, Loyola University Medical Center, Chicago, IL

9:23 a.m. – 9:28 a.m.
Tip and Trick 2 – SACRAL NEUROMODULATION LEAD REMOVAL: A NOVEL TECHNIQUE

9:30 a.m. – 10:30 a.m.
INSIGHTS ON HOW TO NAVIGATE PRODUCT CONTROVERSY
Moderator: Cheryl Iglesia, MD
Panelists: Julie Cantor, MD, JD; Patrick Culligan, MD; Alan Garely, MD

10:30 a.m. – 10:45 a.m.
BREAK

10:45 a.m. – 11:30 a.m.
MASTER SURGEON PRESENTATIONS – EXHIBITION HALL C
Moderators: Felicia Lane, MD; Marlene Corton, MD
Presenters: Nucelio Lemos, MD; Beri Ridgeway, MD

11:30 a.m. – 12:30 p.m.
GENERAL SCIENTIFIC SESSION VI – EXHIBITION HALL C
Moderators: Charles Rardin, MD; Cassandra Carberry, MD

11:30 a.m. – 11:40 a.m.
Paper 27 – DOES THE AUGS NOW RISK CALCULATOR ACCURATELY DISCRIMINATE BETWEEN WOMEN WITH AND WITHOUT POSTOPERATIVE SUI?

11:40 a.m. – 11:50 a.m.
Paper 28 – SLEEP QUALITY AND DAYTIME SLEEPINESS AMONG WOMEN WITH URGENT URINARY INCONTINENCE

11:50 a.m. – 12:00 p.m.
Paper 29 – PATIENT PREPAREDNESS FOR PELVIC FLOOR PHYSICAL THERAPY: STANDARD COUNSELING VS VIDEO
M. Brady, C. M. Fitzgerald, W. Adams, L. Brubaker, E. R. Mueller, C. Brincat. 1Obstetrics and Gynecology, Loyola University Medical Center, Maywood, IL; 2Health Sciences Division, Loyola University Chicago, Maywood, IL

12:00 p.m. – 12:10 p.m.
Paper 30 – THE NATURAL HISTORY OF URINARY INCONTINENCE IN WOMEN: A PROSPECTIVE ANALYSIS OF THE NURSES’ HEALTH STUDY I & II
K. Hagan, E. Erekson, A. M. Austin, V. Minassian, M. K. Townsend, J. P. Bynum, F. Grodstein, 1Brigham and Women’s Hospital, Boston, MA; 2Geisel School of Medicine, Hanover, NH

12:10 p.m. – 12:20 p.m.
Paper 31 – AGE-DEPENDENT CHANGES IN MYELOID CELL RECRUITMENT AND TISSUE REPAIR IN THE MURINE BLADDER FOLLOWING A URINARY TRACT INFECTION
C. Wang. OB/Gyn, Washington University in St. Louis, Saint Louis, MO

12:20 p.m. – 12:30 p.m.
Paper 32 – INDUSTRY FINANCIAL RELATIONSHIPS TO FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE PHYSICIANS: ANALYSIS OF SUNSHINE ACT OPEN PAYMENTS
T. M. Muffly, J. S. Guido, R. Weterings, W. Giamberardino. 1Female Pelvic Medicine and Reconstructive Surgery, Denver Health, Denver, CO; 2University of Colorado School of Medicine, Aurora, CO; 3MJW Technical Services, Amherst, NY

12:30 p.m. – 1:30 p.m.
WHAT ARE UROGYNECOLOGISTS GOING TO GET PAID AND HOW?
Moderator: Jonathan Gleason, MD
Presenters: Mitchell Schuster, MD; Samantha Pulliam, MD

1:30 p.m.
ADJOURN
## EXHIBITOR LISTING

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACell, Inc.</td>
<td>104</td>
</tr>
<tr>
<td>Advanced Tactile Imaging, Inc.</td>
<td>110</td>
</tr>
<tr>
<td>Allergan, Inc.</td>
<td>101</td>
</tr>
<tr>
<td>Allergan Medical Affairs</td>
<td>608</td>
</tr>
<tr>
<td>Alma Lasers</td>
<td>109</td>
</tr>
<tr>
<td>AMAG Pharmaceuticals</td>
<td>711</td>
</tr>
<tr>
<td>American Urogynecologic Society (AUGS)</td>
<td>317</td>
</tr>
<tr>
<td>Astellas Pharma, US, Inc.</td>
<td>701</td>
</tr>
<tr>
<td>Bioteque America Inc.</td>
<td>217</td>
</tr>
<tr>
<td>BK Ultrasound</td>
<td>611</td>
</tr>
<tr>
<td>Boston Scientific</td>
<td>201</td>
</tr>
<tr>
<td>Caldera Medical</td>
<td>200</td>
</tr>
<tr>
<td>CMS Market Research</td>
<td>713</td>
</tr>
<tr>
<td>Cogentix Medical</td>
<td>515</td>
</tr>
<tr>
<td>Coloplast Corp.</td>
<td>211</td>
</tr>
<tr>
<td>CooperSurgical</td>
<td>614</td>
</tr>
<tr>
<td>Cynosure, A Hologic Company</td>
<td>115</td>
</tr>
<tr>
<td>DSE Healthcare Solutions – PRELIEF</td>
<td>218</td>
</tr>
<tr>
<td>Elidad</td>
<td>619</td>
</tr>
<tr>
<td>elliura (by Trophikos)</td>
<td>214</td>
</tr>
<tr>
<td>Emmy Medical</td>
<td>108</td>
</tr>
<tr>
<td>Ethicon US, LLC</td>
<td>314</td>
</tr>
<tr>
<td>Halo Medical Technologies</td>
<td>710</td>
</tr>
<tr>
<td>Icon Undies</td>
<td>106</td>
</tr>
<tr>
<td>InMode</td>
<td>118</td>
</tr>
<tr>
<td>Innovation Compounding, Inc.</td>
<td>709</td>
</tr>
<tr>
<td>International Urogynecological Association</td>
<td>117</td>
</tr>
<tr>
<td>Intuitive Surgical</td>
<td>507</td>
</tr>
<tr>
<td>Invuity, Inc.</td>
<td>705</td>
</tr>
<tr>
<td>LABORIE</td>
<td>316</td>
</tr>
<tr>
<td>Laclede Inc.</td>
<td>617</td>
</tr>
<tr>
<td>Lumenis</td>
<td>603</td>
</tr>
<tr>
<td>Lutronic</td>
<td>719</td>
</tr>
<tr>
<td>Marina Medical Instruments, Inc.</td>
<td>606</td>
</tr>
<tr>
<td>Medspira, LLC</td>
<td>615</td>
</tr>
<tr>
<td>Medtronic</td>
<td>501</td>
</tr>
<tr>
<td>Neomedic International</td>
<td>100</td>
</tr>
<tr>
<td>NinoMed</td>
<td>715</td>
</tr>
<tr>
<td>Norton Medical Group</td>
<td>717</td>
</tr>
<tr>
<td>Olympus</td>
<td>718</td>
</tr>
<tr>
<td>Pacira Pharmaceuticals</td>
<td>716</td>
</tr>
<tr>
<td>Pathnostics</td>
<td>119</td>
</tr>
<tr>
<td>Pelvalon</td>
<td>708</td>
</tr>
<tr>
<td>The Prometheus Group</td>
<td>215</td>
</tr>
<tr>
<td>Sagent Pharma</td>
<td>116</td>
</tr>
<tr>
<td>Sciton</td>
<td>107</td>
</tr>
<tr>
<td>Solace Therapeutics</td>
<td>208</td>
</tr>
<tr>
<td>Syneron Candela</td>
<td>216</td>
</tr>
<tr>
<td>Teleflex</td>
<td>714</td>
</tr>
<tr>
<td>Theralogix</td>
<td>707</td>
</tr>
<tr>
<td>Thermi, an Almirall Company</td>
<td>601</td>
</tr>
<tr>
<td>Tissue Regenix</td>
<td>112</td>
</tr>
<tr>
<td>Viveve, Inc.</td>
<td>607</td>
</tr>
<tr>
<td>Wolters Kluwer</td>
<td>609</td>
</tr>
</tbody>
</table>
Features of our online community:

- Discussion Forums
- Ask the Physician Experts
- Downloadable Resources
- Informational Articles

Our online community, Voices for PFD, is an outlet for women to share their stories, get support from other women, and ask experts about disorders impacting the pelvic floor, such as incontinence and prolapse.

Pelvic Floor Dialogues
Patients can subscribe to our eNewsletter to keep up-to-date on the latest advancements on pelvic floor disorders.

Patient Fact Sheets
Patients can utilize fact sheets to better understand diagnoses and treatment options on a variety of topics.

Voices for PFD YouTube Channel
Women with pelvic disorders can subscribe to the Voices for PFD YouTube Channel to hear from leading physicians about pelvic floor disorder symptoms and treatment options.

Patient educational resources are sponsored by AUGS and supported in part through educational grants from:
ACELL, INC.  
**Booth 104**  
www.acell.com

ACell is a leading regenerative medicine company that develops and manufactures products designed to facilitate the body’s ability to repair and remodel tissue. Our company helps patients in a variety of settings heal differently. ACell’s products are gradually incorporated within the patient’s body and replaced with site-appropriate tissue.

ADVANCED TACTILE IMAGING, INC.  
**Booth 110**  
www.tactile-imaging.com

A developer and manufacturer of innovative medical devices: vaginal treatment and monitoring system (FemTact) composed of a laser device and Vaginal Tactile Imager (VTI); Laparoscopic Tactile Imager (LTI); vaginal tactile and high definition EMG guided therapy device (Restore-IT), and Cervix Monitor (CM) for measurement of cervix elasticity and length.

ALLERGAN, INC.  
**Booth 101**  
www.allergan.com

Allergan plc (NYSE: AGN), is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. For more information, visit Allergan’s website at www.allergan.com.

ALLERGAN MEDICAL AFFAIRS  
**Booth 608**  
www.allergan.com

Allergan plc (NYSE: AGN), is a bold, global pharmaceutical company focused on developing, manufacturing, and commercializing branded pharmaceuticals, devices, and biologic products for patients around the world. For more information, visit Allergan’s website at www.allergan.com.

ALMA LASERS  
**Booth 109**  
www.ooo.com

Alma Lasers is a global innovator of laser, light-based, radiofrequency and ultrasound solutions for the aesthetic and surgical markets. We enable practitioners to offer safe and effective procedures while allowing patients to benefit from state-of-the-art, clinically proven technologies and treatments.

AMAG PHARMACEUTICALS  
**Booth 711**  
www.amagpharma.com

AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune, and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.

AMERICAN UROGYNECOLOGIC SOCIETY (AUGS)  
**Booth 317**  
www.augs.org

The American Urogynecologic Society (AUGS), founded in 1979, is the premier society dedicated to research and education in urogynecology, and the detection, prevention, and treatment of female pelvic floor disorders. As the leader in Female Pelvic Medicine and Reconstructive Surgery, AUGS promotes the highest quality patient care through excellence in education, research, and advocacy. Visit AUGS in Booth 317 for information on membership, the AQUIRE Registry, and patient resources.

ASTELLAS PHARMA US, INC.  
**Booth 701**  
www.astellas.us

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. For more information about Astellas Pharma US, Inc., please visit our web site at www.astellas.us.

BIOTEQUE AMERICA INC.  
**Booth 217**  
www.bioteque.com

Bioteque America Inc is a medical device manufacturer and distributor specializing in gynecology, urogynecology, and urology products. All products manufactured for Bioteque come from an FDA inspected facility. Some of our products include: vaginal supportive pessaries, endometrial sampling devices, vaginal dilators, hsg catheters, cervical dilators, instruments. Allow us to earn your business. ISO 13485; CE 0434

BK ULTRASOUND  
**Booth 611**  
www.bkultrasound.com

BK Ultrasound is a global leader in pelvic floor ultrasound. Our unique multi-compartment solution lets you image the anterior, middle, and posterior compartments allowing you to see the pelvic floor architecture in superb detail and high-resolution 3D. The bk3000 and Flex Focus ultrasound systems deliver excellent image quality, mobility and flexibility.

BOSTON SCIENTIFIC  
**Booth 201**  
www.bostonscientific.com/femalepelvicmedicine

Boston Scientific remains committed to the treatment of pelvic floor disorders and to you and your patients. We are anchored in our guiding principle to provide innovative products that are supported with clinical data and offer robust professional programs to advance the quality of care. We stand by the quality of our products and our overall commitment to women’s health.

CALDERA MEDICAL  
**Booth 200**  
www.calderamedical.com

Caldera Medical is a Women’s Health medical device company which focuses on improving the quality of life for women. Caldera Medical develops, manufactures, and markets differentiated surgical implants for the treatment of Stress Urinary Incontinence (Desara® Sling System) and Pelvic Organ Prolapse (Vertessa® Lite).

CMS MARKET RESEARCH  
**Booth 713**
COGENTIX MEDICAL  
Booth 515  
www.cogentixmedical.com  
Cogenx Medical products include Urgent® PC, a low-risk, office-based OAB TAT that provides clinically significant and durable results; EndoSheath™ Systems that combine state-of-the-art endoscopic technology with a sterile, disposable microbial barrier; and Macroplastique®, a bulking agent for adult female SUI. Cogenxij was formed through a merger of Uroplasty and Vision-Sciences.

COLOPLAST CORP.  
Booth 211  
www.coloplast.us  
With a 60-year legacy of commitment and dedication to women’s health, Coloplast offers innovative solutions for the treatment of SUI and POP, featuring products such as the Altis® Single Incision Sling System, Aris® and Supris® full length slings, Restorelle® Y-Contour™, Restorelle® DirectFix™ and Axis™ and Suspend® biologic grafts.

COOPERSURGICAL  
Booth 614  
www.coopersurgical.com  
Since our founding in 1990, CooperSurgical has researched, developed, and manufactured a wide range of trusted brands that have advanced the standard of care for families. Our diversified portfolio of products and services focuses on women’s health, fertility, and diagnostics. Visit us at booth #614 to interact with our industry leading solutions and experience why CooperSurgical is at the forefront of women’s healthcare.

CYNOUSRE, A HLOGIC COMPANY  
Booth 115  
www.cynosure.com  
 MonaLisa Touch is a revolutionary fractional CO2 laser treatment for the painful symptoms of menopause, including intimacy. It is the only technology for vaginal and vulvar health with over 18 published studies and is sold exclusively to experts in female pelvic health. Patients are calling it life-changing.

DSE HEALTHCARE SOLUTIONS – PRELIEF  
Booth 218  
www.prelief.com  
DSE Healthcare Solutions, LLC offers products that provide solutions for specialty health concerns. Examples of leading specialty health brands include: PRELIEF®, a dietary supplement that reduces up to 95 percent of the acid in foods and beverages so patients can avoid digestive & bladder discomfort caused by acid foods.

ELIDAH  
Booth 619  
www.elidah.com  
Elidah has a conservative non-vaginal treatment for the one in three women with stress urinary incontinence. Elitone™ strengthens the pelvic floor muscles discreetly, non-invasively, and while going about normal activities with surface electrical stimulation. Elitone improves the quality of life for tens of millions of women.

ELLURA (BY TROPHIKOS)  
Booth 214  
www.myellura.com  
Ellura is a medical-grade supplement proven effective as an alternative to antibiotics for UTI prevention. Only Ellura contains 36 mg PAC (proanthocyanidins) and inhibits bacterial adhesion to the bladder wall, stopping the UTI before it starts. Patients can take once daily to prevent recurrent UTIs or choose our convenient ‘on-demand’ sexual intercourse dosing.

EMMY MEDICAL  
Booth 108  
www.cystosure.com  
Emmy Medical has developed Cystosure® a unique 4-Way urinary catheter allowing comprehensive office evaluation to be conducted in under 10 minutes. CystoSure® makes office and OR cystoscopy safe, simple, and standardized for all clinicians. In 2017, Emmy will be launching the Kohli catheter that potentially reduces bladder trauma and UTIs.

ETHICON US, LLC  
Booth 314  
www.ethicon.com  
Ethicon US LLC , a Johnson & Johnson company, commercializes a broad range of innovative surgical products, solutions, and technologies used to treat some of today’s most prevalent medical issues, such as: colorectal and thoracic conditions, women’s health conditions, hernias, cancer, and obesity.

HALO MEDICAL TECHNOLOGIES  
Booth 710  
www.halomedtech.com  
Halo Medical Technologies offers affordable, high-resolution ultrasound for diagnosing fecal incontinence, visualizing mesh and investigating pelvic floor disorders; optimized imaging and proprietary software designed specifically for the urogynecologist; true video recording, and complete post-processing capabilities, and EMR-automated reports. Uniquely-configured probes are interchangeable during exams, for one comprehensive report. Visit us at Booth #710.

ICON UNDIES  
Booth 106  
www.iconundies.com  
Icon Undies are beautiful, reusable, absorbent underwear for bladder leaks. Each pair can hold up to eight tsp. of liquid (light and moderate options available), and are antimicrobial, anti-odor, and machine washable. Every pair purchased helps fund fistula surgeries through our partnership with the Fistula Foundation. Truly life changing underwear!

INMODE  
Booth 118  
www.inmodemd.com  
For over two decades the leaders and scientists behind InMode have been revolutionizing the medical aesthetic industry with state-of-the-art light, RF and laser solutions. The newest addition to their legacy of industry leading technology advancements is Votiva: a safe, gentle, and effective non-surgical solution for feminine health.

INNOVATION COMPOUNDING, INC.  
Booth 709  
www.innovationcompounding.com  
Innovation Compounding is a compounding pharmacy that supports over 1,400 prescribers, 17,000 patients and 39,000 prescriptions across the nation. We commit to individualized pharmaceutical care through being relentless in our drive for personalized medicine, compassionate toward our patients and doctors, as well as being a wellness advocate for our patients’ lives and state of well being. It is our passion to enhance our patients’ quality of life!

INTERNATIONAL UROGYNECOLOGICAL ASSOCIATION (IUGA)  
Booth 117  
www.iuga.org  
The International Urogynecological Association (IUGA) has over 3,000 members who specialize in disorders of the pelvic floor. The association is dedicated to the global advancement of urogynecological knowledge and patient care through education and the promotion of basic and clinical research on disorders of the female pelvic floor.
INTUITIVE SURGICAL
Booth 507
www.intuitivesurgical.com
Intuitive Surgical is the global leader in minimally invasive, robotic-assisted surgery. Its da Vinci® Surgical System – with a 3D-HD vision system and EndoWrist® instrumentation – enables surgeons to offer a minimally invasive approach for a range of complex procedures. da Vinci is used in more than 3,500 hospitals around the world.

INVIVITY, INC.
Booth 705
www.invivity.com
Invivity is a medical technology company focused on pioneering the use of advanced photonics to provide surgeons with improved direct visualization of surgical cavities during open minimally invasive and minimal access procedures. Our patented Intelligent Photonics converts traditional thermally hot, concentrated light output to thermally cool volumetric illumination.

LABORIE
Booth 316
www.laborie.com
LABORIE is proud to celebrate 50 years of innovation and commitment to improving the lives of patients suffering from urologic and gastrointestinal disorders. LABORIE’s product line includes solutions for uro dynamics, anorectal manometry, uroflowmetry, ultrasound and pelvic floor rehabilitation. For more information on LABORIE products and educational offerings please visit www.laborie.com.

LACLEDE INC.
Booth 617
luvenacare.com
Laclede Inc. is the manufacturer of Luvena Vaginal Health products specializing in vaginal dryness. Luvena products containing natural enzymes are free from harmful ingredients such as parabens hormones and chlorhexidine. The product line includes, Luvena Vaginal moisturizer, wipe, enhanced moisturizer, feminine wash and rinse.

LUMENIS
Booth 603
www.lumenis.com
Lumenis is a global developer and distributor of medical laser systems. Lumenis has achieved 50 years of excellence, where products are recognized worldwide as an industry gold standard. Products include UltraPulse and AcuPulse FemTouch fractional CO2 lasers. They deliver high standards of quality and reliability with premium value and service.

LUTRONIC
Booth 719
www.lutronic.com
Lutronic introduces BellaV for vaginal rejuvenation therapy with our ACTION II Er:YAG 2940 nm Laser. BellaV is a safe, simple solution for problems associated with vaginal health. Come visit us at Booth #719!

MARINA MEDICAL INSTRUMENTS, INC.
Booth 606
MarinaMedical.com
Marina Medical is a global medical device company and industry leader in the diagnostic and surgical aspects of Women’s Health. Our mission is to design, develop and deliver surgeon-focused solutions. Stop by our booth to see how our latest innovations can help you.

MEDSPIRA, LLC
Booth 615
www.medsSpiRa.com
MedsPria partners with leading medical institutions to develop and market cost-effective diagnosis and treatment solutions for a variety of medical conditions. MedsPria’s mcompass is a portable anorectal manometry system utilized by private offices and hospitals alike. We are happy to be able to include ultrasound and our new FDA approved biofeedback pelvic floor retraining module on the same hardware platform. The mcompass is a great solution to help in the diagnosis and now treatment of patients with fecal incontinence and chronic constipation.

MEDTRONIC
Booth 501
www.medtronic.com
As a global leader in medical technology, services, and solutions, Medtronic improves the lives and health of millions of people each year. We use our deep clinical, therapeutic and economic expertise to address the complex challenges faced by healthcare systems today. Let’s take healthcare further, together. Learn more at Medtronic.com.

NEOMEDIC INTERNATIONAL
Booth 100
www.neomedic.com
Neomedic International “The Continence Company” provides you with the right product for every case: first and only long term adjustable sling; first and only single incision sling without anchors; first and only knotless incontinence mesh; first and only “anchor pulley system” for sacrospinose fixation. Neomedic Int, “The continence Company”.

NINOMED
Booth 715
www.nino-med.com
Ninomed, LLC is a medical device and business analytics company passionate about inventing and developing innovative products and services designed to provide improved patient care, safety, efficiency, and value. Safe-T-Secure® by Ninomed is the original all-in-one integrated trendelenburg patient positioning solution for robotic and laparoscopic surgery.

NORTON MEDICAL GROUP
Booth 717
www.beanortondoc.com
Norton Medical Group maintains 22 years’ experience operating physician practices and Norton Immediate Care Centers throughout Kentucky and Southern Indiana. Norton Medical Group provides comprehensive management and support services to its medical providers and locations. More than 900 employed medical providers and nearly 2,600 employees work in over 210 locations.

OLYMPUS
Booth 718
www.medical.olympusamerica.com
As a global technology leader, Olympus develops solutions for healthcare professionals to help improve clinical outcomes, reduce overall costs and enhance quality of life for patients. Olympus is a pioneer in developing advanced technologies for performing minimally invasive gynecologic surgeries. We have actively led the way in promoting laparoscopic hysterectomy and laparo-endoscopic single site (LESS) surgery, providing training to surgeons and education to patients.

PACIRA PHARMACEUTICALS, INC.
Booth 716
www.pacira.com
Pacira Pharma Inc, manufacturers of EXPAREL liposomal bupivacaine for post-surgical pain management.

PATHNOSTICS
Booth 119
www.pathnostics.com
Pathnostics is a cutting-edge diagnostic laboratory, focusing on difficult to treat conditions, such as recurrent UTIs, Prostatitis and Interstitial Cystitis. Pathnostics developed a real time molecular PCR test to help diagnose these conditions and a proprietary antibiotic resistance piece to help the clinician with the treatment course.
PELVALON
Booth 708
www.eclipsesystem.com
The Eclipse System is an innovative, non-surgical device company with a comprehensive product portfolio. The Company’s technology enables physicians to provide advanced solutions for a broad range of applications including body contouring, hair removal, tattoo removal, wrinkle reduction, and the treatment of vascular/ pigmented lesions, acne, leg veins, and cellulite.

THE PROMETHEUS GROUP
Booth 215
www.theprogrp.com
Advanced platforms for pelvic floor muscle rehabilitation, urodynamics, anorectal manometry, multi-compartmental ultrasound, and supporting consumables and accessories.

SAGENT PHARMA
Booth 116
www.SagentPharma.com
Sagent Pharmaceuticals is a global provider of medical products and solutions in the fields of vascular and pigmented lesions, acne, leg veins, and cellulite. Sagent markets evidence-based, content-certified nutritional supplements, including TheraCran ONE®, a once-daily capsule independently certified to deliver 36 mg of cranberry proanthocyanidins (PACs), providing round-the-clock bacterial anti-adhesion benefits in the lower urinary tract.

SCITON
Booth 107
www.sciton.com
Sciton is committed to providing best-in-class laser and light solutions for medical professionals who want superior durability, performance and value. Sciton offers high-quality medical devices for laser-assisted lipolysis, fractional and full-coverage skin resurfacing, hair removal, vaginal rejuvenation, phototherapy, wrinkle reduction, treatment of vascular and pigmented lesions, scar reduction, and acne.

SYNERON CANDELA
Booth 216
www.syneron-candela.com
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio. The Company’s technology enables physicians to provide advanced solutions for a broad range of applications including body contouring, hair removal, tattoo removal, wrinkle reduction, and the treatment of vascular/ pigmented lesions, acne, leg veins, and cellulite.

THERALOGIX
Booth 707
www.theralogix.com
Theralogix markets evidence-based, content-certified nutritional supplements, including TheraCran ONE®, a once-daily capsule independently certified to deliver 36 mg of cranberry proanthocyanidins (PACs), providing round-the-clock bacterial anti-adhesion benefits in the lower urinary tract.

THERALOGIX
Booth 707
www.theralogix.com
Theralogix markets evidence-based, content-certified nutritional supplements, including TheraCran ONE®, a once-daily capsule independently certified to deliver 36 mg of cranberry proanthocyanidins (PACs), providing round-the-clock bacterial anti-adhesion benefits in the lower urinary tract.

TELEFLEX
Booth 714
www.teleflex.com
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation—a relentless pursuit of identifying unmet clinical needs—to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine, and respiratory care.

TISSUE REGENIX
Booth 112
www.tissueregenixUS.com
DermaPure®, a next-generation decellularized dermal allograft, signals a new direction for soft tissue surgery. Its intact vascular channels signal cellular activity for enabling graft take, pro-angiogenic response promotes integration, while maintaining the thin profile and biomechanical properties of native tissue for optimized handling designed with the surgeon in mind.

VIVEVE, INC.
Booth 607
www.viveve.com
Viveve, Inc. is dedicated to developing innovative devices in women’s health and wellness. Their flagship product, the Viveve® System delivers cryogen-cooled Monopolar RF (CMRF) energy deep into soft tissue while protecting delicate surface tissue. The Geneveve™ by Viveve procedure is used in nearly 50 countries to treat vaginal laxity and to improve sexual function.

WOLTERS KLUWER
Booth 609
www.lww.com
Wolters Kluwer is a leading publisher of medical, health, and science publications including Female Pelvis Medicine & Reconstructive Surgery. We offer an extensive selection of medical books, journals and electronic media for health professionals and students. Visit booth #609 to browse our comprehensive product line.
SAVE THE DATE

UROGYN UPDATE 2018

Latest Techniques & Emerging Trends

February 22-24, 2018
Andaz Scottsdale Resort and Spa
Scottsdale, AZ

Engage with Innovative Problem Solvers
Implement New Concepts in your Practice
Optimize Patient Care

Expand your knowledge of the latest treatments of complex female pelvic floor disorders and the latest important research in the field. Leave the conference with valuable insights from leaders in the field on complex and challenging clinical scenarios that you can implement immediately.

Register Today!

For more information, visit www.augs.org/update2018.
JACK ROBERTSON LIFETIME ACHIEVEMENT AWARD

Linda Brubaker, MD, MS, FACOG
Thursday, October 5 | 9:15 a.m.
Exhibition Hall C

AUGS’ most prestigious award is presented periodically to an individual who has had a lifetime of outstanding achievements in the field of Female Pelvic Medicine and Reconstructive Surgery and has served as a role model through service, basic or clinical research and teaching.

Dr. Brubaker is recognized for her unparalleled contributions to the field of FPMRS. Her research pedigree includes work establishing the Pelvic Floors Disorders Network (PFDN). She is a tireless advocate for the field of FPMRS, as well as women experiencing pelvic floor disorders. Dr. Brubaker is a past president of AUGS and is currently serving as the Editor of Female Pelvic Medicine and Reconstructive Surgery.

RAYMOND A. LEE ENDOWMENT

Marie Fidela Rustia Paraiso, MD
Thursday, October 5 | 2:00 p.m. – 2:30 p.m.
Exhibition Hall C

The Raymond A. Lee Endowment is a named lectureship created by AUGS to honor one person annually who contributed to the development and surgical advancement of urogynecology and to further advance the knowledge and teaching of gynecologic surgery through ongoing AUGS educational programs.

RESIDENT SCHOLAR AWARDS

This program funds third-year residents who have demonstrated an interest in Female Pelvic Medicine and Reconstructive Surgery to attend the AUGS Annual Scientific Meeting and experience the current research initiatives going on within the field. Each scholar receives a $1,000 award to cover travel, hotel accommodations, and meeting registration.

Kelly Benabou, MD
Brown University/Women and Infants Hospital

Kelly Bree, MD
University of California San Diego

Lindsey Burnett, PhD, MD
University of California San Diego

Meagan Sloan Cramer, MD
Christiana Care Health System

Halley Crissman, MD, MPH
University of Michigan

Kelsey Dressen, MD
UPMC Graduate Medical Education

Allison Price Kellogg, MD
University of Texas Health Science Center at San Antonio

Michele O’Shea, MD, MPH
Northwestern University

Lauren Westbay, MD
Loyola University Medical Center
PFD RESEARCH AWARD RECIPIENTS

ROBIN HAFF RESEARCH AWARD

Ann Meers, BS, RN, CCRC
Friday, October 6 | 8:05 a.m.
Exhibition Hall C

This award is presented annually to an individual in recognition of outstanding and sustained contribution to female pelvic floor disorders research. The Robin Haff Research Award recognizes the important role that clinical research nurses and research coordinators play in the clinical research process. Without dedicated and committed research staff, high quality research would not be possible.

Ms. Meers is recognized for her talents, research skills, and passion. She has been involved in research in women’s health for 20 years, her interest in pelvic floor disorders piqued when she realized the many unanswered questions existed in the research. She is both a leader within Brown University and externally, where she served as the Chair for the NICHD Pelvic Floor Disorders Network Research Coordinator Committee.

PFD RESEARCH FOUNDATION DONOR OF THE YEAR AWARD

Kimberly Kenton, MD
Friday, October 6 | 8:05 a.m.
Exhibition Hall C

The PFD Research Foundation presents the Donor of the Year Award to an individual in recognition of commitment to the Foundation’s mission of transforming the lives of women through the support of innovative and effective research that advances the prevention, treatment, and cure of female pelvic floor disorders.

Dr. Kenton is a consistent and generous donor to the Foundation and a strong supporter of the Foundation’s mission. Her lifetime donations total is more than $20,000.

FOUNDATION GRANT RECIPIENTS

PFD RESEARCH FOUNDATION DONOR OF THE YEAR AWARD

Mary Ackenbom, MD, University of Pittsburgh Medical Center
Postoperative Cognitive Dysfunction in Older Women Undergoing Pelvic Organ Prolapse Surgery

Allison Wyman, MD, University of South Florida
Estimated Levator Ani Subtended Volume (eLASV): A Novel Assay for Predicting Surgical Outcomes in Pelvic Organ Prolapse

JUNE ALLYSON MEMORIAL FUND RESEARCH AWARD

Kimberly Kenton, MD
Friday, October 6 | 8:05 a.m.
Exhibition Hall C

The PFD Research Foundation presents the Donor of the Year Award to an individual in recognition of commitment to the Foundation’s mission of transforming the lives of women through the support of innovative and effective research that advances the prevention, treatment, and cure of female pelvic floor disorders.

Dr. Kenton is a consistent and generous donor to the Foundation and a strong supporter of the Foundation’s mission. Her lifetime donations total is more than $20,000.

ROBIN HAFF RESEARCH AWARD

Ann Meers, BS, RN, CCRC
Friday, October 6 | 8:05 a.m.
Exhibition Hall C

This award is presented annually to an individual in recognition of outstanding and sustained contribution to female pelvic floor disorders research. The Robin Haff Research Award recognizes the important role that clinical research nurses and research coordinators play in the clinical research process. Without dedicated and committed research staff, high quality research would not be possible.

Ms. Meers is recognized for her talents, research skills, and passion. She has been involved in research in women’s health for 20 years, her interest in pelvic floor disorders piqued when she realized the many unanswered questions existed in the research. She is both a leader within Brown University and externally, where she served as the Chair for the NICHD Pelvic Floor Disorders Network Research Coordinator Committee.

PFD RESEARCH FOUNDATION DONOR OF THE YEAR AWARD

Kimberly Kenton, MD
Friday, October 6 | 8:05 a.m.
Exhibition Hall C

The PFD Research Foundation presents the Donor of the Year Award to an individual in recognition of commitment to the Foundation’s mission of transforming the lives of women through the support of innovative and effective research that advances the prevention, treatment, and cure of female pelvic floor disorders.

Dr. Kenton is a consistent and generous donor to the Foundation and a strong supporter of the Foundation’s mission. Her lifetime donations total is more than $20,000.

FOUNDATION GRANT RECIPIENTS

PFD RESEARCH FOUNDATION DONOR OF THE YEAR AWARD

Mary Ackenbom, MD, University of Pittsburgh Medical Center
Postoperative Cognitive Dysfunction in Older Women Undergoing Pelvic Organ Prolapse Surgery

Allison Wyman, MD, University of South Florida
Estimated Levator Ani Subtended Volume (eLASV): A Novel Assay for Predicting Surgical Outcomes in Pelvic Organ Prolapse

JUNE ALLYSON MEMORIAL FUND RESEARCH AWARD

Kimberly Kenton, MD
Friday, October 6 | 8:05 a.m.
Exhibition Hall C

The PFD Research Foundation presents the Donor of the Year Award to an individual in recognition of commitment to the Foundation’s mission of transforming the lives of women through the support of innovative and effective research that advances the prevention, treatment, and cure of female pelvic floor disorders.

Dr. Kenton is a consistent and generous donor to the Foundation and a strong supporter of the Foundation’s mission. Her lifetime donations total is more than $20,000.
Help Support the PFD Research Foundation – Make a Donation Today
Your contribution to the PFD Research Foundation builds a stronger future for Female Pelvic Medicine and Reconstructive Surgery and honors the work and passion of those we respect.

How to Donate
Cash Gifts • Gifts of Stocks and Securities • Honoraria and Speaker Fees
Book Royalties • Planned Giving • AmazonSmile

Visit the AUGS Booth for more information and to make your donation.

Corporate Sponsors
Allergan Foundation
LABORIE
Medtronic, Inc.

Legacy Circle Members
Linda Brubaker, MD, MS
Andrew P. Cassidenti, MD
Vincent Lucente, MD, FACOG

Donor of the Year
Kimberly Kenton, MD, MS
The PFD Research Foundation sincerely thanks the following individuals for their generous support.

*Gifts Received between September 27, 2016 – August 30, 2017

### $1,000 - $4,999

<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Bulla</td>
<td>Roger Goldberg</td>
<td>Kimberly Kenton</td>
<td>Miles Murphy</td>
<td>Peter Scott</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeffrey Clemons</td>
<td>Douglass Hale</td>
<td>Yoko Komesu</td>
<td>Karen Noblett</td>
<td>Sandra Valaitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AnnaMarie Connolly</td>
<td>Cheryl Iglesia</td>
<td>Vincent Lucente</td>
<td>Peter Rosenblatt</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patrick Culligan</td>
<td>Margie Kahn</td>
<td>Timothy McKinney</td>
<td>Kristene Whitmore</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Halina Zyczynski</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### $500 - $999

<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cindy Amundsen</td>
<td>Emily Lukacz</td>
<td>Elizabeth Mueller</td>
<td>Nazema Siddiqui</td>
<td></td>
</tr>
<tr>
<td>Felicia Lane</td>
<td>Danielle Markle Price</td>
<td>Deborah Myers</td>
<td>Steven Swift</td>
<td></td>
</tr>
<tr>
<td>Cindi Lewis</td>
<td>Shawn Menefee</td>
<td>Osvaldo Padron</td>
<td>Jennifer Wu</td>
<td></td>
</tr>
</tbody>
</table>

### $250 - $499

<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vivian Aguilar</td>
<td>Sean Francis</td>
<td>Una Lee</td>
<td>Neven Matthews</td>
<td>Lora Plaskon</td>
</tr>
<tr>
<td>Heidi Brown</td>
<td>Chiara Ghatti</td>
<td>Juraj Letko</td>
<td>Carlos Medina</td>
<td>Mitchell Schuster</td>
</tr>
<tr>
<td>Christopher Chemansky</td>
<td>W. Thomas Gregory</td>
<td>Jerry Lowder</td>
<td>Tyler Muffy</td>
<td>Adam Steinberg</td>
</tr>
<tr>
<td>Sarah Collins</td>
<td>Victoria Handa</td>
<td>Karl Luber</td>
<td>Begum Ozel</td>
<td>Elisa Trowbridge</td>
</tr>
<tr>
<td>Kathleen Connell</td>
<td>Magdalene Karon</td>
<td>Sangee Mahajan</td>
<td>Stephanie Picket</td>
<td></td>
</tr>
</tbody>
</table>

### $100 - $249

<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mary Ackenborn</td>
<td>Elisabeth Erekson</td>
<td>Jessica Hammett</td>
<td>Rhonda Kotarinos</td>
<td>Carmen Sultana</td>
</tr>
<tr>
<td>Michael Bondie</td>
<td>Pamela Fairchild</td>
<td>Marie-Andree Harvey</td>
<td>Christine LaSala</td>
<td>Gary Sutkin</td>
</tr>
<tr>
<td>Sylvia Botros-Brey</td>
<td>Tola Fashokun</td>
<td>Bryan Hill</td>
<td>Jennifer Lee</td>
<td>Jasmine Tan-Kim</td>
</tr>
<tr>
<td>Jessica Bracken</td>
<td>Kimberly Ferrante</td>
<td>Jun Ihara</td>
<td>Quinn Lippman</td>
<td>Babak Vakili</td>
</tr>
<tr>
<td>Catherine Bradley</td>
<td>Peter Finamore</td>
<td>Keisha Jones</td>
<td>Ali Luck</td>
<td>Anthony Visco</td>
</tr>
<tr>
<td>Lauren Cadish</td>
<td>Michael Flynn</td>
<td>Amie Kawasaki</td>
<td>Marisa Mastropietro</td>
<td>Patricia Wallace</td>
</tr>
<tr>
<td>Susan Capelle</td>
<td>Raymond Foster</td>
<td>Kristinell Keil</td>
<td>Brook McFadden</td>
<td>Renee Ward</td>
</tr>
<tr>
<td>Sage Claydon</td>
<td>Anthony Gaddi</td>
<td>Charles Kilpatrick</td>
<td>Jessica McKinney</td>
<td>Emily Whitcomb</td>
</tr>
<tr>
<td>Sandra Culbertson</td>
<td>Elizabeth Geller</td>
<td>Anna Kirby</td>
<td>Kate Menwether</td>
<td>Raul Yordan-Jovet</td>
</tr>
<tr>
<td>Christina Dancz</td>
<td>Karen Gold</td>
<td>Leise Knoepp</td>
<td>Michelle Mornill</td>
<td></td>
</tr>
<tr>
<td>Keisha Dyer</td>
<td>Cara Grimes</td>
<td>Abner Korn</td>
<td>Mikio Nihira</td>
<td></td>
</tr>
<tr>
<td>Autumn Edenfield</td>
<td>Robert Gutman</td>
<td>Elizabeth Kotarinos</td>
<td>John Occhino</td>
<td></td>
</tr>
</tbody>
</table>

### Under $100

<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emily Adams-Piper</td>
<td>Amy Collins</td>
<td>Robert Flora</td>
<td>Kathy Jones-Gutzmer</td>
<td>Cara Ninivaggio</td>
</tr>
<tr>
<td>Danita Akingba</td>
<td>Jill Danford</td>
<td>Elizabeth Frankman</td>
<td>Kimberly Kenne</td>
<td>Michael Noone</td>
</tr>
<tr>
<td>Marianna Alperin</td>
<td>Bhumy Davé</td>
<td>Sean George</td>
<td>Linda Kiley</td>
<td>Cedric Olivera</td>
</tr>
<tr>
<td>Tirst Asfaw</td>
<td>G. Willy Davila</td>
<td>Cynthia Hall</td>
<td>Joseph Kowalski</td>
<td>Anita Pillai-Allen</td>
</tr>
<tr>
<td>Jennifer Bickhaus</td>
<td>Nicolette Deveneau</td>
<td>Anne Hardart</td>
<td>Christina Kwon</td>
<td>Mark Preston</td>
</tr>
<tr>
<td>Katarzyna Bochenksa</td>
<td>Michael Douso</td>
<td>Gerardo Heredia</td>
<td>Aix Leader-Cramer</td>
<td>Megan Schimpf</td>
</tr>
<tr>
<td>Cynthia Brincat</td>
<td>Bruce Drummond</td>
<td>Melero</td>
<td>Doug Miyazaki</td>
<td>David Schleicher</td>
</tr>
<tr>
<td>Kristen Buono</td>
<td>Tanaka Dune</td>
<td>Markus Huebner</td>
<td>Bob Moreland</td>
<td>Saya Segal</td>
</tr>
<tr>
<td>Camille Caldenwood</td>
<td>Sonia Dutta</td>
<td>Melissa Huggins</td>
<td>Margaret Mueller</td>
<td>Neha Taireja</td>
</tr>
<tr>
<td>Cassandra Carberry</td>
<td>Caroline Elmer</td>
<td>Heather Jeffcoat</td>
<td>Erin Myers</td>
<td>Megan Tarr</td>
</tr>
<tr>
<td>Andrew Cassidenti</td>
<td>Chidimma Eto</td>
<td>Peter Jeppson</td>
<td>Hoa Nguyen</td>
<td>Heather van Raalte</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Help Support the PFD Research Foundation – Make a Donation Today

Your contribution to the PFD Research Foundation builds a stronger future for Female Pelvic Medicine and Reconstructive Surgery and honors the work and passion of those we respect.

**How to Donate**

- Cash Gifts
- Gifts of Stocks and Securities
- Honoraria and Speaker Fees
- Book Royalties
- Planned Giving
- AmazonSmile

Visit the AUGS Booth for more information and to make your donation.

**Donor of the Year**

Kimberly Kenton, MD, MS

**Corporate Sponsors**

- Allergan Foundation
- LABORIE
- Medtronic, Inc.

**Legacy Circle Members**

- Linda Brubaker, MD, MS
- Andrew P. Cassidenti, MD
- Vincent Lucente, MD, FACOG
AUGS LEADERSHIP (2016-2017)

BOARD OF DIRECTORS

President
Halina M. Zyczynski, MD
*University of Pittsburgh School of Medicine*

President Elect
Charles R. Rardin, MD, FACOG, FACS
*Alpert Medical School of Brown University*

Vice President
Geoffrey W. Cundiff, MD, FACOG, FACS, FRCSC
*University of British Columbia, OB/GYN*

Treasurer
Raymond T. Foster, Sr., MD, MS, MHSc.
*University of Missouri School of Medicine*

Immediate Past President
Douglass S. Hale, MD
*Methodist Hospital of Indiana*

AUGS Chief Executive Officer
Michelle Zinnert, CAE
*American Urogynecologic Society*

DIRECTORS AT LARGE

Rony A. Adam, MD
*Vanderbilt University*

Jeffrey L. Clemons, MD
*MultiCare Health System*

Shawn A. Menefee, MD
*Kaiser Permanente, San Diego*

Mikio A. Nihira, MD, MPH
*University of California, Riverside*

Adam C. Steinberg, DO
*Hartford Hospital*

Jennifer M. Wu, MD, MPH
*University of North Carolina at Chapel Hill*

Sandra R. Valaitis, MD
*University of Chicago Hospital*

Karen L. Noblett, MD
*University of California Irvine School of Medicine*
PAST PRESIDENTS

Douglass Hale, MD (2015–2016)
Amy Rosenman, MD (2014–2015)
Charles Nager, MD (2013–2014)
Anthony G. Visco, MD (2012–2013)
Matthew D. Barber, MD, MHS (2011–2012)
Deborah Myers, MD (2010–2011)
Rebecca Rogers, MD (2009–2010)
Dee Fenner, MD (2008–2009)
Kris Strohbehn, MD (2007–2008)
Ingrid Nygaard, MD (2006–2007)
Stephen Young, MD (2004–2005)
Peggy Norton, MD (2001–2002)
W. Conrad Sweeting, MD (2000–2001)
Nicolette Horbach, MD (1999–2000)
Mickey Karram, MD (1998–1999)
Alfred Bent, MD (1994–1995)
David A. Richardson (1990–1991)
J. Andrew Fantl, MD (1986–1987)

Gynecologic Urology Society

Donald R. Ostergard, MD (1984–1985)
W. Glenn Hurt, MD (1982–1983)
Hugh M. Shingleton, MD (1981–1982)
Jack R. Robertson, MD (1979–1980)

AUGS STAFF

Michelle Zinnert, CAE
Chief Executive Officer

Colleen Hughes
Chief Operating Officer

Nicole Cranston
Sr. Director, Education Programs

Tresha Russell
Sr. Director, Quality and Performance Improvement

Tristan Wood
Manager, Membership and Community Programs

Lindsay Smith
Membership Assistant

Cynthia Stubits
Events Senior Manager

Ame Petry
Events Coordinator

Cristina Adames
Events Senior Associate

Lauren Lawson
Education Senior Manager

Amanda O’Kane
Marketing and Communications Manager

Jayne Corso
Marketing and Communications Coordinator

Jeffrey Reeves
Staff Accountant
ANCHORSURE® – DO IT SIMPLE

Safe & easy placement

The thinnest applicator, the strongest anchoring

Your less invasive sacrospinous ligament fixation system.

Visit us at Booth 100

For more info, contact us at info@neomedic.com or visit our website www.neomedic.com
COMMITTED TO REDEFINING RELIEF

Twenty years ago, Medtronic introduced you to sacral neuromodulation and transformed the way you treat incontinence.

Today, we’re even more committed to pelvic health and serving patients.

Together, we’ll continue to redefine relief.

Stop by the Medtronic Booth and partner with us to create your personalized OAB care pathway.

Indications for Use:
Sacral Neuromodulation delivered by the InterStim™ system for Urinary Control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.

The following Warning applies only to Sacral Neuromodulation for Urinary Control:

Warning: This therapy is not intended for patients with mechanical obstruction such as benign prostatic hypertrophy, cancer, or urethral stricture.

Sacral Neuromodulation delivered by the InterStim™ system for Bowel Control is indicated for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments.

Contraindications for Urinary Control and for Bowel Control: Diathermy. Patients who have not demonstrated an appropriate response to test stimulation or are unable to operate the neurostimulator.

Warnings/Precautions/Adverse Events:
For Urinary Control: Safety and effectiveness have not been established for bilateral stimulation; pregnancy, unborn fetus, and delivery; pediatric use under the age of 16; or for patients with neurological disease origins.

For Bowel Control: Safety and effectiveness have not been established for bilateral stimulation; pregnancy, unborn fetus, and delivery; pediatric use under the age of 18; or for patients with progressive, systemic neurological diseases.

For Urinary Control and for Bowel Control: The system may be affected by or adversely affect cardiac devices, electrocautery, defibrillators, ultrasonic equipment, radiation therapy, MRI, theft detectors/screening devices. Adverse events include pain at the implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations, including jolting or shock sensations. Patients should be assessed preoperatively for the risk of increased bleeding. For full prescribing information, please call Medtronic at 1-800-328-0810 and/or consult Medtronic’s website at www.medtronic.com. Product technical manual must be reviewed prior to use for detailed disclosure. USA Rx Only. Rev 0517
To learn more, visit ColoplastMD.com or ask your Coloplast sales representative for additional information.


*Dry defined in study as 24 hr pad weight of ≤ 4.0g

Indications: The Altis Single Incision Sling Systems are indicated for the treatment of female stress urinary incontinence (SUI) resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD).

Contraindications: Altis slings should not be used in pregnant women, or in women planning future pregnancies or any patient with potential for future growth. Altis slings should not be used in those who are taking anticoagulant therapy, who have an abnormal urethra, who have an intra-operative urethral injury, are immunocompromised, who have a sensitivity to polypropylene, have a pre-existing local or systemic infection, who are immunocompromised, or women that have a known or suspected pathology which would compromise implant or implant placement.

Warnings and Precautions: It is the responsibility of the surgeon to advise the prospective patients or their representatives, prior to surgery, of the possible warnings and precautions associated with the use of this product and the associated surgical risks. The Altis Sling Systems should only be used by surgeons familiar with the surgical procedures and techniques involving transvaginal placement of non-absorbable meshes and who have adequate education and experience in the treatment of female SUI. Based on physician experience and education, a thorough assessment of each patient should be made to determine the suitability of a synthetic mesh procedure. The patient should be counseled that alternative non-mesh incontinence surgeries may be appropriate, and the reason for choosing a mesh procedure should be explained. Physician should obtain patient consent prior to surgery and ensure that the patient has an understanding of the postoperative risks and potential complications of transvaginal mesh surgery. Patient counseling should include a discussion that the mesh to be implanted is a permanent implant, and that some complications associated with the implanted mesh may require additional surgery; repeat surgery may not resolve these complications. Serious adverse tissue responses or infection may require removal of mesh.

Adverse Effects: Potential adverse events are those associated with surgery using implantable synthetic mesh materials. As with all foreign bodies, the Altis sling is likely to exacerbate any existing infection. Local irritation at the wound site and/or a foreign body response may occur. The following complications are known to occur with synthetic mesh implantation: mesh erosion (e.g., vaginal, bladder), mesh extrusion, mesh exposure, infection, pain (acute or chronic), and bladder, bowel, urethra, vagina, vessel, and/or nerve perforation/injury. There is also the risk of complete failure of the procedure resulting in continued incontinence due to incomplete support or overactive bladder. The occurrence of these events may require partial or complete removal of the sling. Patients should be monitored regularly after the device has been implanted for immediate treatment of any adverse reaction.

See the device instructions for use for detailed information regarding the implant procedure, warnings / precautions, adverse reactions, prior to using this product.

For further information, call Coloplast Corp at 800.258.3476 and/or consult the company website at www.coloplast.us.com

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

Coloplast Corp. 1601 West River Road North, Minneapolis, MN 55411 USA Customer Service 800.258.3476 www.coloplast.us The Coloplast logo and Titan are registered trademarks of Coloplast A/S ©2017 All rights reserved Coloplast Corp.